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Chapter 1: English 
In 1780 Luigi Galvani touched a frogs leg with metal and discovered by accident 
bioelectricity. He did not notice the coherence, but his observation has provided the 
basis for the discovery of electro-chemical cells.  
With the evolvement and progress of neuroscience, the brain has been explored for 
over two centuries and in the 1950s, L-glutamate has been shown to increase 
neuronal firing1. In the 1980s the excitatory neurotransmitter role of glutamate, 
previously considered to be solely a metabolic precursor, has been discovered at 
synapses at squid giant axons2-4. 
Ionotropic glutamate receptors (iGluRs) mediate most excitatory neurotransmission in 
the central nervous system (CNS). These receptors play an important role for the 
development and function of the nervous system and are essential in learning and 
memory. At the beginning of this century iGluRs have been turned photosensitive 
using structure-guided design. Light-switchable agonists based on glutamate have 
been created that can exist in two different configurations. Depending on the 
wavelength of light used for illumination, one configuration of the ligand is favoured 
and according to the design, only one of the two configurations can activate the 
receptor and allosterically open the ion channel5,6.  
X-ray crystallography can provide three-dimensional (3-D) information on 
macromolecular structures and can show details of protein–ligand interactions. 
Numerous crystal structures of iGluRs including different ligands are available. 
However, not much is known about the molecular details concerning the binding 
mechanism and the spatial arrangement of photoswitches in iGluRs. As a proof of 
principle, the crystal structure of the ligand-binding domain (LBD) of GluK2 in 
complex with a photoswitchable agonist has now been solved. This is the first 
structure showing a membrane receptor bound to a synthetic photoswitchable ligand. 
The GluK2-LBD crystallized in a physiological mixed dimer with one closed, ligand-
bound protomer and one open, apo-like protomer. Furthermore, the affinity of the 
ligand towards different glutamate receptor subtypes has been determined with 
isothermal titration calorimetry (ITC) and with microscale thermophoresis (MST). 
Thereby, the intrinsic fluorescence of the proteins has been used to quantify the 
binding affinities with MST, which has been newly developed7.  
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The structural and functional data have formed a powerful platform for deeper 
mechanistic studies and for molecular design investigations concerning different 
long-term objectives in this area of research. With these azobenzene-modified 
ligands, microelectrodes and light, the behaviour of single neurons in the brain could 
be resolved in a precise spatio-temporal manner in the future. Moreover, targeting of 
glutamate receptors in retinal ganglion cells with photoswitchable ligands could 
possibly restore vision to blind retinae8. 
 
With protein design by directed evolution polypeptides with new or enhanced activity 
can be created by mimicing the natural process in a series of diversification and 
selection cycles. On the one hand proteins can be designed de novo by making use 
of chemical information. On the other hand proteins can be redesigned by using an 
existing scaffold as starting template9. 
Ribosome display is a very powerful technique to select proteins binding to a specific 
target immobilized on a surface. Besides antibodies, designed ankyrin repeat 
proteins (DARPins) are established as binding proteins10. The hydrophobic core of 
DARPins is an ideal scaffold to directly bind to an azobenzene moiety. The target 
molecule for the evolvement of an azobenzene-binding protein (ABP) has been 
prepared. If the ribosome display experiments are successful, ABPs could be 
combined with other systems and could for example be applied as light-switchable 
diagnostics and therapeutic agents.   
 
Apart from the role as neurotransmitter, glutamate can be excitotoxic to neurons if 
present at higher concentrations at the appropriate glutamate receptor. Hyperactivity 
at synapses might play a role in schizophrenia and in neurodegenerative disorders 
such as Huntington's chorea, epilepsy and Alzheimer's disease11. Hence, in recent 
years the challenge has been to develop iGluR antagonists with an acceptable 
therapeutic tolerability and a high safety profile. 
Trials to co-crystallize the GluA2-LBD with a photoswitchable ligand resulted in a 
tetrameric structure. But instead of being occupied by the photoswitch, the ligand-
binding cavity harbours a buffer molecule and a sulfate ion. A new class of glutamate 
receptor antagonists has been designed from this structure. The molecule has been 
prepared and electrophysiological experiments have proven the mode of action 
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expected. The solubility of the antagonist in water is very high and the structure 
leaves room for additional substituents in order to influence the affinity towards the 
receptor.  
 
Light-powered molecular machines could play a role in future nanoscale devices12. 
For this purpose an azobenzene with two attachment sites has been prepared. The 
two states of a molecular motor could correlate to the different, possible 
configurations of the molecule. Overall, the molecular motor would be created by 
using DNA origami and the azobenzene molecule. Unfortunatelly, further 
experiments currently stagnate due to early stage technical limitations.  
 
Ortho-substituted azobenzenes show interesting characteristics concerning the 
stability and the absorption behaviour. Particular substituents generate molecules 
with very long half-lifes in both configurations13. Such a molecule has been prepared 
and attempts to monitor molecular chirality induced with circularly polarized light 
could possibly be performed in the near future. 
Other substituents lead to red-shifted action spectra14. This is advantageous for 
medical or biological applications with the depth of penetration increasing and the 
phototoxicity decreasing. For example, red-shifted compounds are in demand for 
experiments concerning the restoration of vision. A building block of a red-shifted 
iGluR agonist has been prepared and final experiments towards the completion of the 
ligand are currently under investigation.  
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Chapter 2: Deutsch 
1780 berührte Luigi Galvani einen Froschschenkel mit Metall und entdeckte zufällig 
die Bioelektrizität. Zwar erkannte er nicht die Zusammenhänge, jedoch legte seine 
Beobachtung die Grundlage für die Entdeckung elektro-chemischer Zellen. 
Durch die Entfaltung und die Fortschritte der Neurowissenschaften wird das Gehirn 
schon seit über zwei Jahrhunderten erforscht und in den 1950er Jahren wurde 
gezeigt, dass L-Glutamat neuronale Reize verstärkt1. In den 1980er Jahren wurde die 
Rolle von Glutamat, das zuvor lediglich als Stoffwechselvorstufe angesehen wurde, 
als aktivierender Neurotransmitter an Synapsen der Riesenaxone des Tintenfisches 
entdeckt2-4. 
Ionotrope Glutamatrezeptoren (iGluRs) steuern die meiste anregende 
Neurotransmission im zentralen Nervensystem (ZNS). Diese Rezeptoren haben eine 
wichtige Rolle in der Entwicklung und in der Funktion des ZNS und sind essentiell für 
Lernvorgänge und für das Gedächtnis. Zu Beginn dieses Jahrhunderts wurden 
lichtempfindliche iGluRs durch strukturbasiertes Design entwickelt. Auf Glutamat 
aufbauend wurden lichtschaltbare Agonisten erstellt, die in zwei unterschiedlichen 
Konfigurationen existieren können. Abhängig von der Wellenlänge des Lichtes der 
gewählten Beleuchtung, ist eine Konfiguration des Liganden bevorzugt, und aufgrund 
des jeweiligen Designs, kann der Ligand nur in einer der zwei Konfigurationen den 
Rezeptor aktivieren und somit den Ionenkanal allosterisch öffnen5,6. 
Mit Hilfe der Röntgenstrukturanalyse können drei dimensionale (3-D) Informationen 
makromolekularer Strukturen gewonnen werden, und es können Details der Protein–
Ligand Wechselwirkung dargestellt werden. Zahlreiche Kristallstrukturen von iGluRs 
mit unterschiedlichen Liganden sind inzwischen verfügbar. Jedoch ist noch sehr 
wenig über den zugrundeliegenden detaillierten Mechanismus der Bindung und der 
räumlichen Orientierung von Photoschaltern und iGluRs bekannt. Als prinzipieller 
Beweis wurde nun die Kristallstruktur der ligandenbindenden Domäne (LBD) des 
GluK2 Rezeptors mit einem gebundenen photoschaltbaren Agonisten gelöst. Dies ist 
die erste Struktur, die einen Membranrezeptor mit einem gebunden, synthetischen 
Photoschalter zeigt. Die GluK2-LBD kristallisierte als ein gemischtes physiologisches 
Dimer mit einem geschlossenen, Liganden gebundenen und einem offenen, Apo 
ähnlichen Protomer. Außerdem wurde die Affinität des Liganden für verschiedene 
Klassen von iGluRs durch isothermale Titrationskalorimetrie (ITC) und durch 
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mikroskalige Thermophorese (MST) bestimmt. Hierbei wurde für die MST die 
intrinsische Fluoreszenz der Proteine verwendet um die Bindungsaffinitäten zu 
quantifizieren. Diese Technik wurde neu entwickelt7.  
Die strukturellen und funktionellen Studien haben eine mächtige Plattform für 
weiterführende Untersuchungen geschaffen, die den Mechanismus und das 
molekulare Design betreffen, um langfristige Ziele in diesem Forschungsgebiet zu 
erreichen. Mit diesen Azobenzol enthaltenden Liganden, mit Mikroelektroden und mit 
Licht, könnte in Zukunft das Verhalten einzelner Neuronen im Gehirn mit einer hohen 
zeitlichen und räumlichen Auflösung bestimmt werden. Des Weiteren kann mit 
lichtschaltbaren Liganden für Glutamatrezeptoren der retinalen Ganglienzellen 
möglicherweise das Sehvermögen in blinden Retinae wiederhergestellt werden8. 
 
Durch das Design von Proteinen mit Hilfe der direkten Evolution können Polypeptide 
durch das Nachahmen des natürlichen Prozesses, in einer Serie von Diversifikations- 
und Selektions-Zyklen, mit neuer oder erhöhter Aktivität erschaffen werden. 
Einerseits können Proteine dementsprechend unter Berücksichtigung der 
chemischen Information de novo gestaltet werden. Andererseits können Proteine 
aber auch umgestaltet werden, indem man zu Beginn des Designs ein existierendes 
Gerüst als Templat verwendet9. 
Ribosomales Display ist eine leistungsstarke Technik um Proteine, die an ein 
bestimmtes immobilisiertes Ziel binden, zu selektieren. Neben Antikörpern wurden 
auch designte Ankyrin-Repeat Proteine (DARPins) als bindende Proteine etabliert10. 
Der hydrophobe Kern der DARPins ist ein ideales Gerüst um direkt an eine 
Azobenzol Gruppe zu binden. Das Zielmolekül für die Entwicklung eines Azobenzol 
Bindeproteins (ABP) wurde synthetisiert. Wenn die Experimente des ribosomalen 
Displays erfolgreich sind, könnten ABPs mit anderen Systemen kombiniert werden 
und zum Beispiel als lichtschaltbare Diagnostika und Therapeutika Anwendung 
finden.   
 
Abgesehen von der Rolle als Neurotransmitter, kann Glutamat auch exzitotoxisch auf 
Neuronen wirken, wenn es in hohen Konzentrationen in der Nähe der 
entsprechenden Glutamatrezeptoren vorliegt. Die Hyperaktivität an Synapsen könnte 
eine Rolle bei Schizophrenie und bei den neurodegenerativen Erkrankungen wie 
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Chorea Huntington, Epilepsie und Alzheimer spielen11. In den vergangenen Jahren 
wurde deshalb versucht iGluR Antagonisten mit einer akzeptablen therapeutischen 
Verträglichkeit und mit einem hohen Sicherheitsprofil zu entwickeln. 
Co-Kristallisationsversuche der GluA2-LBD mit einem lichtschaltbaren Liganden 
ergaben eine tetramere Struktur. Die Bindungsstelle des Liganden war jedoch anstatt 
des Lichtschalters mit einem Puffermolekül und einem Sulfation besetzt. Anhand 
dieser Struktur wurde eine neue Klasse von Glutamatrezeptor Antagonisten 
konzipiert. Das Molekül wurde synthetisiert und elektrophysiologische Experimente 
bestätigten die erwartete Wirkungsweise. Die Wasserlöslichkeit des Antagonisten ist 
sehr hoch und seine Struktur lässt noch Raum für zusätzliche Substituenten um die 
Affinität zu beeinflussen. 
 
Mit Licht betriebene molekulare Maschinen könnten in Zukunft bei Geräten auf der 
Nanometerskala eine Rolle spielen12. Zu diesem Zweck wurde ein Azobenzol mit 
zwei Befestigungsstellen synthetisiert. Die zwei Takte eines molekularen Motors 
könnten den unterschiedlichen möglichen Konfigurationen des Moleküls 
entsprechen. Allgemein würde der molekulare Motor aus DNA Origami und dem 
Azobenzol Molekül bestehen. Jedoch befinden sich die Experimente gegenwärtig in 
einer frühen Phase und stagnieren aufgrund technischer Limitierungen. 
 
Ortho-substituierte Azobenzole besitzen interessante Eigenschaften in Bezug auf die 
Stabilität und das Absorptionsverhalten. Durch bestimmte Substituenten können 
Moleküle erzeugt werden, die sehr lange Halbwertszeiten in beiden Konfigurationen 
aufweisen13. Solch ein Molekül wurde synthetisiert und Versuche der Kontrolle der 
molekularen Chiralität mit zirkular polarisiertem Licht können möglicherweise in naher 
Zukunft durchgeführt werden. 
Andere Substituenten führen zu rot verschobenen Wirkungsspektren14. Dies ist 
aufgrund einer höheren Eindringtiefe und einer geringeren Phototoxizität von Vorteil 
für medizinische und biologische Anwendungen. Rot verschobene Verbindungen 
werden zum Beispiel für Experimente zur Wiederherstellung des Sehvermögens 
benötigt. Ein Baustein eines rot verschobenen iGluR Agonisten wurde hergestellt und 
die letzten Experimente zur Synthese des Liganden werden derzeit durchgeführt. 
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Chapter 3: Ionotropic glutamate receptors 
 
3.1 Appearance 
Chapter 3 about ionotropic glutamate receptors is based on a book and a review 
published in 2008 and 2011, respectively15,16. The CNS is a never resting 
conglomeration of cells permanently receiving, analysing and realizing information. 
To manage all these tasks and to control the entire body directly or in an indirect 
fashion, the nervous system possesses an immense amount of specific cells. In 1891 
Waldeyer formulated his neuron theory, which said that the CNS does not consist of 
a continuum of cytoplasm but many individual cells – the neurons17.  
Although the brain is a very complex neural network there are many characteristics 
that simplify the understanding of its modus operandi. For example, there are only 
two types of signals in the nervous system, an electrical and a chemical one. In 1848 
Du Bois-Reymond showed that electric current plays a role in neural conduction18. 
The electrical signals in all neurons of the body are in principle identical and they are 
very similar in different animals. Therefore, the neural impulse can be handled as 
stereotypical unit and universal carrier for transmitting information. In 1952 Huxley 
and Hodgkin yielded together with Katz the sodium theory of the action potential. 
These signals propagate along the nerve with a velocity of approximately 80 m/s, are 
about 0.1 volt in amplitude and last about 1 millisecond.  
In synapses, a term introduced by Sherington in 1897, the electrical signal can be 
transformed into a chemical one, which passes on the information to the following 
cell. Chemical synapses can be excitatory or inhibitory. The synaptic cleft between 
two neurons spans 20 – 40 nm. It consists of a nerve ending on the presynaptic side 
and the specialized area of a receiving cell on the postsynaptic side. The presynaptic 
nerve ending contains characteristic vesicles, the synaptic vesicles, in which 
transmitters are stored17. These chemical signals are called neurotransmitters. 
Glutamate is a low molecular weight active substance and the most frequently 
occuring excitatory neurotransmitter. The major precursor of the neurotransmitter 
glutamate is glutamine. The conversion of glutamine to glutamate is carried out by 
the enzyme glutaminase in nerve terminal mitochondria19.  
When an action potential arrives at the synapse, vesicles containing glutamate merge 
within the neuron's plasma membrane and release their contents outside the cell. 
INTRODUCTION 
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Glutamate diffuses from the presynaptic to the postsynaptic neuron and binds to 
receptors there, activating the postsynaptic cell. The released glutamate in the cleft is 
cleared away by glutamate transporters20. In summary, chemical transmitters 
released from presynaptic terminals diffuse across the synaptic cleft and activate 
receptors on the postsynaptic cell, with glutamate being the predominant molecule for 
transmitting the flow of information from one neuron to another in an excitatory 
fashion1,21,22. 
 
3.2 General characteristics and architecture 
Proteins can be divided into different classes. Membrane receptor proteins belong to 
the class of membrane proteins and initiate the first step in the cellular response to a 
signal. The subclass of ligand-gated ion channel (LGIC) protein complexes is a group 
of transmembrane ion channels that open or close in response to specific chemical 
ligands, such as neurotransmitters. LGICs that participate in fast synaptic 
transmission comprise the nicotinic acetylcholine, 5-hydroxytryptamine3, γ-
aminobutyric acidA, glycine, P2X and iGluR families23. iGluRs are implicated in nearly 
all aspects of nervous system development and function. Also, they are involved in 
chronic neurodegenerative conditions, in psychatric disorders and in acute injury or 
trauma24-27. 
In general, iGluRs belong to the glutamate receptor family, which also includes 
metabotropic glutamate receptors (mGluRs)28-30. The iGluR subunits can be sub-
divided into four main subfamilies, the N-methyl-D-aspartate (NMDA) type, the α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type, the kainate type 
and the orphan receptors. This thesis only focuses on the AMPA and kainate family 
of non-NMDA ionotropic receptors, which are clearly distinguished from NMDA 
receptors24. Non-NMDA receptors are the key players for mediating excitatory 
synaptic transmission in the brain. Moreover, non-NMDA receptors show kinetics on 
a millisecond timescale in contrast to a timescale of tens of hundreds of milliseconds 
for NMDA receptors31,32. Furthermore, NMDA receptors require membrane 
depolarization to release the magnesium block together with binding of glycine and 
glutamate for activation. In opposition, AMPA and kainate receptors only demand 
glutamate33,34.  
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Despite divergent functional properties, the resemblances between different iGluR 
family members show strong links in the structures. The high homology among all 
iGluRs suggests a common ancestral gene35. NMDA and non-NMDA receptors are 
tetrameric and the given combination of subunits is expressed as a tetramer36,37.  
The identification of different subtypes of receptors is mainly based on 
electrophysiological and biochemical studies using selective agonists and 
antagonists. In 2000, a new terminology for glutamate receptor subunits was 
proposed by Lodge and Dingledine, which is more in line with IUPHAR guidelines 
and the previous and present nomenclature is shown below for non-NMDA 
receptors23. 
 
New terminology GluA1 GluA2 GluA3 GluA4 GluK1 GluK2 GluK3 GluK4 GluK5 
Previous name iGluR1 iGluR2 iGluR3 iGluR4 iGluR5 iGluR6 iGluR7 KA1 KA2 
 AMPA family Kainate family 
           Table 1: Previous and present iGluR nomenclature. 
 
There are four known subunits of AMPA receptors with two alternative splice variants 
of each designated as flip and flop, and five high affinity kainate receptor 
subunits38,39. In 1989, the first functional iGluR has been cloned. Most kainate 
receptor subunits have been cloned in the early 1990s by the groups of Heinemann 
and Seeburg. The genes are denoted GRIK1 – 5 in sequential order of cloning40-43. 
Genes encoding the AMPA receptors are named GRIA1 – 4 and share similar overall 
structures. The translated protein subunits contain 850 – 900 amino acids44,45. All 
AMPA and kainate receptor subtype complexes are permeable to Na+ and K+. 
Receptors lacking Q/R site-edited GluA2 or GluK5/6 subunits are also permeable to 
Ca2+ 46. 
The linear polypeptide chain with the domain organization is shown in figure 1 A and 
the topological overview is illustrated in figure 1 B. All AMPA and kainate receptor 
subunit proteins have an amino- or N-terminal domain (A/NTD) and a LBD, 
extracellularly. The ATD and the LBD show strong sequence homology to 
periplasmic bacterial amino acid binding-proteins and fold into clamshell-like 
structures47,48. In addition there are three transmembrane domains (TMD) M1, M3 
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and M4, one reentrant loop M2, which enters and exits the membrane on the 
cytoplasmic side, and an intracellular C-terminal part49.  
 
Figure 1: Topology of the iGluR subunit and construct for crystallization. (A and B, PDB entry 3KG2) Linear 
polypeptide chain and schematic representations of the domain organization with the ATD in red, the LBD 
consisting of the S1 and S2 segments divided into domain1 (D1) and domain2 (D2) in blue, with a bound agonist 
or competitive antagonist (A) in light blue, the TMD with helices M1, M2, M3 and M4 in green and the C-terminal 
domain (CTD). (C) Construct for crystallization of soluble LBDs with an octa histidine tag (yellow), a thrombin 
cleavage site (orange) and S1 and S2 (blue) connected via a GT dipeptide (magenta). 
 
Previous to the ATD there is a short signal peptide that targets the protein to the 
membrane and which is removed by proteolytic cleavage after membrane insertion24. 
The ATD does not bind glutamate but is important for subunit-specific assembly and 
may have roles in desensitization and modulation of other channel kinetics50,51. The 
bi-lobate LBD-structure is comprised of two separate polypeptide segments named 
S1 and S2, which are intermitted by the ion channel pore52. The notations D1 and D2 
represent the overall folds of the two lobes, which are differing slightly from the S1 
and S2 sequences. The LBD is essential for agonist/competitive antagonist binding.  
It is possible to excise the LBD from an iGluR subunit and express this part as a 
soluble protein suitable for crystallization53,54. Engineering efforts have succeeded in 
creating a recombinant construct, which is depicted in figure 1C and which is 
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composed of the S1 and S2 sequences connected through a short polypeptide53,55. 
For purification reasons there is additionally an N-terminal octa histidine tag, which 
can be removed via a thrombin cleavage site. The soluble construct shows ligand-
binding affinities comparable to that of full-length subunits and has been crystallized 
in complex with a number of agonists and antagonists56-63.  
In the full-length receptor the LBD is connected to the membrane-spanning ion 
channel through three short linker segments. These linker regions are important for 
gating in response to agonist binding64-66. For example, the S1-M1 linker harbours a 
short pre-M1 helix acting like a cuff around the top of the ion channel domain60.  
M1, M3 and M4 are transmembrane spanning α-helices and M2 is a central pore-like 
helix67,68. M1 and M4 reside on the exterior of the ion channel, with M4 making 
extensive interactions with adjacent subunits resembling its crucial role in receptor 
assembly60,66. M2 is found within the pore and M3 lines the inside of the ion channel 
forming the putative ion permeation pathway60,69. Superimposing the TMD of GluA2 
onto the K+ channel from S. lividans (KcsA) shows an overall similarity of the ion 
conduction pathway. Moreover, the central cavity in GluA2 is similar to that observed 
in potassium channels60,68. The region in KcsA that confers ion selectivity, however, 
is disordered and completely different in amino acid sequence. This is consistent with 
the fact that K+ channels are highly selective in contrast to iGluRs.  
The C-terminal intracellular domain, which is involved in receptor localization and 
regulation, is highly variable in sequence and size among iGluRs and can be 
alternatively spliced and modulated by specific interactions with phosphatases and 
protein kinases. This is the main anchoring domain for protein–protein interactions as 
well24,70,71.  
 
3.3 Quaternary structure 
Mature functional iGluRs are tetramers existing as dimer of dimers formed in the 
endoplasmic reticulum49. Although native receptors are thought to exist almost 
exclusively as heterotetramers72-74, AMPA and kainate subunits can also form 
functional homotetramers37,75-77. 
Electron microscopy structures supported the tetrameric stoichiometry of 
recombinant and native AMPA receptors78-80. In 2009, the X-ray structure of an intact 
full-length homotetrameric eukaryotic GluA2 receptor in complex with a competitive 
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antagonist has been solved at 3.6 Å resolution by Sobolevsky and presents detailed 
informations about symmetry and mechanisms60. This structure is shown in figure 2. 
Figure 2: GluA2 quaternary structure. Full-length GluA2 homotetramer (PDB entry 3KG2) shown with a 
translucent surface bound to ZK200775 highlighted as spheres in blue. The individual subunits are diagramed as 
cartoons in green, yellow, red and blue, respectively, and the membrane is displayed as a gray rectangle. 
 
The three main domains are arranged in layers, with the LBD sandwiched in between 
the TMD and the ATD. The receptor is shaped like the capital letter Y and reflects an 
overall axis of two-fold symmetry with the extracellular domains organized as pairs of 
local dimers and the ion channel featuring four-fold symmetry60. The overall two-fold 
axis relates one LBD- and ATD-dimer to the second, respectively, and half of the 
pore-forming TMD to the other half81,82.  
The ATDs and the LBDs form each two different types of subunit–subunit contacts, 
one within each dimer and one at the dimer–dimer interface, which is located on the 
overall axis of symmetry. This is in accordance with data observed in crystals of the  
isolated LBD and ATD56,82. However, the local dimer two-fold axes for the ATDs and 
LBDs do not align with each other, the relationship between LBD dimers is not 
perfectly two-fold symmetric and there is a subunit-crossover between the ATD- and 
the LBD-layer. This means, that subunits switch proximity to the overall two-fold axis 
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between the ATD and LBD layer, which is mediated by the polypeptides linking the 
individual domains60.  
This unorthodox subunit arrangement and molecular symmetry has been confirmed 
by subunit disulphide crosslinking experiments under native conditions60. Due to the 
observation that GluK2-ATD and -LBD structures show similar dimer-of-dimer 
arrangements, kainate receptors should exhibit a similar quaternary structure as 
well83,84. 
The four-fold axis of the pore is very well aligned with the overall two-fold axis of 
symmetry. Transitions in symmetry between the ion channel and the extracellular 
domains are located on the linker regions between the LBD and TMD. These linker 
regions are the central elements of the gating machinery transforming ligand-induced 
changes in the LBD into movement of the TMD60.  
Altogether, the full-length GluA2 structure proves the mechanisms developed for 
activation, desensitization and inhibition. The basis for the development of 
mechanistic models for functional and pharmocological features of iGluRs have been 
provided by the huge amount of LBD and ATD X-ray structures solved beforehand.  
 
3.4 Ligand-binding mode 
The LBD folds into a clamshell-like structure with S1 and S2 individually comprising 
most of each clamshell (D1 and D2). D1 is predominantly composed of the N-
terminal side of M1 in S1 and D2 is in large part formed by the S2 segment between 
M3 and M4. The binding pocket is located deep within the cleft between the two 
globular domains, which are held together by a flexible hinge region. The numerous 
crystal structures existing are the structural basis for evaluating agonist selectivity 
among different subclasses and molecular determinants of full agonists and partial 
agonists as well as competitive antagonists85,86. The ligand glutamate interacting with 
receptor residues of GluA2 and GluK2 is depicted in figure 3 A and B, respectively. 
In GluA2 the α-amino group of glutamate forms a tetrahedral network of interactions 
with the backbone carbonyl group of a proline (P478), the hydroxyl group on the side 
chain of a threonine (T480) and the γ-carboxyl group on the side chain of a glutamic 
acid residue (E705) of the protein. The α-carboxyl group interacts with the 
guanidinium group on the side chain of an arginine (R485), the backbone NH of a 
threonine (T480) and the backbone NH of a serine (S654). The γ-carboxyl group 
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forms a contact to the backbone NH and to the hydroxyl group on the side chain of a 
threonine (T655) protein residue. The position occupied by the γ-carboxyl group of 
glutamate shows some variability among different iGluR agonists. For example, the 
interaction of the isoxazole hydroxyl group of AMPA and the backbone NH of the 
same threonine (T655) is mediated via a water molecule. The side chain of a tyrosine 
(Y450) forms a lid and narrows the space in the ligand-binding pocket56. On the basis 
of ligand-binding affinities comparable to the full-length subunit, this binding mode 
observed in the crystallizable LBD construct accurately resembles the binding sites in 
intact receptors60.  
 Figure 3: Glutamate–receptor interactions in the binding pocket. (A and B) Overview of the GluA2 (PDB 
entry 2UXA) and GluK2 (PDB entry 1S7Y) ligand-binding sites (gray sticks), respectively,  with bound glutamate 
(green sticks) and trapped water molecules (red spheres). Black, dashed lines indicate hydrogen bonds and ion 
pair interactions. Residues are numbered according to the total protein without the signal peptide for GluA2 and 
with the signal peptide for GluK2.  
 
In contrast to AMPA receptors, kainate receptors have larger binding cavities. GluK1 
and GluK2 binding pockets are 40% and 16% larger than the one of GluA2. 
Therefore, steric occlusion is one important parameter to discriminate between 
AMPA and kainate receptors as well as between GluK1 and GluK287,88. According to 
the available space in the binding pocket, there are different amounts of water 
molecules involved in the binding of glutamate. Six and five water molecules are 
present in GluK1 and GluK2, respectively, opposed to four in GluA2. The additional 
water molecule in GluK1 is responsible for selective ligands over GluK261. Thus, the 
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arrangement of water molecules participating in bridged interactions is the key for 
subunit selectivity. 
Another difference in GluK2 is a missing hydrogen bond present between the α-
amino group of glutamate and the side chain hydroxyl group of a threonine in GluA2 
(T480) and in GluK1 (T533)89. The threonine is replaced by an alanine (A518) at this 
position and an additional water molecule forms a hydrogen bond to the α-amino 
group of glutamate61. 
Competitive antagonists in contrast stabilize a conformation similar to the empty apo 
state with little or no clamshell closure. This is in agreement with the fact that 
clamshell closure is needed for receptor activation60. There are three mechanisms 
known for competitive antagonism. One is steric hindrance of cleft closure by a bulky 
γ-substituent (ATPO). Other molecules (DNQX) shield the agonist from binding to its 
initial contact sites and the third type of molecules (willardiines and ZK200775) have 
a bulky γ-substituent and stabilize the LBD closer to the resting state59,62.  
 
3.5 Mechansims for activation, gating and desensitization 
The mechanism for activation and gating involves a sequence of discrete 
conformational changes. While in NMDA receptors all four subunits in the tetramer 
are required to be activated in order to open the channel, in AMPA receptors each 
subunit can autonomously activate the ion channel37,90. First, the energy-generating 
process of agonist binding concomitantly changes the conformation of the LBD from 
the open apo state to the closed holo state56,91-93. Binding of glutamate proceeds via 
a two step dock-and-lock mechanism. A fast docking of the ligand to the residues on 
S1 is follwed by a slow closure with ligand–S2 and D1–D2 interactions taking 
place94,95. The clamshell closure is allosterically coupled to the opening of the pore 
through a rotation-leverarm-combination mechanism.  
Dimer structures show the monomers to be arranged as two-fold symmetric pairs 
with the dimer interface formed between the D1 domains via hydrophobic 
interactions56,60,61,96. Therefore, D1 is relatively fixed, whereas D2 is free to move. M1 
and M3 of the TMD are attached to the LBD at a position that corresponds to the 
dipeptide linking S1 and S2 in the construct used for crystallization. An alignment of 
an apo and a holo structure shows a striking displacement of this linker region by 
several angstroms as can be seen in figure 4. Upon ligand binding, D2 movement 
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consequently leads to a displacement of this linker region and therefore exposes M1 
and especially M3 to conformational strain, driving the channel to open56,61,93,97. With 
this mechanism not only agonism, but antagonism and partial agonism can be 
explained as well. The differences of clamshell closure correspond to a variation in 
strain pulled on the TMD58.  
Mutational studies showed that the molecular determinants critical for gating appear 
to be within M3, whichg contains the SYTANLAAF motif97-99. This highly conserved 
motif is in proximity to the crossing of the M3 helices in the closed conformation, 
occluding the ion channel permeation pathway. Furthermore, the pathway is clogged 
above this motif by a pair of methionine residues60.  The extent of conformational 
movement is greater for the distal subunits when compared to the proximal pairs. 
Consequently, they might be more important for gating. All in all, the transmembrane 
helices will be bend and splay away from the central axis of the channel upon ligand-
binding, mimicking the iris-like opening of K+ channels60,100. 
Figure 4: Separation of linker segments upon ligand binding. Closed GluA2-LBDglutamate (PDB entry 
1FTJ; D1 green and D2 blue) and open apo GluA2-LBD (PDB entry 1FTO; D1 light grey and D2 dark gray) 
structure. The alignment of the glutamate bound GluA2-LBD-D1 with the apo GluA2-LBD-D1 shows a rotation of 
D2 (19°) upon ligand binding along with a displacement of the linker region (red, 5 Å) that corresponds to the 
attachment of the transmembrane domains in the full length subunits. 
 
In addition to the agonist-binding site, the LBD is also involved in binding of various 
allosteric modulators that can influence desensitization and deactivation. 
Desensitization could modulate the excitatory postsynaptic transmission, but may 
also provide a protective mechanism against receptor overactivation101,102. AMPA 
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and kainate receptors exhibit a fast desensitization. Domains involved in 
desensitization have been determined by mutational studies and the dimer interface 
of the LBD is important for the transition to this state96,103,104. On a structural basis, 
the strain generated through closing of the clamshell upon agonist binding can either 
be released by movement of the gating domain in the ion channel or by reorientation 
of the dimer interface into a relaxed, desensitized conformation, with a different dimer 
interface, which is energetically more favorable81. The rupture of the LBD D1–D1 
interface and rigid-body rotation of the individual binding domains allow the receptor 
to stay in a closed like state, without opening the LBD. This rearrangement should 
also demand movement of the ATD and ATD-LBD linkers60. In contrast, 
Cyclothiazide, an inhibitor of desensitization and a non-desensitizing mutant, both 
mediate additional interactions and influence the stability of the dimer interface. By 
stabilization of the constraint interface cleft opening and agonist release is prevented. 
Therefore the receptor is trapped in the active state105. 
 
Chapter 4: Azobenzenes 
 
4.1 Characteristics 
Chapter 4 briefly summarizes a book and a review published in 2009 and 2012, 
respectively106,107. In 1834, azobenzene has been  observed for the first time by 
Mitscherlich108. In 1856, Noble described azobenzene as yellowish-red crystalline 
plates109. The completely reversible photochemical E,Z-isomerization of the –(N=N)– 
bond has been reported by Hartley in 1937110. The isomerization is shown for 
azobenzene (1) in scheme 1. 
 
Scheme 1: Azobenzene isomerization. Photoisomerization between the two azobenzene (1) states is reversible 
and the (E) configuration (left) is thermodynamically more stable than the (Z) configuration (right). 
 
N N
N N
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Upon absorption of photons of different wavelenghts of light (hυ, hυ') the steady-state 
trans–cis composition in the photostationary state can be shifted. The unique steady-
state composition mainly depends on the quantum yields (Φtrans and Φcis) and the 
thermal relaxation. In general, the trans form, which adopts a planar structure with 
C2h symmetry is about 50 kJ/mole more stable than the cis isomer assuming a non-
planar conformation with C2 symmetry. In the dark > 99.99% are in the trans state111-
114. The energy barrier of the photoexcited state is about 200 kJ/mol and the barrier 
for thermal isomerization is about 90 kJ/mole115,116. Azobenzenes show a high 
photostability even after prolonged irradiation and due to the thermodynamic stability 
of the trans isomer, the cis → trans isomerization occurs spontaneously in the dark, 
except for bulky substituted azobenzenes or inverted bridged azobenzenes89,117. 
Ortho-alkylated azobenzenes show twisting of the phenyl rings in the trans 
configuration and slower thermal isomerization rates can be attributed to steric 
hindrance between the ortho alkyl substituent and the orbitals on N-atoms 
undergoing inversion118,119.  
Spectra of trans- and cis-azobenzenes are distinct but can be overlapping. The trans-
azobenzene has two well seperated absorption bands. A strong, symmetry allowed π 
→ π∗ ultraviolet (UV) band, and a weak, symmetry forbidden n → π∗ visible region 
band. The n → π∗ transition is allowed because of vibrational coupling and a minimal 
extent of nonplanarity120,121. The cis-azobenzene has a weaker π → π∗ transition, but 
the n → π∗ transition absorbs more strongly than the trans-azobenzene122,123. The 
different transitions excite azobenzenes to S1 (n → π∗) and S2 (π → π∗) states124,125.  
The strong absorption of the π system can be affected by different substituents on the 
phenyl ring and can thereby vary from the UV to visible red regions. Ortho- or para-
substitution with electron donating groups leads to the group of aminoazobenzenes, 
which have very close, almost overlapping n → π∗ and π → π∗ bands. Acceptor- and 
donor-substitution with a push–pull substitution pattern shifts the π → π∗ to the red, 
but does not change the n → π∗, leading to a reversed ordering of absorption bands 
observable in this class of pseudo-stilbenes114,126.  
This effect can be explained by regarding the excited state with a higher dipole 
character than the ground state. Donating substituents better stabilize the excited 
state, which leads to ground state red-shifts with increasing dipole character. The 
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activation barrier is lower, and therefore thermal relaxation is accelerated as 
well122,127,128.  
Moreover, the absorption of azobenzenes can also be solvent- and packing-
dependent (π-stacking), amino- and pseudo-stilbene-azobenzenes can show 
fluorescence, but phosphorescence is absent in all azobenzenes. The chemical fine 
tuning of these compounds was extensively studied in connection with dyes and 
colorants and approximately 70% of the world's commercial dyes are azobenzene 
derivatives129,130.  
 
4.2 Mechanism of isomerization 
The first cis-azobenzene was isolated more than eighty years ago by Hartley110. 
However, the mechanism of isomerization is still of interest and there is a lot of 
controversy about it. The rotation about the N–N bond with a rupture of the π bond is 
one possibility. In the other, the molecule has a semilinear and hybridized transition 
state with the π bond intact. The two pathways described are depicted in scheme 2.  
Rotation changes the C–N–N–C dihedral angle while the N–N–C angle remains fixed 
at 120°131. In the inversion mechanism, one N=N–C angle increases to 180° while the 
C–N=N–C dihedral angle remains fixed at 0° with one sp-hybridized azo-nitrogen 
atom132. Also, concerted-inversion and inversion-assisted rotation mechanisms are in 
discussion107.  
Relaxation to trans and cis is allowed from all transition states. Thermal relaxation 
occurs via rotation, whereas photochemically both routes seem to be 
accomplishable133. First, a rotation mechanism with little inversion contribution has 
been favoured, but more recently inversion is strongly supported134,135. Calculations 
report both pathways to be energetically accessible136,137. The preferred pathway 
depends on the substitution pattern and the environment138.  
Upon isomerization, the characteristics of azobenzenes change. The phenyl rings are 
twisted about 55° out of plane from the azo group, the distance between the 4 and 4' 
positions is reduced from 0.99 nm in the trans to 0.55 nm in the cis state and the 
dipole moment increases from near zero for trans to 3.1 D for cis110,139-141. 
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Scheme 2: Azobenzene isomerization. The isomerization from (E)-azobenzene (1) (left) to the (Z)-isomer 
(right) can, inter alia, proceed via inversion (top) or through rotation (bottom).  
 
Chapter 5: Azobenzenes in biology 
 
5.1 General background 
Chapter 5 mainly refers to a book and a review published in 2009 and 2011, 
respectively106,142. The most interesting property of azobenzenes is the 
conformational change they undergo upon irradiation, and in combination with their 
geometrically rigid structure the molecules have a great potential for different 
applications5,143-146. Diverse biological processes such as photosynthesis and vision 
are triggered by light147,148. Here, proteins have light sensitive properties in regard to 
the chromophore they harbour. Opsin, for example, is regulated through cis/trans 
isomerization of the reversibly bound cofactor retinal149.  
One of the earliest studies of azobenzenes in biological systems regarded these 
molecules in model membrane systems, and pioneering work with azobenzenes and 
acetylcholine receptor channels in the late 1970s showed their potential for future 
investigations150,151. The important changes of properties such as molecular shape 
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and dipole moment can be imparted to structures hosting the azobenzene. The 
volume required for isomerization via inversion and rotation is about 0.12 nm3 and 
0.38 nm3, respectively, and the force generated is on the nanoscale117,152-154. In 
molecular dimensions this is a very large volume and therefore it is ideal for affecting 
host systems like proteins155. The isomerization of azobenzenes is in the picosecond 
timescale, thus faster than most biological processes156,157. 
Photoregulated polypeptides with reversibel α-helix to β-sheet conversions or DNA-
binding have been investigated158-162. Also, light dependent activity control of 
enzymes such es papain, chymotrypsin, lysozyme, tyrosinase and of restriction 
enzymes have been in the context of research163-166. Other research topics are the 
incorporation of non-natural chiral azobenzene amino acids into proteins and 
monitoring of protein folding167-170. Moreover, light can also be a powerful external 
stimulus to trigger a change of the properties of effectors such as membrane proton 
pumps. A bacteriorhodopsin analog hosting an azobenzene rather than retinal was a 
model for studying rhodopsin and the physicochemical properties of the complex171.  
 
5.2 Photoswitchable ligands 
The photocontrol of proteins can be achieved via two different approaches. On the 
one hand, azobenzene photoswitches can be directly used to influence the protein 
structure and thereby function by crosslinking experiments or incorporation of 
azobenzenes into proteins168,172-176. On the other hand, protein function can be 
controled with photoswitchable ligands. In contrast to the caging approach with 
irreversible photochemistry the most widely used class of azobenzene photoswitches 
are reversible ones177. 
Ligands in general control the function of many proteins by means of binding to their 
active sites, thereby activating or inhibiting their response. Photochromic ligands 
(PCLs) are ligands, which are conjugated to an azobenzene. With different 
wavelengths of light, the azobenzene can be reversibly isomerized affecting the 
ligand structure and activity. Photoswitched tethered ligands (PTLs) act the same 
way as PCLs, but can be additionally attached to the protein, for example via 
conjugation to a cysteine.  
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Erlanger and Lester have performed essential work with photoswitchable ligands of 
the nicotinic acetylcholine receptor and with blockers on chymotrypsin178-180. In 1991, 
Gramicidin, a small protein ion channel, has been turned photosensitive181-183.  
Trauner, Isacoff and Kramer applied this concept of photo-controling ion channels to 
K+ channels and iGluRs5,146. By switching between cis and trans states of the 
azobenzene, substituents on the phenyl ring concomittant move and perform a task. 
Initially, K+ ion channels could be gated with light by reversibly blocking or unblocking 
the pore184-186. The experiments showed high spatiotemporal precision and the 
possibility to quickly and cleanly turn a biological process on and off using light in 
combination with azobenzenes. More recently, iGluRs could be controlled with light 
by conjugating an azobenzene to the neurotransmitter glutamate. After transferring 
the PTL approach, also the PCL strategy has been applied to these ligand-gated ion 
channels6,187.  
In figure 5, 4-Gluazo (2), a PCL reversibly acting on iGluRs, is shown. In the trans 
configuration (500 nm) the ligand binds to the LBD and upon binding the LBD closes 
like a clamshell. This closure is allosterically coupled to the opening of the pore. In 
contrast, with the ligand in its cis configuration (380 nm), the clamshell cannot close 
significantely. Therefore, the channel remains in its closed state. However, in order to 
confirm this mode of action, an image of 4-Gluazo (2) bound to its target would be 
highly informative. X-ray crystallography provides the most direct way of forming 
images of macromolecules like proteins. With a 3-D image at atomic resolution, 
detailed information about the binding mode can be obtained. 
Biological systems like hippocampal neurons and Purkinje neurons have been 
photoregulated in vitro with this glutamate derivative188. The PTL strategy with light-
gated iGluR (LiGluR) has also been applied in vivo, and the behaviour of a zebrafish 
could be controlled with light189. Although the PTL approach shows a high degree of 
specificity, it is often more practical to target wild type systems. For example, the 
expression of modified genes may have disadvantages under certain environments 
like the human retina142.  
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Figure 5: Schematic mode of action and chemical structure of the photoswitch 4-Gluazo (2). (A) Schematic 
representation of iGluRs with the ATD (red), the LBD (blue) and the TMD (green). The membrane is shown as a 
gray rectangle. The trans configuration of the switch stabilizes the LBD in the closed, active conformation and 
allosterically opens the pore (left), whereas the cis form prevents the LBD from closure upon binding (right). (B) 
Chemical structure of 4-Gluazo (2) in the trans state (500 nm) and in the cis state (380 nm). 
 
The photoswitchable ligand approach has also been applied to other and new targets 
like nicotinic acetyl choline and GABAA receptors, lately190-193. Basically, it is possible 
to reprogram a wealth of photoinactive biological systems into phototriggerable 
systems by incorporating azobenzenes, and the studies in this field range from 
answering fundamental questions to the exploitation of applications. 
However, the use inside living organsims is more complicated, since azobenzenes 
have to fulfill several prerequesites in order to function in vivo. Extracellular LBDs of 
iGluRs have been targeted194. Though, in order to address targets intracellularly, the 
photoswitch should be membrane permeable. Also, the wavelength used for 
isomerization should be compatible with cells and tissues. Moreover, the azobenzene 
must be stable in the reducing intracellular environment195,196. Some azobenzenes 
could be reduced by glutathione in vitro, while others survived an overnight period, 
and experiments with azobenzenes have already been successfully conducted inside 
cells with excellent photoswitching for at least two days197-200.  
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Chapter 6: Directed evolution 
 
6.1 Ribosome display 
Chapter 6 is based on a review published in 2012201. Protein design by evolutionary 
mimicry can be divided into three parts. First, mutations are introduced to randomize 
genes. Within the second step, the selection process, interesting molecules are 
separated. Members with particular properties can be identified either by scrutinizing 
each member individually or by testing all members simultaneously. Finally, during 
amplification beneficial mutations accumulate202.  
In nature, peptides and proteins have, due to stability reasons, mainly replaced RNA 
ligands during evolution. With a nucleic acid selection method termed systematic 
evolution of ligands by exponential enrichment (SELEX) the in vitro evolution of 
functional proteins has been achieved203. However, the first entirely in vitro performed 
evolution technology for proteins is ribosome display. After key observations, 
ribosome display has first been described in 1994 and Plückthun reported the first 
application to whole proteins in 1997204-206. The selection method couples phenotype 
(protein) and genotype (mRNA), and random mutagenesis can be incorporated into 
the procedure207.  
In the first step of ribosome display, which is described in scheme 3, DNA with an 
open reading frame (ORF) of the protein of interest is ligated into the ribosome 
display vector pRDV, genetically fusing it 3' to a spacer sequence in-frame. The 
spacers are often derived from the E. coli genes tolA or tonB. At the 5' end, a strong 
promoter for transcription (T7) and a translation initiation region (a ribosome binding 
site (RBS) on mRNA level) is provided. In order to prevent the mRNA from 
degradation through ribonucleases (RNases), the construct should additionally 
include 5' and 3' stemloops206. The final ribosome display construct is obtained by a 
polymerase chain reaction (PCR) amplification of both flanking regions and the library 
insert208. In vitro transcription of this PCR product yields mRNA, which does not 
contain a stop codon. The encoding mRNA is read by the ribosome with the small 
subunit mediating codon–anti-codon contact to the tRNA and cell-free in vitro 
translation can run to the end of this mRNA. 
The protein slides out of the ribosomal tunnel within the large subunit with the peptide 
chain staying connected to the peptidyl-tRNA through an ester bond within the P-site. 
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Scheme 3: Overview of the ribosome display selection cycle and target molecule. A DNA library coding for 
DARPins is ligated into pRDV and amplified by PCR with flanking regions. In vitro transcription yields mRNA and 
after in vitro translation, the ternary mRNA-ribosome-protein complex is used for affinity selection of the 
immobilized target molecule, which is shown in the box in the center. Upon elution and washing, the mRNA is 
isolated, reverse transcribed and amplified by PCR. This cycle can be repeated iteratively with the selected pools 
of binders until a binding protein with high affinity has evolved. 
 
Thus, neither protein nor mRNA can leave, generating the ternary complex consisting 
of displayed proteins and mRNA with the ribosome as the connector. An unstructured 
region of the protein occupies the ribosomal tunnel and correlates to the spacer on 
DNA level. Between 20 and 30 C-terminal amino acids are covered by the ribosome 
and best results have been achieved with a much more longer spacer209-211. The 
upstream encoded protein is outside the ribosome, can fold correctly and there is 
sufficient space and flexibility to recognize and interact with ligands. Nascent proteins 
can fold co-translationally in a cell free system on ribosomes and the crystal structure 
of the large ribosomal subunit provides the basis for understanding this 
process212,213. After an optimized period of time with the amount of ternary complex 
being at the maximum, translation is stopped by fourfold dilution at low 
temperatures206. These complexes are stable for several days under the appropriate 
conditions214. Next, the ribosomal complexes are exposed to the target of interest in a 
magnesium containing buffer. One possible target for future experiments is biotin 
azobenzene glutamate (BAG) (3), which is shown in the center of scheme 3. The 
INTRODUCTION 
 28 
target includes a biotin moiety in order to be immobilized to a surface via streptavidin, 
neutravidin or avidin interactions. The overall ligand contains a 30 Å linker towards 
the biotin moiety, such that the actual ligand part is still accessible to the protein and 
not hidden in the streptavidin binding pocket. Proteins binding to the target are 
enriched on the target and competitors are used to wash out binders with low affinity 
and selectivity. After selection, the small and large ribosomal subunits are eluted and 
dissociated by the addition of EDTA. The mRNAs are directly isolated, reverse 
transcribed and PCR amplified for the transcription of the next cycle of ribosome 
display. Also, random mutagenesis, dNTP analogues or low-fidelity DNA 
polymerases could be implemented at this stage to diversify the initial library, if 
evolution is desired215-217. Only proteins that survived the selection will be further 
used, and during all following selections the mutated proteins have to compete with 
their progenitors214. Thus, this technology allows continuous expanding of new 
diversity during selection.  
In the course of a standard ribosome display reaction 1 – 3 x 1013 mRNA molecules 
are applied and from the amount of E. coli extract used, a sufficient excess of about 
1 – 4 x 1014 assembled ribosomes pass each cycle. With the screening of very large 
libraries, the possibility to select high affinity binders increases tremendously218. 
Moreover, in contrast to phage technologies, there is no need to introduce the 
genetic information into cells, which can be quite laborious and library-size limiting219-
221. Furthermore, in vitro methods show a higher degree of control216. In ribosome 
display transcription and translation can be carried out either in coupled or in 
separate reactions, depending on the conditions. T7 RNA polymerase for example 
requires β-mercaptoethanol, which is reductive, but the generation of disulfide bonds 
in proteins requires oxidizing conditions222,223. Individual steps can be tailored to the 
optimal conditions of the protein species assayed.  
With the use of a ribosome display system specific binders can be identified from a 
pool of variants or a given structure can evolve in order to generate new or improved 
functions224,225. Besides identifying or enhancing binding interactions, factors like 
enzymatic turnovers, protein stability and biophysical properties in general could be 
influenced, too226-228. Ribosome display can be combined with other selection 
technologies and at the end of the ribosome display procedure individual mutants are 
expressed in E. coli and can be analyzed by different assays229,230.  
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6.2 DARPins 
Proteins comprising an ankyrin repeat motif mediate key protein–protein interactions 
in nature231,232. These proteins have repeating structural motifs of 20 – 50 amino 
acids which stack together to form elongated stable structures to allow large surface 
areas for potential binding233.  
First, ribosome display evolved and selected specific antibody scFv fragments from 
immune libraries225. More recently, DARPins, which are artificial antibody mimetic 
binding proteins, have been used with ribosome display successfully, too234.  
DARPins contain no cystein residues, are robust in engineering, show favorable 
biophysical properties and fold extremely well in an in vitro translation system. 
DARPins consist of a β-turn followed by two antiparallel α-helices and a loop 
reaching the β-turn of the next repeat235,236. Overall, the repeating units are a 33 
amino acid sequence and seven residues can be randomized. The theoretical 
diversity of this module is 7.2 x 107. Randomizing these seven residues is enough to 
screen sufficient sequence space without destroying the structure and function of the 
protein. Moreover, one domain usually consists of four to six stacking repeats, 
thereby potentiating the theoretical diversity232.  
DARPins have been generated through consensus and structure based design. The 
introduction of N- and C-terminal capping repeats is essential for efficient folding and 
avoids aggregation. While the internal ankyrin repeats have two hydrophobic 
interfaces, the capping repeats only have one. Instead of the second interface, they 
have a solvent exposed hydrophilic surface10. Thus, the hydrophobic core is shielded 
from the solvent and a concave, groove-like binding surface is generated. The overall 
structure is stabilized by hydrophobic interactions and hydrogen bonds within and 
between adjacent repeats.  
The domains comprise a variable and modular target-binding surface and typically 
interact with their partners via the protruding β-turns and the following α-helices. 
There are numerous possibilities for binding a diverse set of ligands in a specific 
manner, and high affinity binders, some with novel binding specifities, could already 
be generated down to the picomolar range234,237-241. Moreover, DARPins allow 
addition, deletion and exchange of individual repeats10,240,242,243. Most of the 
characteristics mentioned above are in demand for biotechnological applications.  
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Chapter 7: Bonus 
 
7.1 Glutamate receptor antagonists 
The synapse is the site of action of external regulation, i.e. the influence of drugs and 
toxins. Numerous anaesthetics affect synaptic transmission and synapses are the 
site of a wide range of pathological disorders17. iGluRs may be important in various 
pathological conditions and AMPA antagonists may be good candidates for clinical 
development, as they lack the psychotomimetic action and neurotoxicity observed 
with NMDA antagonists244. 
Neuroprotective effects with the competitive AMPA receptor antagonist NBQX have 
first been reported in gerbil global ischaemia, but clinical development has been 
stopped due to the low solubility and the risk of formation of crystals in the tubuli of 
the kidney245,246. The introduction of a phosphonate group has improved the solubility 
of quinoxaline diones while maintaining the activity and ZK200775 has had a long 
therapeutic window. The molecule has made it to the clinic and has progressed to 
phase IIa, but has then been abandonned247.  
Newer molecules appear to show increased solubility, selectivity for various iGluR 
subunits and seem to produce more robust effects244. The newly developed 
antagonists morpholino bisphosphonate (MOBIPHOS) (4), shown in figure 6, is of 
interest as neuroprotective agent. Moreover, this molecule could possibly be turned 
into a photoswitchable antagonist. 
 
Figure 6: MOBIPHOS (4). An AMPA receptor antagonist. 
 
 
 
 
PO3H2
PO3H2
N
O
(4)
INTRODUCTION 
 31 
7.2 Molecular motors 
Another application of azobenzenes is the photo-control of DNA. Photoswitchable 
molecules can interact with oligonucleotides but can also be covalently tethered to 
oligonucleotides in order to control gene expression with light248,249.  
An artificial molecular motor based on azobenzenes has already been demonstrated 
and recently linear movement of DNA has been achieved12,250. In principle it may be 
possible to design and build a bio-inspired, light driven artificial molecular motor using 
DNA-Origami and azobenzenes251,252. The fuel for switching the motor between two 
states, a contracted and an extended one, like with two-cycle Otto motors, would be 
light. Myosin switches between two states, too, hydrolysing ATP with the transition 
being activated by Brownian motion253.  
Azobenzene bis(iodoacetamide) (ABA) (5), depicted in figure 7, could be used to 
incorporate an azobenzene into DNA. This type of molecule can be directly attached 
to a modified DNA backbone via its bis(iodoacetamide) moiety through reaction with 
a phosphorothioate. 
 
Figure 7: ABA (5). An azobenzene with two attachment sites. 
 
The molecular motor would consist of DNA and would glide on a track consisting of 
DNA as well. The track would exhibit an affinity gradient repeating itself within each 
monomer. One could imagine this for example in the context of a charged track. In 
contrast to the rail, the molecular motor would be asymmetric with a forward negativ 
and a backward positive charge. Moreover, the molecular motor would contain the 
azobenzene switch. A structural element, for example two rings, would keep the 
motor on the track. Switching with light between the two different azobenzene 
configurations would move the motor away from or close to the track. The movement 
of the motor would be driven by Brownian motion254.  
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7.3 Ortho-substituted azobenzenes 
The properties of azobenzenes can be influenced by different substituents. Bulky 
ortho substituted azobenzenes can be stable in both configurations. For example, 
tetramethyl substituted azobenzenes, like 2,2',6,6'-tetramethyl – quaternary-
ammonium – azobenzene – quaternary-ammonium (QAQ) (6), pictured in figure 8, is 
a Kv channel blocker and exhibits very long half-lifes of the cis-isomer13,255. This 
property is ideal for monitoring the molecular chirality of the azobenzene induced by 
circularly polarized light. A possible enrichment of one enantiomer upon exposure to 
right or left circularly polarized light could possibly be interesting for different 
applications in material science and technology256,257. 
Other ortho-modified azobenzenes allow photoswitching without UV light. This might 
be useful for biological applications, because UV light can lead to sideeffects in 
biological systems, like cellular apoptosis14. Moreover, red-shifted iGluR ligands, 
similar to 2,2',6,6'-tetrachloro – maleimide – azobenzene – glutamate (MAG) (7), 
shown in figure 8, could possibly be used to treat blindness in humans suffering from 
macular degeneration and retinitis pigmentosa8.  
 
Figure 8: 2,2',6,6'-tetramethyl QAQ (6) and 2,2',6,6'-tetrachloro MAG (7). Ortho-substituted azobenzenes with 
interesting properties. 
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Chapter 8: Co-crystallization of an azobenzene modified ligand with 
iGluR-LBDs  
In order to study the specific interactions of 4-Gluazo (2) with the GluK2- and GluA2-
LBDs a co-crystal structure is highly revealing. Therefore, the photoswitch has to be 
prepared. Moreover, the LBDs of GluK2 and GluA2 have to be expressed and 
purified. With both, photoswitch and protein in a state of high purity, affinity 
measurements and co-crystallization experiments have been performed. Finally, 
diffraction data have been collected from crystals and the structure has been solved, 
showing the protein–ligand interactions in molecular detail. Results are illustrated in 
chapter 15. The overview of the synthesis of 4-Gluazo (2) is depicted in scheme 4. 
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Scheme 4: Synthesis of 4-Gluazo (2). 
 
The preparation is achieved starting from L-pyroglutamic acid (8), which is protected 
as an ester using thionylchloride in ethanol to give L-pyroglutamic acid ethyl ester (9), 
which is further protected under Steglich conditions to give N-Boc-L-pyroglutamic acid 
ethyl ester (10). Diastereoselective alkylation of (10) is carried out with LiHMDS and 
propargyl bromide to yield propargyl pyroglutamate (11). Bromination with N-
bromosuccinimide gives bromoalkyne (12), which undergoes a palladium catalyzed 
hydrostannylation, to afford vinyl stannane (13). Iodoazobenzene (14) is obtained by 
the condensation of nitrosobenzene (15) and 4-iodoaniline (16). Stille cross coupling 
of 13 and 14 gives azobenzene pyroglutamate (17). Saponification and 
pyroglutamate hydrolysis yields N-Boc azobenzene glutamic acid (18), which is 
deprotected with TFA to result in 4-Gluazo (2) as the monosodium dihydrate salt6. 
Detailed procedures for the individual steps are specified in chapter 13.2. 
 
In scheme 5 a flow chart is shown, illustrating the different steps towards the co-
crystal structure of the protein and 4-Gluazo (2). In protein crystallography, the purity 
of a protein is the most important requisite. In order to achieve highest purity, 
different methods can be performed. To begin with, a crystallizable construct of the 
protein of interest is required. In this case S1S2 constructs of the GluK2- and GluA2-
LBD (provided by Dr. Mark Mayer) are ligated into the expression vectors pET-22b(+) 
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and pETGQ (derivative of pET30b), respectively. After isolation, amplification and 
validation, the plasmids are transformed into E. coli and the proteins are 
overexpressed and purified. In order to purify the proteins, Ni-NTA affinity 
chromatography, cation exchange chromatography and gel filtration have been 
performed. After Ni-NTA, a thrombin digest is carried out to remove the N-terminal 
histidine tag. Prior to protein–ligand co-crystallization and structure determination, 
affinity measurements are conducted to receive an impression about the strength of 
ligand binding. The detailed experimental methods used for transformation, 
overexpression and purification of iGluR-LBDs and experimental details regarding the 
affinity measurements and the co-crystallization process are described in chapter 
14.2.  
 
Scheme 5: Flow chart of the protein–ligand co-crystallization process. 
 
Chapter 9: Synthesis of an azobenzene target for ribosome display  
The ultimate goal of this research topic is the creation of a protein scaffold, which 
binds to the azobenzene moiety with high affinity and specificity. In order to evolve a 
DARPin based ABP, the target molecule and competitors, which are used in the 
selection process of ribosome display, have to be prepared and characterized. The 
molecules (scheme 6: 3 and 29; scheme 7: 6 and 35) have been sent to the group 
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of Prof. A. Plückthun (University of Zürich, Department of Biochemistry, 8057 Zürich, 
Switzerland; Email: Plueckthun@bioc.uzh.ch). In this group, the ribosome display 
technique with a library of DARPins is going to be carried out in the near future in 
order to develop an ABP. The new binding protein could be regulated with light by 
directly binding to the chromophore and switchable unit. ABPs could affect a wide 
range of life sciences and could in general be used as a toolbox in research. 
Results are described in chapter 16. The synthetic route leading to the target 
molecule BAG (3) is described in scheme 6 and experimental procedures are 
described in chapter 13.3. After protection of (S)-2-pyrrolidone-5-carboxylic acid (8) 
as an ester with tert-butyl acetate in the presence of perchloric acid yielding L-
pyroglutamic acid tert-butyl ester (19), the molecule was further protected to give N-
Boc-L-pyroglutamic acid tert-butyl ester (20)258. 
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                              Scheme 6: Synthesis of BAG (3). 
 
Diastereoselective allylation with LiHMDS and allyl bromide yields allylpyroglutamate 
(21). Grubbsʼ cross metathesis with acrylic acid gives acrylic acid pyroglutamate (22), 
which undergoes hydrogenation with palladium on carbon to afford carboxylic acid 
pyroglutamate (23). 2,6-dimethyl-4-nitroaniline (24) is obtained by starting from 2,6-
dimethylaniline (25) in a tosylation – nitration – detosylation three step procedure via 
the intermediates N-tosyl-2,6-dimethylaniline (26) and N-tosyl-2,6-dimethyl-4-
nitroaniline (27)259. Oxidative coupling of two equivalents of 2,6-dimethyl-4-
nitroaniline (24) with potassium permanganate yields nitroazobenzene (28), which is 
reduced to aminoazobenzene (29) with sodium sulfide. Carboxylic acid 
pyroglutamate (23) and aminoazobenzene (29) are coupled in the presence of EDCl 
and HOBt to give aminoazobenzene pyroglutamate (30), which is acetylated to yield 
N-acyl-aminoazobenzene pyroglutamate (31). Hydrolysis of the ɣ-lactam with 
aqueous lithium hydroxide gives azobenzene glutamic acid ester (32), which is 
converted to the mixed anhydride with iso-butyl chloroformate and reacted in situ with 
1,11-diamino-3,6,9-trioxaundecane to give azobenzene glutamic acid ester γ-amide 
(33). An activated biotin derivative is generated by the action of PFP-TFA on biotin 
and azobenzene glutamic acid ester γ-amide (33) is added in situ to the crude 
pentafluorophenyl ester. Thus, biotin azobenzene glutamic acid ester γ-amide (34) is 
realized. Finally, deprotection with TFA yields BAG (3).  
BAG is composed of a biotin, an azobenzene, a glutamate and a linker moiety. For 
the technique of ribosome display, the biotin functionality is needed in order to 
immobilize the molecule on the surface. The linker, in combination with the glutamate 
part, ensures sufficient distance between the biotin and the azobenzene part, which 
is the target of the DARPin to be evolved.  
In order to generate a specific high affinity binder, several competitors are needed 
during the selection process of ribosome display. Therefore, azobenzene glutamic 
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acid γ-amide (35), aminoazobenzene (29) and 2,2',6,6'-tetramethyl-QAQ (6) have 
also been prepared and experiments are described in chapter 13.3 and 13.4. 
The preparation of aminoazobenzene (29) is described in scheme 6. The synthesis 
of azobenzene glutamic acid γ-amide (35) and 2,2',6,6'-tetramethyl-QAQ (6) is shown 
in scheme 7. Global deprotection of azobenzene glutamic acid ester γ-amide (33) 
with TFA yields azobenzene glutamic acid γ-amide (35). The synthesis of 2,2',6,6'-
tetramethyl-QAQ (6) starts with the conversion of the betaine analogon (36) to the 
betaine acid chloride (37), which is added to aminoazobenzene (29) in a double 
amidation reaction to give 2,2',6,6'-tetramethyl-QAQ (6).  
 
Scheme 7: Synthesis of azobenzene glutamic acid γ-amide (35) and 2,2',6,6'-tetramethyl-QAQ (6). 
 
Azobenzene glutamic acid γ-amide (35) resembles the structure of BAG (3) without 
the biotin part. In contrast to BAG (3), aminoazobenzene (29) and 2,2',6,6'-
tetramethyl-QAQ (6) are sterically less and more demanding at the 4 and 4' positions 
of the azobenzene core, respectively. With these three competitors, low affinity 
binders and unspecific binders can be removed during the selection process of 
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competitor, are washed away. Accordingly, the background of molecules binding 
unspecifically is reduced. An additional strategy to develop high affinity binders is to 
immobilize just a minimal amount of the target. Binders with different affinities will 
equilibrate and just high affinity binders will occupy all the sites.  
 
Chapter 10: Structure-based design and synthesis of an AMPA 
receptor antagonist 
Co-crystallisation experiments of GluA2-LBD and 4-Gluazo (2) resulted in a LBD 
dimer of dimers structure occupied by 2-(N-morpholino)ethanesulfonic acid (MES), 
sulfate and ethylene glycol, which is described in chapter 15.7. This structure 
provides molecular insights into key interactions between MES, a sulfate and the 
receptor and paves the way for molecular modeling studies, which are illustrated in 
figure 9. MES in combination with the sulfate ion have been used as a lead structure 
for the design of MOBIPHOS (4), which is a GluA2 antagonist.  
 
Figure 9: Longitudinal cross section of GluA2-LBDMES and design of MOBIPHOS (4). (A and B) Surface 
representation and cross section of the GluA2-LBD with D1 and D2 coloured in shades of green (D1: dark green, 
D2: light green) with (A) MES and sulfate (sticks) and (B) designed (S)-MOBIPHOS (4, mixed salmon and gray 
sticks) which is superimposed onto the MES and sulfate positions. (C) Close-up view with the protein ligand-
binding cavity shown as a wheat surface with (S)-MOBIPHOS (4, mixed salmon and gray sticks), water molecules 
(red spheres), sulfate (sticks) and parts of D1 (dark green cartoon) and D2 (light green cartoon). 
 
MOBIPHOS (4) is preshaped to match the geometry of the binding site of the protein. 
In order to restrict the conformational flexibility and to gain high hydrophobicity, a 
phenyl ring is introduced to combine the position of the sulfate ion with MES. A high 
degree of hydrophobicity and conformationally constrained ligands show higher 
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specificity and affinity compared to more hydrophilic and more relaxed counterparts, 
because of more solvent release and a smaller conformational entropy loss upon 
binding260. Different substitution patterns of the phenyl ring have been applied and 
meta substitution have resulted in the best alignment. This sort of substitution can 
best balance the low structural stability of the ligand-binding region of the apo-like 
protein conformation. Afterwards, differnt additional substituents can be introduced by 
molecular engineering. For synthetic reasons, the sulfonate moiety of MES and the 
sulfate ion are replaced by phosphonate moieties, which mimic these two groups.  
Finally, MOBIPHOS (4) is modeled into the GluA2-LBDMES structure (Fig. 9 A) in a 
way, that it perfectly aligns with MES and the sulfate ion (Fig. 9 B and C). This does 
not represent the energetically most favorable conformation of MOBIPHOS (4), but 
with the angle of clamshell closure of the protein being variable, the LBD might adopt 
a slightly different orientation compared to the GluA2-LBDMES structure, when it is 
bound to MOBIPHOS (4). In order to eliminate this potential problem the derivative 
MOBIPHOSen (38) has been prepared in addition to MOBIPHOS (4). These two 
molecules exhibit different dihedral angles between the phenyl and the phosphonate 
group.  
The synthesis of MOBIPHOS (4) and MOBIPHOSen (38) is depicted in scheme 8 
and starts with a Horner-Wadsworth-Emmons (HWE) reaction of isophtalaldehyde 
(39) to give the bisphosphonate (40). The morpholine part is introduced via a newly 
developed 1,4-addition method for phosphonates to yield morpholino bisphosphonate 
(41). The remaining double bond is hydrogenated with platinum on carbon to produce 
morpholino dihydrobisphosphonate (42). Finally, the phosphonate moieties are 
deprotected with TMSI to result in MOBIPHOS (4). MOBIPHOSen (38) is prepared by 
deprotection of morpholino bisphosphonate (41) with TMSI. The biological activity of 
the final molecules has been confirmed with electrophysiological experiments and 
detailed synthetic procedures are given in chapter 13.5. Results are depicted in 
chapter 17. 
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Scheme 8: Synthesis of MOBIPHOS (4) and MOBIPHOSen (38). 
 
Chapter 11: Synthesis of an azobenzene with two attachment sites  
The plunger of a light driven molecular motor could be an azobenzene molecule. In 
order to build this molecular motor, ABA (5) has to be prepared and characterized. 
After the synthesis, the molecule has been sent to the group of Prof. T. Hugel (TUM, 
Department of Physics, 85748 Garching,Germany; Email: 
thorsten.hugel@ph.tum.de) and DNA origami and further experiments leading to a 
light driven molecular motor will be carried out in this group.  
The synthesis is described in scheme 9 and starts with the commercially available 
4,4'-diaminoazobenzene (43). After the reaction with two equivalents of chloroacetyl 
chloride in the presence of TEA, a Finkelstein reaction with sodium iodide gives ABA 
(5). Experiments are specified in chapter 13.6 and results are described in chapter 
18.  
 
               Scheme 9: Synthesis of ABA (5). 
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Chapter 12: Synthesis of ortho-substituted azobenzenes 
Ortho-substituted azobenzenes show interesting characteristics. Results of this topic 
are specified in chapter 19. The synthesis of 2,2',6,6'-tetramethyl-QAQ (6), which is 
stable in both azobenzene configurations, is shown in scheme 7 and detailed in 
chapter 13.4. The molecule has been sent to the group of Prof. E. Riedle (LMU, 
Department of Physics, 80538 Munich, Germany; Email: riedle@physik.uni-
muenchen.de), where optical activity studies to examine the possibility of chiral 
induction of a racemic mixture of the azobenzene by exposure to circular polarized 
light will be carried out. Irradiation of the racemate with circular polarized light should 
cause a partial enrichment of one of the enantiomers. 
2,2',6,6'-tetrachloro-MAG (7) is prepared in collaboration with the group of Prof. A. 
Woolley (University of Toronto, Department of Chemistry, M5S 3H6 Toronto, Canada; 
Email: awoolley@chem.utoronto.ca). The synthesis of the building block carboxylic 
acid pyroglutamate (23) is depicted in scheme 6 and is accurately described in 
chapter 13.3. The molecule has been prepared and sent to Toronto, where the 
synthesis towards 2,2',6,6'-tetrachloro-MAG (7) will be completed. The molecule will 
be tested for its switching behaviour and activity on iGluRs with electrophysiological 
experiments.  
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Chapter 13: Chemistry 
 
13.1 General conditions 
All reactions were carried out with magnetic stirring and, if air or moisture sensitive, in 
flame-dried glassware under argon or nitrogen. Syringes, which were used to transfer 
reagents and solvents, were purged with argon or nitrogen prior to use. 
 
13.1.1 Solvents 
Solvents were dried according to standard methods by distillation over drying agents 
as stated below or were purchased and used without further purification. They were 
stored under argon or nitrogen.  
 
Solvents Supplier 
Acetone Acros (water < 0.005%) 
Acetonitrile Acros (over molecular sieves, water < 0.005%) 
Dichloromethane Acros (over molecular sieves, water < 50 ppm) 
Diisopropylethylamine Sigma-Aldrich (continuously refluxed over calcium hydride under nitrogen and 
distilled off) 
Dimethylformamide Acros (over molecular sieves, water < 50 ppm) 
Ethyl acetate Acros (water < 0.005%) 
Methanol Acros (over molecular sieves, water < 0.005%) 
Pyridine Sigma-Aldrich (anhydrous, 99.8%) 
Tetrahydrofuran Acros (continuously refluxed and freshly distilled from sodium benzophenone 
ketyl under nitrogen) 
Triethylamine Sigma-Aldrich (continuously refluxed over calcium hydride under nitrogen and 
distilled off) 
Table 2: Solvents. 
 
13.1.2 Reagents 
Commercially available reagents of > 98% purity were used as obtained. 
Organolithium solutions were titrated prior to use with diphenylacetic acid and 
organozinc solutions were titrated at 0 °C with benzoic acid and (phenyl)[4-
(phenylazo)phenyl]amine as indicator261. Tributyltin hydride (6.8 x 10-1mbar, 75 °C) 
and acrylic acid (44 °C, 20 mbar) were freshly distilled prior to use. 
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13.1.3 Chromatography 
Mixtures were separated and analysed by thin layer chromatography (TLC) using 
precoated [(normal phase: Merck silica gel 60, F254); (reversed phase: Mechery-
Nagel, Silica RP-18W/UV254)] glass plates. Colourless substances were detected due 
to fluorescence quenching under UV light and/or by staining with iodine or with one of 
the solutions below. 
 
Basic KMnO4:  
KMnO4 (0.3 g), K2CO3 (20 g), KOH (0.3 g) in water (300 mL). 
 
CAM: 
Ammonium molybdate (25.0 g), Ce(SO4)2 (5.0 g), conc. H2SO4 (50 mL) in water (450 
mL). 
 
Normal phase flash column chromatography was performed using silica gel (60 Å, 
40 – 63 µm) from Merck. Reversed phase flash column chromatography was 
performed using preparative C18 (125 Å, 55 – 105 µm) bulk packing material from 
waters corporation. The diameters of the columns and the amount of the stationary 
phase were estimated by experience. The solvents for chromatography were distilled 
or used as received in p.a. or HPLC quality. 
 
13.1.4 Chemical analysis 
 
Methods Instruments 
HPLC/LCMS Varian SD1/Agilent 1260 G1964 
(HR-)MS Finnigan MAT 95Q (EI) 
Thermo Finnigan LTQ FT (ESI) 
IR spectroscopy Perkin Elmer Spectrum BX-59343 FT-IR 
Melting point Büchi B-450 
NMR spectroscopy Varian NMR-systems (200, 300, 400, 600 MHz) 
                            Table 3: Analytical methods and instruments. 
 
For nuclear magnetic resonance (NMR) spectra, chemical shifts were reported in 
parts per million (ppm) and refer to tetramethylsilane (TMS, δH: 0.00, δC: 0.00) in 
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CDCl3 as internal standard or were reported relative to the solvent residual signals. 
Melting points were uncorrected and infrared (IR) spectra were detected with a 
Smiths Detection DuraSampleIR II Diamond attenuated total reflection (ATR) sensor 
and were recorded from 4000 – 650 cm-1.  
 
13.2 Preparation of 4-Gluazo6  
 
13.2.1 L-pyroglutamic acid ethyl ester  
L-pyroglutamic acid (25.0 g, 194 mmol) was dissolved in ethanol (360 mL). It was 
cooled to 0 °C and thionylchloride (16.0 mL, 221 mmol) was slowly added to the 
suspension. After stirring for 10 min at the stated temperature, it was allowed to warm 
to room temperature and was stirred for 2 h 30 min. A saturated solution of NaHCO3 
was added and the mixture was extracted with chloroform. The combined organic 
layers were washed with a saturated solution of NaCl, dried over Na2SO4, filtered and 
concentrated in vacuo. The product was allowed to crystallize at 4 °C overnight to 
yield 9 (28.6 g, 182 mmol, 94%) as a colourless solid. The product was directly used 
for the next step without further purification. 
 
 
 
13.2.2 N-Boc-L-pyroglutamic acid ethyl ester  
Triethylamine (72.0 mL, 518 mmol) was added to a solution of L-pyroglutamatic acid 
ethyl ester (9) (27.0 g, 172 mmol), di-tert-butyl dicarbonate (75.4 g, 345 mmol) and 4-
(dimethylamino)-pyridine (3.50 g, 28.6 mmol) in CH2Cl2 (440 mL) and the reaction 
was stirred at room temperature overnight. The mixture was washed with 10% citric 
acid and with a saturated solution of NaCl, was dried over Na2SO4, filtered and 
concentrated in vacuo. Purification by normal phase chromatography (hexanes : 
EtOAc = 3 : 2, Rf = 0.35) and recrystallization from ethanol yielded 10 (40.7 g, 
158 mmol, 92%) as a colourless solid. 
 
N
H
O CO2Et
EXPERIMENTS 
 49 
 
 
mp.: 60 °C. 
IR (ATR): ν~ max (cm
-1) = 2978 (m), 1770 (vs), 1734 (vs), 1701 (m), 1459 (w), 1366 
(m), 1306 (s), 1273 (s), 1209 (m), 1144 (s), 1046 (s), 1025 (s), 905 (w), 842 (w), 778 
(m), 751 (w).  
1H-NMR (300 MHz, CDCl3, 23 °C): δ (ppm) = 4.60 (dd, J = 3 Hz and 12 Hz, 1H), 4.24 
(q, J = 6 Hz, 2H), 2.59 (m, 1H), 2.49 (m, 1H), 2.31 (m, 1H), 2.01 (m, 1H), 1.48 (s, 
9H), 1.28 (t, J = 9 Hz, 3H). 
13C-NMR (75 MHz, CDCl3, 23 °C): δ (ppm) = 173.4, 171.3, 149.3, 83.5, 61.7, 59.0, 
31.1, 27.9, 21.5, 14.2. 
HR-MS (ESI) [M + H]+: calc for [C12H20NO5]+: 258.1333; found: 258.1330. 
 
13.2.3 Propargyl pyroglutamate  
Freshly prepared lithium bis(trimethylsilyl)amide [n-BuLi (23.3 mL, 58.2 mmol, 
2.50 M) was added dropwise to a solution of hexamethyldisilazane (12.4 mL, 
58.4 mmol) in THF (195 mL) at −78 °C and was stirred for 1 h at the stated 
temperature] was added dropwise  to a solution of N-Boc-L-pyroglutamic acid ethyl 
ester (10) (12.0 g, 46.6 mmol) in THF (52.2 mL) at −78 °C. After stirring at −78 °C for 
1 h, propargyl bromide (15.0 mL, 80% in toluene, 174 mmol) was added fast and the 
resulting solution was stirred for additional 2 h at −78 °C. A saturated solution of 
ammonium chloride was added at −78 °C. After extraction with CH2Cl2, the combined 
organic layers were washed with a saturated solution of NaCl, dried over Na2SO4, 
filtered, and concentrated. Purification by normal phase chromatography (hexanes : 
Et2O = 1 : 1, , Rf = 0.45) gave 11 (2.45 g, 8.3 mmol, 18%) as a colourless solid. 
 
NO
OO
CO2Et
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mp.: 78 °C. 
IR (ATR): ν~max (cm
-1) = 3373 (br), 3270 (s), 2981 (m), 1735 (vs), 1710 (vs), 1593 
(m), 1366 (m), 1318 (s), 1259 (m), 1204 (m), 1148 (s), 1017 (m), 666 (m).    
1H-NMR (200 MHz, CDCl3, 23 °C): δ (ppm) = 4.61 (dd, J = 2 Hz and 8 Hz, 1H), 4.28 
(q, J = 6 Hz, 2H), 2.87 (m, 1H), 2.68 (m, 1H), 2.49 (m, 1H), 2.30 (m, 2H), 2.0 (t, J = 2 
Hz, 1H), 1.49 (s, 9H), 1.32 (t, J = 9 Hz, 3H). 
13C-NMR (75 MHz, CDCl3, 23 °C): δ (ppm) = 173.0, 171.2, 149.3, 83.8, 80.1, 70.7, 
61.8, 57.0, 40.7, 27.9, 27.5, 19.4, 14.2. 
HR-MS (ESI) [M + H]+: calc for [C15H22NO5]+: 296.1490; found 296.1490. 
 
13.2.4 Bromoalkyne  
N-bromosuccinimide (1.27 g, 7.14 mmol) and propargyl pyroglutamate (11) (1.91 g, 
6.47 mmol) were dissolved in acetone (26.0 mL). Silver nitrate (97.0 mg, 0.573 mmol) 
was added and the mixture was stirred for 2 h at room temperature. Hexanes were 
added and the mixture was washed with water. After extracting the separated 
aqueous layer with a mixture of diethylether and hexanes (1:1) the combined organic 
layers were dried over Na2SO4 and filtered through a pad of silica. Evaporation of the 
solvent gave 12 (2.32 g, 6.22 mmol, 96%) as a colourless oil (hexanes : Et2O = 1 : 1, 
Rf = 0.45). 
 
 
 
N
Boc
O CO2Et
N
Boc
O CO2Et
Br
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IR (ATR): ν~ max (cm
-1) = 2981 (m), 2936 (m), 1789 (s), 1742 (s), 1717 (s), 1311 (s), 
1147 (vs). 
1H-NMR (200 MHz, CDCl3, 23 °C): δ (ppm) = 4.61 (dd, J = 2 Hz and 10 Hz, 1H), 4.26 
(q, J = 6 Hz, 2H), 2.76 (m, 2H), 2.46 (m, 1H), 2.25 (m, 2H), 1.50 (s, 9H), 1.29 (t, J = 6 
Hz, 3H).  
13C-NMR (75 MHz, CDCl3, 23 °C): δ (ppm) = 172.9, 171.1, 149.3, 83.8, 76.1, 61.8, 
57.0, 40.7, 40.6, 27.9, 27.6, 20.7, 14.2. 
HR-MS (EI) [M]+: calc for [C15H20BrNO5]+: 373.0525; found: 373.0529. 
 
13.2.5 Vinyl stannane  
Triphenylphosphine (34.0 mg, 0.13 mmol), bromoalkyne (12) (1.22 g, 3.26 mmol), 
and tris(dibenzylideneacetone)dipalladium (15.0 mg, 0.0170 mmol) were dissolved in 
THF (17.0 mL) and tributyltin hydride (1.80 mL, 6.70 mmol) was added dropwise over 
30 min at 0 °C. After stirring the mixture at room temperature for 2 h, a saturated 
aqueous solution of KF was added. The reaction mixture was extracted with hexanes 
and the separated organic layer was washed with water and a saturated solution of 
NaCl. After drying over Na2SO4, filtration and evaporation of the solvent, the crude 
product was purified by normal phase chromatography (hexanes : Et2O = 5 : 1; 
Rf = 0.20) to yield 13 (1.57 g, 2.67 mmol, 82%) as a colourless oil. 
 
 
 
IR (ATR): 2959 (m), 2925 (m), 1793 (s), 1748 (s), 1718 (s), 1458 (w), 1368 (m), 1315 
(vs), 1189 (s), 1153 (vs), 1027 (m), 773 (m). 
1H-NMR (300 MHz, CDCl3, 23 °C): δ (ppm) = 5.97 (m, 1H), 5.87 (m, 1H), 4.56 (dd, J 
= 3 Hz and 12 Hz, 1H), 4.25 (q, J = 6 Hz, 2H), 2.77 (m, 2H), 2.25 (m, 1H), 2.15 (m, 
1H), 2.04 (m, 1H), 1.51 (s, 9H), 1.48 (m, 6H), 1.29 (m, 9H), 0.89 (m, 15H). 
13C-NMR (75 MHz, CDCl3, 23 °C): δ (ppm) = 174.6, 171.4, 149.5, 144.4, 132.0, 83.5, 
61.6, 57.2, 41.2, 38.6, 29.1, 27.9, 27.8, 27.2, 14.2, 13.7, 9.4. 
N
Boc
O CO2Et
Bu3Sn
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MS (EI): m/z (%) = 530.4 (85) [M – C4H9], 514.4 (7). 
 
13.2.6 Iodoazobenzene  
Nitrosobenzene (15) (2.00 g, 18.6 mmol) was dissolved in glacial acetic acid 
(130 mL) and 4-iodoaniline (16) (3.40 g, 15.5 mmol) was added to the solution. After 
stirring at 40 °C for 12 h, the mixture was diluted with water and extracted with 
CH2Cl2. The organic layer was washed with a saturated solution of NaCl, dried over 
Na2SO4, filtered, and concentrated in vacuo. Purification by normal phase 
chromatography (100 : 1, hexanes : Et2O, Rf = 0.29) afforded 14 (4.34 g, 14.1 mmol 
91%) as an orange solid. 
 
 
 
mp.: 95 °C. 
IR (ATR): ν~ max (cm
-1) = 3072 (w), 1563 (m), 1474 (s), 1391 (m), 1294 (m), 1049 (m), 
998 (s), 838 (s), 768 (s).  
1H-NMR (200 MHz, CDCl3, 27 °C): δ (ppm) = 7.89 (m, 4H), 7.68 (m, 2H), 7.50 (m, 
3H). 
13C-NMR (75 MHz, CDCl3, 23 °C): δ (ppm) = 152.4, 151.9, 138.4, 131.4, 129.2, 
124.5, 123.0, 97.7. 
HR-MS (ESI) [M + H]+: calc for [C12H10IN2]+: 308.9880; found: 308.9876. 
 
13.2.7 Azobenzene pyroglutamate  
Vinyl stannane (13) (1.27 mg, 2.17 mmol), 4-iodoazobenzene (14)  (514 mg, 
1.67 mmol), tetrakis(triphenylphosphine)palladium (96.0 mg, 0.0830 mmol) and 
copper iodide (32 mg, 0.168 mmol) were dissolved in DMF (50.0 mL) and stirred at 
65 °C overnight. Water (770 mL) was added and the mixture was extracted with 
EtOAc. The combined organic layers were washed with a saturated solution of NaCl, 
dried over Na2SO4, filtered and concentrated. Purification by normal phase 
N N
I
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chromatography (hexanes : Et2O = 4 : 1, Rf = 0.23) yielded 17 (741 mg, 1.55 mmol, 
93%) as an orange solid.  
 
 
 
mp.: 115 °C. 
IR (ATR): ν~ max (cm
-1) = 2957 (br), 1782 (vs), 1746 (s), 1597 (w), 1463 (w), 1389 (w), 
1368 (w), 1314 (m), 1286 (m), 1252 (m), 1195 (m), 1148 (s), 1032 (w), 838 (w), 764 
(w), 685 (m).  
1H-NMR (600 MHz, CDCl3, 23 °C): δ (ppm) = 7.89 (m, 4H), 7.48 (m, 5H), 6.56 (d, J = 
16 Hz, 1H), 6.30 (m, 1H), 4.60 (dd, J = 2 Hz and 10 Hz, 1H), 4.25 (q, J = 8 Hz, 2H), 
2.79 (m, 2H), 2.43 (m, 1H), 2.23 (m, 1H), 2.11 (m, 1H), 1.51 (s, 9H), 1.29 (t, J = 8 Hz, 
3H). 
13C-NMR (150 MHz, CDCl3, 23 °C): δ (ppm) = 174.2, 171.2, 152.7, 151.7, 149.4, 
139.6, 132.4, 130.9, 129.1, 127.9, 126.8, 123.3, 122.8, 83.6, 61.7, 57.1, 41.6, 33.7, 
27.9, 27.8, 14.2. 
HR-MS (ESI) [M + H]+: calc for [C27H32N3O5]+: 478.2334; found: 478.2327. 
 
13.2.8 N-Boc azobenzene glutamic acid  
An aqueous solution of LiOH (60.0 mL, 60 mmol, 1 M) was slowly added to a solution 
of azobenzene pyroglutamate (17) (530 mg, 1.11 mmol) in THF (60.0 mL). After 
stirring at room temperature for 2 h, the mixture was acidified to pH = 2 with an 
aqueous solution of HCl (1 M) and extracted with EtOAc. The combined organic 
layers were dried over Na2SO4, filtered, and concentrated. Purification by normal 
phase chromatography (CH2Cl2 : MeOH : AcOH = 94 : 4 : 2, Rf = 0.26) afforded 18 
(467 mg, 1.00 mmol, 90%) as an orange solid. 
 
N
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mp.: 85 °C. 
IR (ATR): ν~max (cm
-1) = 2976 (br), 1707 (vs), 1394 (w), 1154 (m). 
1H-NMR (400 MHz, CD3OD, 27 °C): δ (ppm) = 7.86 (m, 4H), 7.51 (m, 5H), 6.53 (d, J 
= 16 Hz, 1H), 6.38 (m, 1H), 4.17 (m, 1H), 2.70 (m, 1H), 2.56 (m, 1H), 2.51 (m, 1H), 
2.24 (m, 1H), 1.79 (m, 1H), 1.42 (s, 9H). 
13C-NMR (100 MHz, CD3OD, 27 °C): δ (ppm) = 176.7, 174.6, 156.7, 152.7, 151.5, 
140.4, 131.4, 130.7, 128.8, 126.6, 122.7, 122.3, 79.1, 78.0, 52.0, 41.9, 35.9, 33.0, 
27.3. 
HR-MS (ESI) [M + H]+: calc for [C25H30N3O6]+: 468.2126; found: 468.2132. 
 
13.2.9 4-Gluazo  
Anisole (0.940 mL, 8.59 mmol) and N-Boc azobenzene glutamic acid (18) (136 mg, 
0.291 mmol) were dissolved in CH2Cl2 (9.40 mL). TFA (5.10 mL, 69.0 mmol) was 
added dropwise at 0 °C and after stirring the mixture at room temperature for 1 h, 
Et2O (85.0 mL) was added. The resulting precipitate was separated from the solution 
by centrifugation. The remaining solution was concentrated and subsequently 
redissolved in a minimal amount of methanol and a saturated solution of NaHCO3. 
Purification by reversed phase chromatography (H2O : MeOH = 100:0 → 70:30) gave 
2 (61.8 mg, 0.146 mmol, 50%) as an orange solid as the monosodium dihydrate salt. 
  
N N
HO2C CO2H
NHBoc
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mp.: 290 °C (dec.). 
IR (ATR): ν~max (cm
-1) = 3030 (br), 1565 (vs), 1401 (s), 1153 (m), 766 (m), 686 (m). 
1H-NMR (400 MHz, D2O, 27 °C): δ (ppm) = 7.55 (m, 2H), 7.50 (d, J = 8 Hz, 2H), 7.38 
(m, 3H), 7.32 (d, J = 8 Hz, 2H), 6.35 (d, J = 16 Hz, 1H), 6.20 (m, 1H), 3.58 (m, 1H), 
2.42 (m, 1H), 2.34 (m, 1H), 2.28 (m, 1H), 2.04 (m, 1H), 1.81 (m, 1H).  
13C-NMR (100 MHz, D2O, 27 °C): δ (ppm) = 182.5, 175.1, 152.0, 150.7, 140.7, 
131.5, 130.7, 130.5, 129.4, 126.9, 122.9, 122.3, 53.5, 44.9, 36.2, 33.0. 
MS (ESI) [M + H]+: calc for [C20H22N3O4]+: 368.1602; found: 368.1606. 
 
13.3 Preparation of BAG  
 
13.3.1 N-tosyl-2,6-dimethylaniline259  
Tosyl chloride (63.9 g, 336 mmol) was dissolved in pyridine (75.0 mL). 2,6-
dimethylaniline (25) (35.0 mL, 281 mmol) and 4-(dimethylamino)-pyridine (500 mg, 
4.00 mmol) were added and the mixture was heated to 125 °C for 4 h. The solution 
was allowed to cool to room temperature and was added to an aqueous solution of 
HCl (2 M, 250 mL). After extracting with Et2O, the solvent was removed in vacuo and 
the remaining crude product was recrystallized from ethanol. 26 (64.2 g, 233 mmol, 
83%) was isolated as a colourless solid (hexanes : EtOAc = 4 : 1; Rf = 0.44).  
 
 
 
NHS
O
O
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mp.: 134 °C.  
IR (ATR): max (cm
-1) = 3267 (w), 1597 (w), 1370 (w), 1325 (m), 1157 (s), 672 (s). 
1H-NMR (400 MHz, CD3OD, 25 °C): δ (ppm) = 7.58 (d, J = 8 Hz, 2H), 7.29 (d, J = 8 
Hz, 2H), 7.01 (m, 3H), 2.41 (s, 3H), 1.99 (s, 6H). 
13C-NMR (100 MHz, CD3OD, 25 °C): δ (ppm) = 143.3, 138.9, 137.9, 133.1, 129.2, 
128.1, 127.1, 126.7, 20.0, 17.6. 
HR-MS (EI) [M]+: calc for [C15H17NO2S]+: 275.0980; found: 275.0975. 
 
13.3.2 N-tosyl-2,6-dimethyl-4-nitroaniline259  
Water (435 mL), glacial acetic acid (435 mL) and concentrated nitric acid (90.0 mL) 
were added to N-tosyl-2-6-dimethylaniline (26) (21.2 g, 76.8 mmol). Sodium nitrite 
(10.6 g, 154 mmol) was added and the mixture was heated to 140 °C. After 4 h the 
solution was cooled to room temperature and was kept at −80 °C overnight. The 
colourless crystalline product (27)  (17.1 g, 53.4 mmol, 69%), (hexanes : EtOAc = 3 : 
1, Rf = 0.31) was filtered off, washed with cold water and dried under high vacuum. 
 
 
 
mp.: 165 °C. 
IR (ATR): max (cm
-1) = 3267 (m), 1596 (w), 1510 (s), 1332 (vs), 1156 (vs), 673 (vs). 
1H-NMR (400 MHz, CD3OD, 27 °C): δ (ppm) = 7.87 (s, 2H), 7.57 (d, J = 8 Hz, 2H), 
7.33 (d, J = 8 Hz, 2H), 2.41 (s, 2H), 2.10 (s, 2H). 
13C-NMR (100 MHz, CD3OD, 27 °C): δ (ppm) = 146.0, 143.9, 139.8, 139.6, 138.6, 
129.4, 126.6, 122.6, 20.0, 17.8. 
HR-MS (EI) [M]+: calc for [C15H17NO4S]+: 320.0831; found: 320.0823. 
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13.3.3 2,6-dimethyl-4-nitroaniline259  
N-tosyl-2,6-dimethyl-4-nitroaniline (27) (8.04 g, 25.1 mmol) was dissolved in a 
mixture of H2SO4 (96% v/v, 41.0 mL) and water (3.00 mL). After stirring the solution 
in a sealed tube at 40 °C overnight, it was slowly added to an aqueous solution of 
NaOH (2 M, 80.0 mL) at 0 °C. The resulting suspension was extracted with EtOAc, 
dried over Na2SO4, filtered and concentrated. The remaining crude product was 
purified by normal phase chromatography (hexanes : CH2Cl2 = 1 : 1, Rf = 0.30) to 
yield 24 (2.67 g, 16.1 mmol, 64%) as a yellow solid. 
 
 
 
mp.: 162 °C. 
IR (ATR): max (cm
-1) = 3494 (m), 3387 (m), 1624 (s), 1594 (s), 1487 (vs), 1240 (s), 
888 (s), 748 (s). 
1H-NMR (300 MHz, CD3OD, 27 °C): δ (ppm) = 7.84 (s, 2H), 2.22 (s, 6H). 
13C-NMR (75 MHz, CD3OD, 27 °C): δ (ppm) = 151.2, 136.6, 124.0, 120.1, 16.3. 
HR-MS (ESI) [M − H]-: calc for [C8H9N2O2]-: 165.0672; found: 165.0671. 
 
13.3.4 Nitroazobenzene  
2,6-dimethyl-4-nitroaniline (24) (2.00 g, 12 mmol) was dissolved in CH2Cl2 (120 mL) 
and a homogenous mixture of KMnO4 (6.00 g, 38.0 mmol) and FeSO4  · 7 H2O (6.00 
g, 21.6 mmol) was added. After heating the suspension to 50 °C overnight, the 
mixture was filtered through celite and the residue was washed with CH2Cl2 and Et2O. 
The organic solvents were removed in vacuo and the remaining crude product was 
purified by normal phase chromatography (hexanes : CH2Cl2 = 1 : 1, Rf = 0.51) to 
give 28 (827 mg, 2.52 mmol, 21%) as purple needles.  
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mp.: 244 °C (dec.). 
IR (ATR): max (cm
-1) = 3093 (m), 2928 (m), 2359 (w), 1505 (vs), 1350 (vs), 1301 
(vs), 1108 (s), 1036 (s), 943 (s), 900 (vs), 810 (s), 722 (vs). 
1H-NMR (200 MHz, CDCl3, 23 °C): δ (ppm) = 8.06 (s, 4H), 2.47 (s, 12H). 
13C-NMR (75 MHz, CDCl3, 23 °C): δ (ppm) = 154.8, 146.9, 132.6, 124.4, 19.6. 
MS (ESI) [M − H]-: calc for [C16H15N4O4]-: 327.1102; found: 327.1097. 
 
13.3.5 Aminoazobenzene  
Nitroazobenzene (28) (50.0 mg, 0.152 mmol) was dissolved in a mixture of methanol 
and water (3 : 1, 1.70 mL) and heated to 70 °C. Na2S (420 mg, 5.38 mmol) was 
slowly added at this temperature. Additional methanol and water (3 : 1, 1.70 ml) was 
added,  in order to rinse the flask, and the mixture was heated to 90 °C for 45 min. 
After acidifying to pH = 7 with an aqueous solution of HCl (1 M), the mixture was 
cooled to room temperature, diluted with a saturated solution of NaHCO3 and was 
extracted with EtOAc. The organic layer was washed with water, a saturated solution 
of NaHCO3, a saturated solution of NaCl, and was dried over Na2SO4 and filtered. 
The organic solvent was removed in vacuo and purification by normal phase 
chromatography (CH2Cl2 : methanol = 98 : 2, Rf = 0.44) gave 29 (36 mg, 0.134 mmol, 
88%) as a red solid.  
 
 
 
mp.: 196 °C (dec.). 
IR (ATR): max (cm
-1) = 3418 (w), 3327 (w), 3202 (w), 2909 (w), 1593 (vs), 1463 (m), 
1372 (m), 1317 (s), 1164 (s), 1035 (m), 851 (vs). 
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1H-NMR (400 MHz, CD3OD, 27 °C): δ (ppm) = 6.43 (s, 4H), 2.37 (s, 12H). 
13C-NMR (100 MHz, CD3OD, 27 °C): δ (ppm) = 147.7, 143.1, 133.8, 115.2, 20.1. 
HR-MS (ESI) [M + H]+: calc for [C16H21N4]+: 269.1758; found: 269.1757. 
 
13.3.6 L-pyroglutamic acid tert-butyl ester258  
(S)-2-pyrrolidine-5-carboxylic acid (8) (40.0 g, 310 mmol) was suspended in tert-butyl 
acetate (200 mL) and perchloric acid (10.0 mL, 70% v/v) was slowly added. After 
stirring for 24 h at room temperature, the mixture was cooled to 0 °C and a saturated 
solution of NaHCO3 (500 mL) was added. Furthermore, solid NaHCO3 was added in 
order to neutralize the solution.  The mixture was extracted with EtOAc and the 
organic layer was washed with a saturated solution of NaCl, dried over Na2SO4 and 
filtered. The solvent was removed in vacuo and the product (19) (34.4 g, 186 mmol, 
60%) was isolated as a colourless solid, which was directly taken for the next step 
without further purification.  
 
 
 
13.3.7 N-Boc-L-pyroglutamic acid tert-butyl ester258  
Triethylamine (37.0 mL, 266 mmol) was added to a solution of L-pyroglutamatic acid 
tert-butyl ester (19) (16.3 g, 87.9 mmol), di-tert-butyl dicarbonate (38.5 g, 176 mmol) 
and 4-(dimethylamino)-pyridine (1.80 g, 14.7 mmol) in CH2Cl2 (225 mL). After stirring 
the reaction at room temperature overnight, the mixture was washed with 10% citric 
acid (2x, 500 mL), with a saturated solution of NaCl and was dried over Na2SO4. After 
filtration, the mixture was concentrated in vacuo. Purification by normal phase 
chromatography (hexanes : EtOAc = 3 : 2, Rf = 0.43) and recrystallization from 
ethanol yielded 20 (18.1 g, 63.5 mmol, 72%) as a colourless solid. 
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[α]25D (c 1.0, in CHCl3): −39.8. 
mp.: 57 °C. 
IR (ATR): max (cm
-1) = 2975 (m), 1774 (s), 1720 (s), 1363 (m), 1288 (s), 1142 (vs), 
1023 (m), 842 (m). 
1H-NMR (300 MHz, CDCl3, 23 °C): δ (ppm) = 4.47 (dd, J = 3 Hz and 12 Hz, 1H), 2.55 
(m, 1H), 2.45 (m, 1H), 2.26 (m, 1H), 1.96 (m, 1H), 1.48 (s, 9H), 1.46 (s, 9H). 
13C-NMR (75 MHz, CDCl3, 23 °C): δ (ppm) = 173.5, 170.3, 149.3, 83.3, 82.2, 59.6, 
31.1, 27.9, 27.9, 21.6, 15.5. 
HR-MS (ESI) [M + Na]+: calc for [C14H23NNaO5]+: 308.1466; found: 308.1466.  
 
13.3.8 Allylpyroglutamate  
N-Boc-L-pyroglutamic acid tert-butylester (20) (6.00 g, 21.0 mmol) was dissolved in 
THF (86.0 mL) and cooled to −78 °C. Fresh LiHMDS solution (36.0 mL, 0.670 M) 
[prepared by the dropwise addition of n-BuLi (10.5 mL, 26.3 mmol, 2.50 M) to a 
solution of HMDS (5.60 mL, 26.3 mmol) in THF (20.0 mL) at 0 °C and stirring for 1 h 
at −78 °C] was added dropwise at −78 °C and the mixture was stirred for 1 h at the 
stated temperature. A solution of allyl bromide (7.30 mL, 85.0 mmol) in THF (73.0 
mL), cooled to −78 °C, was added fast and the reaction mixture was stirred for 2 h 30 
min at −78 °C. A saturated solution of NH4Cl was added at −78 °C and the reaction 
mixture was extracted with CH2Cl2. The organic fractions were combined, washed 
with a saturated solution of NaCl, dried over Na2SO4, filtered and concentrated. 
Purification by normal phase chromatography (hexanes : Et2O = 3 : 2, Rf = 0.43) 
gave 21 (2.73 g, 8.40 mmol, 40%) as a colourless solid. 
 
 
 
[α]25D (c 5.0, in CHCl3): −28.52. 
mp.: 47 °C. 
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IR (ATR): max (cm
-1) = 3355 (s), 2972 (s), 2291 (w), 1695 (vs), 1519 (s), 1366 (s), 
1250 (s), 1152 (vs), 1026 (m), 852 (w). 
1H-NMR (300 MHz, CDCl3, 27 °C): δ (ppm) = 5.77 (m, 1H), 5.11 (m, 2H), 4.45 (dd, J 
= 3 Hz and 12 Hz, 1H), 2.69 (m, 2H), 2.18 (m, 2H), 2.00 (m, 1H), 1.52 (s, 9H), 1.49 
(s, 9H). 
13C-NMR (75 MHz, CDCl3, 27 °C): δ (ppm) = 174.5, 170.3, 149.4, 134.5, 117.6, 83.3, 
82.3, 57.8, 41.1, 34.5, 27.9, 27.9. 
HR-MS (ESI) [2M + Na]+: calc for [C34H54N2NaO10]+: 673.3668; found: 673.3667.  
 
13.3.9 Acrylic acid pyroglutamate  
Allylpyroglutamate (21) (1.50 g, 4.62 mmol) was dissolved in CH2Cl2 (22.0 mL) and 
freshly distilled acrylic acid (0.950 mL, 13.8 mmol) was added at room temperature. 
After adding the mixture to Grubbsʼ 2nd generation catalyst (197 mg, 0.232 mmol, 5 
mol%), the mixture was stirred at 40 °C overnight. The solvent was removed in vacuo 
and purification by normal phase chromatography (CH2Cl2 : EtOAc = 8.5 : 1.5 with 
1% AcOH, Rf = 0.25) afforded 22 (1.36 g, 3.68 mmol, 80%) as a colourless solid.  
 
 
 
[α]25D (c 1.2, in CHCl3): −24.1. 
mp.: 160 °C. 
IR (ATR): max (cm
-1) = 2979 (w), 1778 (s), 1732 (m), 1683 (m), 1650 (m), 1370 (m), 
1290 (s), 1250 (s), 1147 (vs), 991 (m), 959 (m), 842 (m), 776 (s), 687 (m). 
1H-NMR (600 MHz, CDCl3, 27 °C): δ (ppm) = 6.98 (m, 1H), 5.90 (d, J = 18 Hz, 1H), 
4.44 (dd, J = 6 Hz and 12 Hz, 1H), 2.80 (m, 2 H), 2.32 (m, 1H), 2.18 (m, 1H), 1.91 (m, 
1H), 1.49 (s, 9H), 1.46 (s, 9H). 
13C-NMR (150 MHz, CDCl3, 27 °C): δ (ppm) = 173.6, 170.7, 170.0, 149.2, 147.3, 
123.2, 83.6, 82.6, 57.6, 40.5, 33.0, 28.1, 27.9, 27.9. 
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HR-MS (ESI) [2M + Na]+: calc for [C36H54N2NaO14]+: 761.3466; found: 761.3465. 
 
13.3.10 Carboxylic acid pyroglutamate  
Acrylic acid pyroglutamate (22) (1.33 g, 3.60 mmol) was dissolved in methanol (240 
mL) and Pd/C (600 mg, 0.560 mmol) was added. The solution was stirred under an 
atmosphere of hydrogen overnight and was filtered through celite. The solvent was 
removed in vacuo and the product (23) (1.27 g, 3.42 mmol, 95%) was isolated as a 
colourless solid (CH2Cl2 : EtOAc = 8.5 : 1.5 with 1% AcOH, Rf = 0.25). 
 
 
 
[α]25D (c 1.0, in CHCl3): −25.0. 
mp.: 82 °C. 
IR (ATR): max (cm
-1) = 2978 (w), 2361 (w), 1779 (s), 1732 (s), 1704 (s), 1368 (m), 
1320 (s), 1249 (s), 1150 (vs), 1010 (m), 942 (m), 844 (m), 777 (m), 732 (m). 
1H-NMR (600 MHz, CDCl3, 27 °C): δ (ppm) = 4.41 (dd, J = 6 Hz and 12 Hz, 1H), 2.56 
(m, 1H), 2.33 (m, 2H), 2.17 (m, 1H), 1.92 (m, 2H), 1.65 (m, 2H), 1.47 (m, 9H), 1.45 
(m, 9H), 1.38 (m, 1H). 
13C-NMR (150 MHz, CDCl3, 27 °C): δ (ppm) = 178.5, 175.3, 170.3, 149.4, 83.4, 82.3, 
57.8, 41.4, 34.1, 29.7, 28.4, 27.9, 27.9, 22.1. 
HR-MS (ESI) [M + Na]+: calc for [C18H29NNaO7]: 394.1834; found: 394.1832. 
 
13.3.11 Aminoazobenzene pyroglutamate  
Aminoazobenzene (29) (360 mg, 1.34 mmol), HOBt (137 mg, 1.01 mmol; + 12% H2O 
→ 153 mg) and EDCI (168 mg, 0.880 mmol) were dissolved in acetonitrile (27.0 mL). 
DIPEA (0.588 mL, 3.38 mmol) was added slowly and a solution of carboxylic acid 
pyroglutamate (23) (250 mg, 0.673 mmol) in acetonitrile (4.00 mL) was added 
dropwise at 0 °C. After stirring at room temperature overnight, CH2Cl2 (100 mL) was 
ν~
N
Boc
CO2t-BuO
HO
O
EXPERIMENTS 
 63 
added and the mixture was washed with a saturated solution of NaHCO3 and with a 
saturated solution of NaCl. The organic fraction was dried over Na2SO4, filtered and 
the solvent was removed in vacuo. Purification by normal phase chromatography 
(CH2Cl2 : MeOH = 98 : 3, Rf = 0.33) gave 30 (355 mg, 0.571 mmol, 85%) as an 
orange solid.  
 
 
 
[α]25D (c 0.5, in CHCl3): 65.2. 
mp.: 98 °C. 
IR (ATR): max (cm
-1) = 3360 (w), 2976 (w), 2361 (w), 1782 (s), 1734 (m), 1672 (m), 
1597 (s), 1536 (m), 1456 (m), 1368 (m), 1311 (s), 1249 (w), 1147 (vs), 845 (m), 728 
(s). 
1H-NMR (400 MHz, CD3OD, 27 °C): δ (ppm) = 7.31 (s, 2H), 6.43 (s, 2 H), 4.48 (dd, J 
= 4 Hz and 8 Hz, 1H), 2.61 (m, 1H), 2.42 (s, 6H), 2.39 (m, 2H), 2.34 (s, 6H), 2.23 (m, 
1H), 2.05 (m, 1H), 1.90 (m, 1H), 1.75 (m, 3H), 1.47 (s, 18H). 
13C-NMR (100 MHz, CD3OD, 27 °C): δ (ppm) = 176.4, 172.5, 170.7, 149.5, 149.4, 
148.3, 141.9, 137.1, 135.5, 131.4, 120.1, 114.8, 83.2, 82.2, 58.0, 41.2, 36.2, 29.7, 
27.8, 26.8, 26.7, 22.4, 20.4, 19.1. 
HR-MS (ESI) [M + H]+: calc for [C34H48N5O6]+: 622.3596; found: 622.3596.  
 
13.3.12 N-acyl-aminoazobenzene pyroglutamate  
Aminoazobenzene pyroglutamate (30) (350 mg, 0.563 mmol) was dissolved in THF 
(31.0 mL). DIPEA (192 µL, 1.13 mmol) was added and acetyl chloride (61.0 µL, 
0.845 mmol) in THF (12.0 mL) was added at 0 °C over 45 min. After stirring for 15 
min at this temperature, the reaction mixture was allowed to warm to room 
temperature and was stirred for 1 h. The solvent was removed in vacuo and the 
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remaining crude product was purified by normal phase chromatography (CH2Cl2 : 
MeOH = 95 : 5, Rf = 0.33) to provide 31 (362 mg, 0.546 mmol, 97%) as an orange 
solid.  
 
 
 
[α]25D (c 0.5, in CHCl3): 76.8. 
mp.: 126 °C. 
IR (ATR): max (cm
-1) = 3333 (w), 2977 (w), 2361 (w), 1782 (s), 1737 (m), 1673 (m), 
1594 (s), 1533 (s), 1473 (m), 1368 (s), 1315 (s), 1249 (s), 1150 (vs), 1037 (w), 868 
(m), 727 (vs). 
1H-NMR (600 MHz, CDCl3, 27 °C): δ (ppm) = 7.65 (s, 1H), 7.34 (s, 2H), 7.29 (s, 2H), 
4.44 (dd, J = 6 Hz and 12 Hz, 1H), 2.63 (m, 1H), 2.45 (m, 1H), 2.42 (s, 12H), 2.22 (m, 
1H), 2.18 (s, 3H), 1.99 (m, 3H), 1.81 (m, 2H), 1.63 (m, 1H), 1.49 (s, 9H), 1.47 (s, 9H).  
13C-NMR (150 MHz, CDCl3, 27 °C): δ (ppm) = 175.5, 170.9, 170.2, 168.3, 149.3, 
147.5, 147.3, 137.8, 137.6, 133.4, 133.4, 130.3, 120.2, 120.1, 83.4, 82.4, 57.8, 41.5, 
37.2, 29.6, 28.5, 27.9, 27.9, 24.7, 22.7, 20.6, 20.6, 19.8. 
HR-MS (ESI) [M + H]+: calc for [C36H50N5O7]+: 664.3702; found: 664.3704. 
 
13.3.13 Azobenzene glutamic acid ester  
N-acyl-aminoazobenzene pyroglutamate (31) (351 mg, 0.529 mmol) was dissolved in 
THF (70.0 mL). An aqueous solution of LiOH (1.00 M, 16.5 ml, 16.5 mmol) was 
added dropwise at 0 °C. After stirring for 1 h, EtOAc (46.0 mL) and a saturated 
solution of NaHCO3 (46.0 mL) were added and the mixture was stirred for 1 h at 0 °C. 
Water (70.0 ml) was added and the mixture was acidified to pH = 2 with an aqueous 
solution of HCl (1 M) at 0 °C. The reaction mixture was extracted with EtOAc and the 
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combined organic layers were washed with water and a saturated solution of NaCl, 
dried over Na2SO4 and the solvent was removed in vacuo after filtration. Purification 
by normal phase chromatography (CH2Cl2 : MeOH : AcOH = 94 : 4 : 2, Rf = 0.21) 
yielded 32 (288 mg, 0.423 mmol, 80%) as an orange solid. 
 
 
 
[α]25D (c 0.25, in MeOH): 3.2. 
mp.: 136 °C. 
IR (ATR): max (cm
-1) = 3311 (w), 2976 (w), 2361 (m), 1671 (s), 1594 (s), 1540 (s), 
1366 (s), 1319 (s), 1256 (s), 1152 (vs), 1033 (m), 865 (m), 747 (m), 668 (m). 
1H-NMR (400 MHz, CD3OD, 27 °C): δ (ppm) = 7.87 (s, NH, exch.), 7.38 (s, 2H-trans), 
7.37 (s, 2H-trans), 7.20 (s, 2H-cis), 7.19 (s, 2H-cis), 4.00 (dd, J = 4 Hz and 12 Hz, 
1H), 2.52 (m, 2H), 2.41 (s, 12H-trans), 2.13 (m, 1H), 2.12 (s, 3H-trans+cis), 1.87 (s, 
12H-cis), 1.70 (m, 4H), 1.59 (m, 2H), 1.44 (s, 9H), 1.42 (s, 9H). 
13C-NMR (100 MHz, CD3OD, 27 °C): δ (ppm) = 177.7, 172.8, 172.1, 170.3, 156.7, 
147.1, 147.1, 138.5, 132.7, 132.7, 128.6, 120.1, 112.0, 81.2, 79.0, 53.1, 42.0, 36.3, 
33.4, 32.0, 27.3, 26.8, 23.1, 22.5, 19.4, 19.4, 17.8. 
HR-MS (ESI) [M + H]+: calc for [C36H52N5O8]+: 682.3808; found 682.3806. 
 
13.3.14 Azobenzene glutamic acid ester γ-amide  
Azobenzene glutamic acid ester (32) (262 mg, 0.384 mmol) was dissolved in THF 
(66.0 mL) and triethylamine (69.5 µL, 0.497 mmol) was added. Iso-butyl 
chloroformate (59.6 µL, 0.461 mmol) was added at −40 °C and the mixture was 
stirred at this temperature for 1 h. The mixed anhydride was added dropwise to 1,11-
diamino-3,6,9-trioxaundecane (146 µL, 0.770 mmol) in THF (224 mL) at 0 °C and the 
mixture was stirred for 1 h at 0 °C followed by 1 h at room temperature. After adding 
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a saturated solution of NaCl (280 mL) at 0 °C, the mixture was allowed to warm to 
room temperature and was extracted with EtOAc. The organic layers were washed 
with water and the aqueous layer was reextracted with EtOAc. The combined organic 
fractions were washed with a saturated solution of NaCl, dried over Na2SO4 and 
concentrated. The solvent was removed in vacuo and the crude mixture was purified 
by column chromatography (amine functionalized silica, EtOAc : CH2Cl2 : MeOH = 
100 : 0 : 0 → 0 : 100 : 0  → 0 : 99 : 1 ) to give 33 (148 mg, 0.173 mmol, 45%) as a 
red solid (CH2Cl2 : MeOH : TEA = 93 : 5 : 2, Rf = 0.19). The product was 
characterized by mass spectrometry and was directly taken for the next step. 
 
 
 
HR-MS (ESI) [M + H]+: calc for [C44H70N7O10]+: 856.5176; found: 856.5176.  
 
13.3.15 Biotin azobenzene glutamic acid ester γ-amide  
D-biotin (20.3 mg, 0.0829 mmol) was dissolved in DMF (5.00 mL) and TEA (35.0 µL, 
0.2487 mmol) was added at 0 °C. After stirring for 10 min, pentafluorophenyl 
trifluoroacetate (17.2 µL, 0.0995 mmol) was added and the reaction mixture was 
allowed to warm to room temperature and was stirred for 4 h. Azobenzene glutamic 
acid ester γ-amide (33) (71.0 mg, 0.0829 mmol) was dissolved in DMF (2.50 mL) and 
was added dropwise to the biotin pentafluorophenyl ester. The reaction was stirred 
overnight at room temperature and the crude mixture was purified by normal phase 
chromatography (CHCl3 : MeOH = 9 : 1, Rf = 0.38) to yield 34 (88.0 mg, 0.0814 
mmol,  98%) as a red solid. 
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[α]25D (c 0.5, in MeOH): 13.8. 
mp.: 250 °C. 
IR (ATR): max (cm
-1) = 3305 (m), 1691 (vs), 1597 (vs), 1539 (s), 1155 (s). 
1H-NMR (400 MHz, CD3OD, 27 °C): δ (ppm) = 7.39 (s, 2H-trans), 7.37 (s, 2H-trans), 
7.21 (s, 2H-cis), 7.20 (s, 2H-cis), 4.43 (m, 1H), 4.25 (m, 1H), 3.87 (dd, J = 8 Hz and 
12 Hz, 1H), 3.53 (m, 14H), 3.32 (t, J = 6 Hz, 2H), 3.14 (m, 1H), 2.86 (m, 1H), 2.68 (d, 
J = 12 Hz, 1H), 2.41 (s, 12H-trans), 2.37 (m, 2H), 2.17 (m, 3H), 2.12 (s, 3H-
trans+cis), 1.87 (12H-cis), 1.62 (m, 9H), 1.43 (s, 9H), 1.43 (s, 9H), 1.39 (m, 2H). 
13C-NMR (100 MHz, CD3OD, 27 °C): δ (ppm) = 175.6, 174.6, 172.8, 172.0, 170.3, 
164.6, 156.7, 149.2, 147.1, 138.6, 138.3, 132.7, 128.6, 120.0, 120.0, 119.7, 119.6, 
81.2, 79.0, 70.2, 70.1, 69.8, 69.2, 61.9, 60.2, 55.5, 52.9, 43.2, 39.6, 38.9, 36.5, 35.3, 
33.7, 32.5, 28.3, 28.1, 27.4, 26.8, 25.4, 23.4, 22.6, 19.5, 17.9, 17.8. 
HR-MS (ESI) [M + H]+: calc for [C54H84N9O12S]+: 1082.5952; found: 1082.5952. 
 
13.3.16 BAG  
Biotin azobenzene glutamic acid ester γ-amide (34) (2.60 mg, 0.00240 mmol) was 
dissolved in CH2Cl2 (2.60 mL) and anisole (15.7 µL, 0.140 mmol) was added. After 
adding TFA (0.162 mL, 2.20 mmol) dropwise at 0 °C, the mixture was stirred at room 
temperature for 1 h. The addition of TFA and stirring for 1 h was sequentially 
repeated six times. The reaction mixture was stirred overnight, diluted with Et2O (26.0 
mL), and the resulting precipitate was collected by centrifugation to yield 3 (2.00 mg, 
0.00216 mmol, 90%) as an orange solid as the free base. In order to prepare the HCl 
salt, the solid was dissolved in MeOH (2.00 mL) and HCl in MeOH (0.500 M) was 
added dropwise until the colour changed to red. 
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1H-NMR (600 MHz, CD3OD, 27 °C): δ (ppm) = 7.40 (s, 2H-trans), 7.37 (s, 2H-trans), 
7.22 (s, 2H-cis), 7.20 (s, 2H-cis), 4.45 (m, 1H), 4.26 (m, 1H), 3.59 (m, 15H), 3.34 (t, J 
= 6 Hz, 2H), 3.15 (m, 1H), 2.88 (m, 1H), 2.68 (d, J = 12 Hz), 2.52 (m, 2H), 2.41 (s, 
12H-trans), 2.20 (m, 3H), 2.13 (s, 3H-trans+cis), 1.87 (s, 12H-cis), 1.64 (m, 9H), 1.41 
(t, J = 6 Hz, 2H). 
13C-NMR (150 MHz, CD3OD, 27 °C): δ (ppm) = 176.3, 174.8, 172.7, 170.3, 164.6, 
147.1, 138.6, 132.7, 128.6, 120.0, 120.0, 119.7, 119.6, 113.7, 70.1, 70.0, 69.8, 69.7, 
69.3, 69.2, 61.9, 60.2, 55.6, 39.6, 38.9, 38.8, 36.4, 35.3, 28.3, 28.1, 25.5, 23.2, 22.5, 
19.5, 17.8. 
HR-MS (ESI) [M + H]+: calc for [C45H68N9O10S]+: 926.4802; found: 926.4814. 
 
13.3.17 Azobenzene glutamic acid γ-amide  
Azobenzene glutamic acid ester γ-amide (33) (2.70 mg, 0.00317 mmol) was 
dissolved in CH2Cl2 (3.40 mL) and anisole (20.7 µL, 0.190 mmol) was added. After 
adding TFA (0.214 mL, 2.90 mmol) dropwise at 0 °C, the mixture was stirred at room 
temperature for 1 h. The addition of TFA and stirring for 1 h was sequentially 
repeated four times. The reaction mixture was stirred overnight, diluted with hexanes 
(34.0 mL) and the resulting precipitate was collected by centrifugation to yield 35 
(2.00 mg, 0.00286 mmol, 90%) as an orange solid as the free base. In order to 
prepare the HCl salt, the solid was dissolved in MeOH (2.00 mL) and HCl in MeOH 
(0.500 M) was added dropwise until the colour changed to red. 
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1H-NMR (400 MHz, CD3OD, 25 °C): δ (ppm) = 7.41 (s, 2H-trans), 7.39 (s, 2H-trans), 
7.23 (s, 2H-cis), 7.21 (s, 2H-cis), 3.62 (m, 13H), 3.42 (t, J = 4Hz, 2H), 3.13 (t, J = 
4Hz, 2H), 2.58 (m, 2H), 2.43 (s, 12H-trans), 2.19 (m, 1H), 2.14 (s, 3H-trans+cis), 1.88 
(s, 12H-cis), 1.69 (m, 6H). 
13C-NMR (100 MHz, CD3OD, 25 °C): δ (ppm) = 175.9, 172.7, 170.3, 147.1, 147.1, 
138.7, 138.6, 132.7, 132.7, 120.0, 119.7, 70.0, 70.0, 69.6, 69.6, 69.2, 66.4, 52.1, 
42.9, 39.1, 38.9, 36.2, 33.0, 31.3, 23.0, 22.5, 19.4, 17.8. 
MS (ESI) [M + H]+: calc for [C35H54N7O8]+: 700.4026; found: 700.4030. 
 
13.4 Preparation of 2,2',6,6'-tetramethyl-QAQ  
 
13.4.1 Betaine acid chloride  
Triethylammonium acetate (36) (100 mg, 0.628 mmol) was dissolved in MeCN (0.60 
mL) and a solution of oxallyl chloride in CH2Cl2 (0.314 mL, 0.628 mmol, 2.00 M) was 
added. After adding two drops of DMF, the solution was stirred at room temperature 
for 15 min. The solvent was removed in vacuo and the product (37) (134 mg, 0.628 
mmol, quant.) was isolated as a light yellow solid and was used without further 
purification. 
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13.4.2 2,2',6,6'-tetramethyl-QAQ  
Aminoazobenzene (29) (48.0 mg, 0.179 mmol) was dissolved in MeCN : DMF = 1 : 1 
(10.0 mL) and DIPEA (106 µL, 0.628 mmol) was added. Betaine acid chloride (37) 
(134 mg, 0.628 mmol) in MeCN : DMF = 1 : 1 (20.0 mL) was added at 0 °C over 1 h. 
The reaction was stirred for 15 min, warmed to room temperature and was stirred 
overnight. The precipitate was collected by centrifugation. Purification by reversed 
phase chromatography (H2O : MeOH = 100 : 0 → 80 : 20, 0.1% formic acid) gave 6 
(57.0 mg, 0.089 mmol, 50%) as an orange solid. 
 
 
 
mp.:  276 °C. 
IR (ATR): max (cm
-1) = 3377 (w), 2980 (w), 1683 (m), 1593 (vs), 1472 (s), 1364 (s), 
1318 (s), 1159 (m), 1007 (m), 880 (m), 765 (m).  
1H-NMR (400 MHz, CD3OD, 25 °C): δ (ppm) = 7.46 (s, 2H-trans), 7.29 (s, 2H-cis), 
4.20 (s, 4H), 3.67 (q, J = 16 Hz, 12H), 2.44 (s, 12H-trans), 1.91 (s, 12H-cis), 1.40 (t, J 
= 8Hz, 16H). 
13C-NMR (100 MHz, CD3OD, 25 °C): δ (ppm) = 161.7, 147.7, 137.4, 132.9, 120.3, 
56.2, 54.4, 19.3, 17.8, 6.6.  
HR-MS (ESI) [M − H]+: calc for [C32H51N6O2]+: 551.4071; found 551.4077. 
 
13.5 Preparation of MOBIPHOS and MOBIPHOSen  
 
13.5.1 Bisphosphonate  
Tetraethyl methylenebisphosphonate (3.00 mL, 12.1 mmol) was dissolved in THF 
(28.0 mL) and n-BuLi (4.40 mL, 11.0 mmol, 2.50 M) was added dropwise at −78 °C. 
After stirring at this temperature for 15 min, a solution of isophthalaldehyde (39)  (736 
mg, 5.49 mmol) in THF (14.0 mL) was cooled to 0 °C and added fast at −78 °C. The 
mixture was allowed to warm to room temperature and was stirred overnight. The 
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crude mixture was concentrated and purified by normal phase chromatography (Et2O 
: hexanes : MeOH = 5 : 4 : 1, Rf = 0.26) to yield 40 (2.12 g, 5.27 mmol, 96%) as a 
colourless solid.  
 
 
 
mp.: 102 °C.  
IR (ATR): max (cm
-1) = 2978 (w), 1616 (m), 1429 (w), 1234 (s), 1165 (m), 1019 (s), 
1108 (s), 940 (vs), 848 (s), 787 (s). 
1H-NMR (300 MHz, CDCl3, 27 °C): δ (ppm) = 7.47 (m, 6H), 6.27 (m, 2H), 4.12 (m, 
8H), 1.33 (t, J = 9 Hz, 12H). 
13C-NMR (75 MHz, CDCl3, 27 °C): δ (ppm) = 147.7, 147.6, 135.7, 135.7, 135.4, 
135.4, 129.4, 129.1, 126.7, 116.6, 114.1, 61.9, 61.9, 16.4, 16.3. 
31P-NMR (80 MHz, CDCl3, 23 °C): δ (ppm) = 19.9. 
HR-MS (EI) [M]+: calc for [C18H28O6P2]+: 402.1361; found: 402.1358. 
 
13.5.2 Morpholino bisphosphonate  
ZnCl2 (3.14 g, 23.0 mmol) and LiCl (1.94 g, 46.0 mmol) were heated to 150 °C under 
high vacuum for 6 h. After cooling to room temperature, THF (20.0 mL) was added 
and the suspension was stirred at 60 °C overnight. Isopropylmagnesium chloride 
(0.750 mL, 1.50 mmol, 2.00 M) was added dropwise to a solution of morpholine (132 
µL, 1.50 mmol) in THF (15.0 mL) at 0 °C. After stirring for 30 min, ZnCl2 ⋅ 2 LiCl 
(ZnCl2: 1.15 M, LiCl: 2.30 M) in THF (0.660 mL) was added dropwise and the solution 
was stirred at 0 °C for 30 min. The freshly prepared 
(morpholine)2Zn ⋅ 2 MgCl2 ⋅ 2 LiCl solution was titrated prior to use and the 
concentration was determined to be 52.0 mM. The in situ prepared morpholine 
compound (11.7 mL, 608 µmol) was added dropwise to the bisphosphonate (40) 
(82.0 mg, 203 µmol) in THF (6.00 mL) at 0 °C. The solution was allowed to warm to 
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room temperature and was slowly heated to 40 °C for 4 hours. After stirring overnight 
at room temperature, a saturated solution of NH4Cl was added and the mixture was 
extracted with CH2Cl2. The organic layer was washed with water and a saturated 
solution of NaCl, dried over Na2SO4, filtered and concentrated. Purification by normal 
phase chromatography (Et2O : hexanes : MeOH = 10 : 7 : 3, Rf = 0.25) yielded 41 
(39.0 mg, 80.0 µmol, 39%) as a colourless oil. 
 
 
 
IR (ATR): max (cm
-1) = 3447 (w), 2981 (w), 2361 (w), 1619 (w), 1447 (w), 1393 (w), 
1229 (s), 1115 (m), 1020 (vs), 958 (vs), 849 (s), 804 (s). 
1H-NMR (400 MHz, CD3CN, 27 °C): δ (ppm) = 7.55 (m, 1H), 7.42 (m, 4H), 6.45 (m, 
1H), 4.08 (m, 4H), 3.96 (m, 2H), 3.86 (m, 2H), 3.81 (m, 1H), 3.60 (m, 4H), 2.49 (m, 
2H), 2.38 (m, 4H), 1.32 (t, J = 4 Hz, 6H), 1.20 (t, J = 4 Hz, 3H), 1.11 (t, J = 4 Hz, 3H). 
13C-NMR (100 MHz, CD3CN, 27 °C): δ (ppm) = 147.8, 147.8, 134.9, 134.6, 130.9, 
128.4, 128.1, 127.0, 115.9, 114.1, 69.8, 66.6, 64.1, 61.6, 61.6, 61.2, 61.1, 49.6, 28.9, 
27.5, 15.8, 15.7, 15.7, 15.6, 15.6, 15.6. 
31P-NMR (80 MHz, CD3CN, 23 °C): δ (ppm) = 19.7, 29.9. 
HR-MS (ESI) [M + H]+: calc for [C22H38NO7P2]+:  490.2115; found: 490.2111. 
 
13.5.3 Morpholino dihydrobisphosphonate  
Morpholino bisphosphonate (41) (39.0 mg, 0.0800 mmol) was dissolved in EtOAc 
(3.90 mL) and 5% Pt/C (25 wt%, 9.70 mg) was added. After stirring under an 
atmosphere of H2 at 5 bar for five hours, the mixture was filtered through celite. 
Removal of the solvent gave 42 (38.0 mg, 0.0770 mmol, 96%) as a colourless oil. 
The product (Et2O : hexanes : MeOH = 10 : 7 : 3, Rf = 0.25) did not need further 
purification.  
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IR (ATR): max (cm
-1) = 3464 (w), 2980 (w), 2361 (w), 1449 (w), 1239 (s), 1116 (m), 
1022 (vs), 955 (vs), 803 (s), 707 (m). 
1H-NMR (600 MHz, CD3CN, 27 °C): δ (ppm) = 7.21 (m, 4H), 4.06 (m, 4H), 3.97 (m, 
2H), 3.89 (m, 2H), 3.81 (m, 1H), 3.59 (m, 4H), 2.87 (m, 2H), 2.50 (m, 1H), 2.38 (m, 
4H), 2.27 (m, 1H), 2.06 (m, 2H), 1.29 (t, J = 6 Hz, 6H), 1.21 (t, J = 6 Hz, 3H), 1.13 (t, 
J = 6 Hz, 3H). 
13C-NMR (150 MHz, CD3CN, 27 °C): δ (ppm) = 141.0, 140.9, 137.6, 137.5, 128.7, 
128.0, 127.3, 126.9, 66.6, 64.2, 61.5, 61.4, 61.4, 61.3, 61.3, 61.2, 49.6, 28.9, 28.3, 
28.2, 27.9, 27.2, 26.3, 15.8, 15.8, 15.7, 15.7, 15.7, 15.6. 
31P-NMR (80 MHz, CD3CN, 23 °C): δ (ppm) = 31.3, 30.3. 
HR-MS (ESI) [M + H]+: calc for [C22H40NO7P2]+: 492.2272; found: 492.2269. 
 
13.5.4 MOBIPHOS  
The crude hydrogenation product (42) (32.0 mg, 0.0650 mmol) was dissolved in 
MeCN (7.00 mL) and the solution was cooled to 0 °C. After adding trimethylsilyl 
iodide (39.0 µL, 0.260 mmol) in MeCN (97.0 µL) dropwise at 0 °C and stirring for 1 h 
at this temperature, the solution was warmed to room temperature and was 
additionally stirred for 1 h. The reaction mixture was concentrated in vacuo and 
MeCN : water : AcOH (8 : 1 : 1, 5.00 mL) was added to the crude mixture. The 
mixture was stirred for 20 min and was concentrated. Again MeCN : water : AcOH (8 
: 1 : 1, 5.00 mL) was added and evaporated immediatelly. After co-evaporation with 
toluene (2x), the solid was taken up in water (5.00 mL) and concentrated two times. 
Purification by reverse phase HPLC (5% MeCN in H2O, 0.1% TFA, Microsorb 60 
C18, L x ID (mm) = 250 x 4.6, retention time of the peak of interest: 9 min) gave 4 
(29.0 mg, 0.0580 mmol, 89%) as the TFA salt as a colourless oil. 
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IR (ATR): max (cm
-1) = 2606 (w), 2331 (w), 1785 (m), 1667 (m), 1449 (m), 1123 (s), 
903 (vs), 775 (s), 704 (s). 
1H-NMR (400 MHz, D2O, 27 °C): δ (ppm) = 7.30 (m, 4H), 4.44 (m, 1H), 3.89 (m, 2H), 
3.56 (m, 3H), 3.09 (m, 1H), 2.95 (m, 1H), 2.82 (m, 3H), 2.53 (m, 2H), 1.98 (m, 2H). 
13C-NMR (100 MHz, D2O, 27 °C): δ (ppm) = 142.3, 142.2, 130.4, 130.3, 130.3, 
129.7, 129.4, 127.9, 67.3, 67.3, 63.8, 63.8, 50.5, 48.0, 28.5, 28.0, 28.0, 27.2. 
31P-NMR (80 MHz, D2O, 23 °C): δ (ppm) = 20.3, 31.0. 
HR-MS (ESI) [M + H]+: calc for [C14H24NO7P2]+: 380.1020; found: 380.1020. 
 
13.5.5 MOBIPHOSen  
Morpholino bisphosphonate (41) (20.0 mg, 0.0410 mmol) was dissolved in MeCN 
(4.50 mL) and the solution was cooled to 0 °C. After adding trimethylsilyl iodide (25.0 
µL, 0.160 mmol) in MeCN (65.0 µl) dropwise at 0 °C and stirring for 1 h at this 
temperature, the solution was warmed to room temperature and was additionally 
stirred for 1 h. The reaction mixture was concentrated in vacuo and MeCN : water : 
AcOH (8 : 1 : 1, 5.00 mL) was added to the crude mixture. After stirring for 20 min, 
the mixture was concentrated. Again MeCN : water : AcOH (8 : 1 : 1, 5.00 mL) was 
added and evaporated immediatelly. After co-evaporation with toluene (2x), the solid 
was taken up in water (5.00 mL) and concentrated two times. Purification by reverse 
phase HPLC (5% MeCN in H2O, 0.1% TFA, Microsorb 60 C18, L x ID (mm) = 250 x 
4.6, retention time of the peak of interest: 7 min) gave 38 (10.0 mg, 0.0200 mmol, 
50%) as the TFA salt as a colourless oil. 
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IR (ATR): max (cm
-1) = 2301 (br), 1668 (m), 1439 (m), 1126 (s), 931 (vs), 791 (s), 
702 (s).  
1H-NMR (400 MHz, D2O, 27 °C): δ (ppm) = 7.62 (m, 1H), 7.40 (m, 4H), 6.44 (m, 1H), 
4.50 (m, 1H), 3.93 (m, 2H), 3.60 (m, 3H), 3.14 (m, 1H), 2.99 (m, 1H), 2.84 (m, 1H), 
2.49 (m, 2H). 
13C-NMR (100 MHz, D2O, 27 °C): δ (ppm) = 144.2, 144.2, 136.3, 136.0, 131.2, 
131.1, 131.0, 129.7, 129.4, 129.1, 119.7, 117.9, 117.7, 114.8, 67.4, 63.9, 50.6, 47.8, 
28.6, 27.3. 
31P-NMR (80 MHz, D2O, 23 °C): δ (ppm) = 17.1, 18.9. 
MS (ESI) [M − H]-: calc for [C14H20NO7P2]-: 376.0723; found: 376.0720 (100). 
 
13.6 Preparation of ABA  
4,4ʼ-diaminoazobenzene (43) (127 mg, 0.600 mmol) was dissolved in THF (25.0 mL). 
TEA (0.240 mL, 1.75 mmol) was added and the mixture was stirred for 5 min. After 
adding chloroacetylchloride (0.140 mL, 1.75 mmol) dropwise at 0 °C, the mixture was 
stirred for 30 min at this temperature, was allowed to warm to room temperature and 
was stirred for 4 h. The mixture was filtered and the solvent was removed in vacuo. 
Sodium iodide (10.0 g, 66.0 mmol) was dissolved in acetone (40.7 mL) and THF 
(12.5 mL), was cannulated to the crude mixture and the solution was stirred overnight 
protected from light. The reaction mixture was filtered and the solvent was 
evaporated. The solid was dissolved in THF (5.00 mL) and after filtra, icecold water 
(7.00 mL) was added. The precipitate (5) (39.0 mg, 0.0720 mmol, 12%) was collected 
by centrifugation. 
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mp.: 252 °C (dec.). 
IR (ATR): ν~max (cm
-1) = 3474 (br), 3297 (m), 3264 (m), 3143 (w), 1656 (s), 1610 (m), 
1544 (s), 1411 (m), 1332 (m), 1081 (w), 844 (m). 
1H-NMR (200 MHz, DMSO, 23 °C): δ (ppm) = 10.63 (s, 2H), 7.88 (d, J = 10 Hz, 4H), 
7.78 (d, J = 10 Hz, 4H), 3.85 (s, 4H). 
13C-NMR (100 MHz, DMSO, 27 °C): δ (ppm) = 167.5, 148.3, 143.0, 123.9, 119.8, 
1.8. 
HR-MS (ESI) [M + H]+: calc for [C16H15I2N4O2]: 548.9276; found: 548.9282. 
 
Chapter 14: Biology 
 
14.1 Materials 
 
14.1.1 Chemicals and reagents 
Commercially available reagents of > 98% purity were used as obtained. 
 
14.1.2 Buffers, solutions and media 
 
Buffers, solutions and 
media 
Components 
Cation exchange buffer 
(GluK2) 
A = 20 mM NaOAc pH = 5.0, 1 mM EDTA, 1 mM monosodium glutamate, 5 
mM methionine 
B = 20 mM NaOAc pH = 5.0, 1 M NaCl, 1 mM EDTA, 1 mM monosodium 
glutamate, 5 mM methionine 
Cation exchange buffer 
(GluA2) 
A = 20 mM NaOAc pH = 6.0, 1 mM EDTA, 1 mM monosodium glutamate, 5 
mM methionine 
B = 20 mM NaOAc pH = 6.0, 0.5 M NaCl, 1 mM EDTA, 1 mM monosodium 
glutamate, 5 mM methionine 
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Cell lysis buffer 50 mM Tris pH = 8.0, 200 mM NaCl, 5 mM MgCl2 
Coomassie staining 
solution 
41.5% MeOH, 8.3% HOAc, 50% H2O, 0.2% (w/v) Coomassie Brilliant Blue 
R 250 
Crystallization buffer  10 mM HEPES pH = 8.0, 150 mM NaCl, 1 mM EDTA 
Destaining solution 10% HOAc, 20% EtOH, 70% H2O 
DNase solution 4000 units/mL in 10 mM HEPES pH = 7.0, 150 mM NaCl, 10% (w/v) 
glycerol 
ITC buffer 10 mM HEPES pH = 8.0, 100 mM NaCl, 1 mM EDTA, 5 mM methionine 
LB agar LB medium with 15 g/l agar-agar 
LB medium 10 g tryptone (peptone from casein), 10 g NaCl, 5 g yeast extract, per litre, 
pH = 7.5 
Lysozyme solution 4 mg/mL in 10 mM HEPES pH = 7.0, 150 mM NaCl, 5% (w/v) glycerol 
Ni-NTA buffer  
(GluK2 and GluA2) 
A = 50 mM Tris pH = 8.0, 200 mM NaCl, 2 mM monosodium glutamate 
B = 50 mM Tris pH = 8.0, 200 mM NaCl, 2 mM monosodium glutamate, 500 
mM imidazole 
Post Ni-NTA buffer 10 mM HEPES pH = 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM monosodium 
glutamate, 5 mM methionine 
Seperating gel buffer 1.5 M Tris pH = 8.8 
Stacking gel buffer 1 M Tris pH = 6.8 
TE buffer 10 mM Tris pH = 8.0, 1 mM EDTA 
Thrombin solution 100 units/mL in 10 mM HEPES pH = 6.5, 0.1% (w/v) BSA 
10x SDS running buffer 0.25 M Tris, 1.92 M glycine, 1% SDS 
5x SDS sample buffer 0.2 M Tris pH = 6.8, 10% (w/v) SDS, 20% (v/v) glycerol, 10 mM DTT or β-
mercapto-ethanol, 0.05% (w/v) bromphenolblue  
Table 4: Buffers, solutions and media. 
 
14.1.3 Additives  
 
Additive 
Final 
concentration 
Ampicilline 100 µg/mL 
Complete, EDTA free, protease inhibitor cocktail tablets; Roche 1 tablet per 50 mL  
IPTG 100 µM 
Kanamycine 15 µg/mL 
PEFA 1 mM 
Protein Marker, BioLabs, Broad Range, 2 – 212 kDa #P7702S; Fermentas 
#sm1891 
10 µL/pocket 
SOC medium (Novagen) as obtained 
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Tetracycline  12.5 µg/mL 
Table 5: Additives. 
 
14.1.4 Enzymes 
 
Enzyme Supplier 
DNase I Roche 
Lysozyme Sigma-Aldrich 
Thrombin Sigma-Aldrich 
                                                                 Table 6: Enzymes. 
 
14.1.5 Bacterial strains 
 
Strain Resistances Supplier 
NEB 10-beta Streptomycin BioLabs 
Origami B (DE3) Kanamycin, Tetracyclin Novagen 
                                          Table 7: Bacterial strains. 
 
14.1.6 Plasmids 
 
Plasmid Resistance Supplier 
pET-22b(+) Ampicillin Dr. Mark Mayer 
pETGQ (derivative of pET30b) Ampicillin Dr. Mark Mayer 
                                 Table 8: Plasmids. 
 
14.1.7 Equipment 
 
Equipment Supplier 
−80 °C freezer GFL 
37 °C incubater Memmert 
0.45 µM Spin-X filter unit Corning Life Sciences 
AEKTA purifier GE Healthcare 
Autoclave Systec 
Bio Photometer Eppendorf 
Centrifuge 5810R Eppendorf 
Centrifuge rotor A-4-62 Eppendorf 
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Centrifuge rotor F-34-6-38 Eppendorf 
Centrifuge rotor F45-30-11 Eppendorf 
Centrifuge rotor SLA-3000 Thermo 
Centrifuge rotor SS-34 Thermo 
Centrifuge Sorval EvolutionRC Thermo 
Concentrators (15 mL, 10 kDa MWCO) Millipore 
Concentrators (0.5 mL, NMWL membrane, -10 K) Millipore 
Crystallization plates VDX 24 well Hampton Research 
CrystalQuick 96 well sitting drop plate (Greiner) Hampton Research 
Crystallization robot Tecan 
Dialysis tubing, 10K MWCO Roth 
French pressure cell press Thermo 
Gel shaker neoLab 
HiLoad 16/60 Superdex 75 prep grade (gelfiltration) GE Healthcare 
HiPrep 26/10 (desalting) GE Healthcare 
HisTrapTM HP (Ni-NTA, 5 mL (GluK2), 1 mL (GluA2)) GE Healthcare 
HiTrapTM SP HP (cation exchange, 1 mL) GE Healthcare 
ITC-200 calorimeter MicroCal 
MASTERBLOCK 96 deep well plate (Greiner) Hampton Research 
Microscale thermophoresis instrument NanoTemper 
Microscope Leica 
NanoDrop UV Spectrometer ND-1000 PeqLab 
pH electrode Mettler Toledo 
pH meter SevenEasy pH S20 Mettler Toledo 
Pipettes Eppendorf 
Power supply PowerPac BioRad 
Mini-PROTEAN Tetra Cell protein gel chamber  BioRad 
Seeding tool Hampton Research 
Shaker incubator 44R New Brunswick Scientific 
Siliconized glass cover slides Hampton Research 
Thermomixer comfort Eppendorf 
TrayCell 105.800 Hellma 
Ultrapure water TKA MicroPure  
UV-Vis spectrometer Varian 
Vortex mixer VWR 
                 Table 9: Equipment. 
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14.2 Methods  
 
14.2.1 Methods in Molecular Biology262 
 
Plasmid recovery from filter paper: 
Indicated circles were cut out from filter paper (Whatmann 3MM) and incubated in 50 
µL TE buffer (containing nuclease inhibitor) for 10 min. The solution was separated 
from the filter paper and chemically competent bacteria were transformed (see 
14.2.2) in order to amplify the plasmids provided by Dr. Mark Mayer. 
 
Isolation and purification of plasmid DNA from bacteria: 
Small-scale DNA preparations from 4 mL overnight culture were performed with the 
HiYield Plasmid Mini Kit provided by SLG. The kit was used according to the 
manufacturerʼs recommendations. 
 
Assessment of DNA concentration: 
The DNA concentration was determined by an absorption measurement at 260 nm. 
The purity of the DNA sample was assessed by considering the ratio of A260/A280. A 
ratio of 1.8 and higher indicates the absence of protein contaminants and therefore 
good quality of DNA. 
 
Sequencing of the purified plasmid DNA: 
In order to validate the sequence of the purified plasmid DNA it was sent to GATC-
Biotech and the .fas, .seq and .ab1 files were evaluated with the software 4Peaks 
and SerialCloner. 
 
14.2.2 Methods in Microbiology  
 
Transformation of chemically competent bacteria: 
E. coli can be rendered competent for DNA uptake by exposure to a heat shock263. 
50 μL of chemically competent cells (DNA amplification: E. coli, NEB 10-beta; protein 
expression: E. coli, Origami B (DE3)) were thawed on ice and 40 ng of purified 
plasmid DNA was added. The suspension was mixed by gently tapping the tube and 
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was incubated on ice for 30 min. Cells were transformed by exposing them to a heat-
shock for 30 sec at 42 °C and cooled down on ice for 5 min. 250 µL SOC medium 
without antibiotics was added and the bacteria culture was incubated at 37 °C on a 
thermomixer at 50 rpm for 1h. After the bacteria were given time to express the 
resistancy genes, 5 µL and 295 µL of the mixture were plated on separate agar 
plates containing the appropriate antibiotic. Plates were incubated at 37 °C overnight. 
 
Protein expression in bacteria by induction with IPTG: 
The pET series of vectors allow regulated expression of foreign genes264. For large-
scale protein expression, 5 L of LB medium containing the appropriate antibiotics 
were inoculated to an OD600 of 0.05 using an overnight culture (100 mL), which was 
inoculated with 500 µL from a −80 °C glycerol stock of transformed bacteria. The 
bacteria were grown at 37 °C while shaking. The OD600 was monitored over time 
against an aliquot of LB medium used for expression. When the OD600 reached a 
value of 0.9, the temperature was immediately changed to 20 °C. IPTG was added at 
this temperature to a final concentration of 100 µM. After induction of expression, 
cells were incubated shaking at 20 °C overnight.  
 
Preparation of a cleared bacterial cell lysate: 
For the recovery of proteins cells can be disrupted265. Induced bacteria were 
harvested by centrifugation at 8000 rpm for 8 min at 4 °C. The supernatant was 
discarded and the pellet was stored at −80 °C if desired. On the day of purification, 
pellets from 5 L of culture were thawed and resuspended in 50 mL of icecold lysis 
buffer containing one tablet of complete EDTA free protease inhibitor, 500 µL/L 
DNAse solution and 500 µL/L lysozyme solution. The suspension was passed 
through a pre-cooled French press 5 to 6 times at 4 °C. The insoluble fraction was 
removed by centrifugation at 18000 rpm for 30 min at 4 °C. The resulting supernatant 
was used for protein purification (see 14.2.4). 
 
14.2.3 Protein qualification and quantification 
 
Protein qualification: 
Proteins were separated according to their molecular weight by discontinuous SDS-
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PAGE266. The solutions of the seperating and stacking gel were prepared according 
to the following pipetting scheme (volumes are given for one gel): 
 
 Stacking gel (5%) Seperating gel (10%) 
30% acrylamide (mL) 0.42 1.68 
10% APS (µL) 25 50 
10% SDS (µL) 25 50 
Seperating gel buffer (mL) - 1.25 
Stacking gel buffer (mL) 0.32 - 
TEMED (µL) 2.5 5 
Water (mL) 1.7 1.98 
                         Table 10: SDS-PAGE. 
 
Both mixtures were prepared without APS and TEMED. To start polymerization, APS 
and TEMED were added to the seperating gel. The gels were cast into the gel 
cassettes and overlayed with isopropanol. After polymerization, the isopropanol was 
decanted and APS and TEMED were added to the stacking gel mixture. The stacking 
gels were poured, combs were inserted and the gels were incubated to polymerize. 
For immediate use, gels were assembled into an electrophoresis cell, running buffer 
was added and the combs were removed. Otherwise, the gels were wrapped in 
aluminium foil for storage at 4 °C. 
Protein samples were appropriately diluted and 5x SDS sample buffer was added. 
After 5 min of incubation at 95 °C, samples were centrifuged at 4000 rpm for 1 min 
and pipetted into the pockets of the gel. Electrophoresis was carried out with SDS 
running buffer at 120 mV constant voltage for 1 h at room temperature. Finally, the 
cell was disassembled and gels were fixed and stained by incubation in Coomassie 
staining solution modified from Neuhoff at room temperature for 1 h on a shaker267. 
Wash out was carried out by heating the gels in destaining solution in a microwave 
and incubating for 1 h on a shaker. Gels were inspected and scanned.  
The purity of the protein sample was also controled by considering the ratio of 
absorption at 260 nm and 280 nm, respectively. A ratio of A260/A280 of about 0.6 is 
characteristic of pure protein with almost no DNA contamination. 
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Protein quantification: 
For protein quantification, the BioRad Protein Bradford Assay was used. It was 
carried out according to the manufacturer´s recommendations. 
Purified protein was also quantified by comparison of the intensity of gel bands and 
for a more precise determination of the concentration the absorbance at 280 nm was 
measured using a NanoDrop ND1000 or a TrayCell in a photometer with a molar 
extinction coefficient of 40005 M-1 cm-1 for GluK2 (M = 29336 Da) and 41620 M-1 cm-1 
for GluA2 (M = 30276 Da), respectively. 
 
14.2.4 Protein purification 
All protein purification methods were performed on an AEKTA purifier at 4 °C. All 
buffers were cooled to 4 °C prior to use and in order to minimize losses, sample size 
never exceeded 80% of the loading loop volume. 
 
Ni-NTA affinity chromatography: 
Histidine-tags are used for affinity purification of proteins268. After preparation of a 
cleared bacterial cell lysate the Ni-NTA column was equilibrated. During equilibration 
of the 5 mL (GluK2) or 1 mL (GluA2) Ni-NTA column with 3 column volumes (CV) of 
Ni-NTA buffer A, samples were spun for 2 min at 18000 rpm at 4 °C. After 
equilibrating the column, the sample was loaded from a 50 mL superloop with a flow 
rate of 2 mL/min (GluK2) or 1 mL/min (GluA2), followed by washing away unbound 
material with 10 CV of 5% Ni-NTA buffer B (GluK2 and GluA2). Competitive elution 
was performed using a stepwise gradient starting with 10% B over a length of 6 CV 
followed by 20% B over 6 CV collecting 5 mL fractions (GluK2) or with 10% B over 6 
CV followed by 20% B over 10 CV collecting 2 mL fractions (GluA2). It was continued 
with 40% B over 6 CV collecting 3 mL fractions (GluK2) or with 40% B over 10 CV 
collecting 1 mL fractions (GluA2). At the end, the program was terminated with a 
linear gradient with a target concentration of 66% B over 5 CV while collecting 5 mL 
(GluK2) or 2 mL fractions (GluA2). Finally, the columns were cleaned with 5 CV 
100% B, followed by 5 CV 0% B and for storage the solution was changed to 20% 
ethanol after rinsing with water.  
GluK2 and GluA2 both eluted at 40% B. Peak fractions were pooled on the basis of 
the absorption at 280 nm and the buffer was changed to Post Ni-NTA buffer by 
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dialysis (3 x 102 fold dilution) overnight at 4 °C. The concentration was determined by 
the methods described and the protein purity was evaluated by SDS-PAGE. Purified 
protein was snap frozen in liquid nitrogen and stored at −80 °C until further use in 
order to perform a thrombin cleavage (see 14.2.5). For crystallization experiments it 
was continued on the next day without freezing the protein in between. 
 
Desalting: 
Desating can replace the sample buffer with a new buffer269. After thrombin cleavage 
(see 14.2.5) the sample was concentrated to 5 – 10 mg/mL using a 15 mL 
concentrator (10 kDa MWCO) and was loaded from a 2 mL sample loop with a flow 
rate of 10 mL/min on the pre-equilibrated (cation exchange buffer A, 2 CV) desalting 
column in order to change to cation exchange buffer A. 3 mL fractions were collected 
while eluting isocratically over 1.5 CV. The column was cleaned with 0.2 M NaOH 
followed by water and was stored in 20% ethanol. After pooling peak fractions on the 
basis of the absorption at 280 nm it was continued with cation exchange 
chromatography.  
 
Cation exchange chromatography: 
Ion exchange chromatography seperates proteins based on their molecular 
charge270. After desalting, the sample was loaded from a 2 mL loop on the pre-
equilibrated (cation exchange buffer A, 5 CV) cation exchange column at a flow rate 
of 1 mL/min. After applying the sample, unbound material was washed away with 10 
CV of 0% cation exchange buffer B (GluA2) or with 7 CV of 0% cation exchange 
buffer B (GluK2). Elution was performed using a stepwise gradient starting with 5% B 
over 10 CV followed by 10% B over 10 CV (GluA2) or with 5.5% B over 5 CV 
followed by 8% B over 8 CV (GluK2), while collecting 1 mL (GluA2) or 0.8 mL 
(GluK2) fractions. It was continued with a linear gradient with a target concentration 
of 40% B over 20 CV while collecting 2 mL fractions (GluA2 and GluK2). Finally, the 
column was cleaned with 5 CV 100% B, was re-equilibrated with 5 CV 0% B and for 
storage of the column, the buffer was changed to 20% ethanol, 0.2 M sodium acetate 
pH = 4.8, after rinsing with water.  
Usually GluA2 and GluK2 eluted at 10% and 8% B, respectively. Peak fractions were 
pooled, the concentration was determined and the protein purity was evaluated by 
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SDS-PAGE. It was continued either with affinity measurements (see 14.2.6 and 
14.2.7) or with gel filtration.  
 
Gel filtration: 
Gel filtration seperates molecules on the basis of their molecular size269. After cation 
exchange, the buffer was changed to crystallization buffer by dialysis at 4 °C. The 
sample was concentrated to 10 mg/mL using a 15 mL concentrator (10 kDa MWCO) 
and was loaded from a 2 mL sample loop with a flow rate of 1 mL/min on the pre-
equilibrated (2 CV, crystallization buffer) gel filtration column. 2.5 mL fractions were 
collected while eluting isocratically over 1.5 CV. After rinsing with water, the column 
was flushed with 20% ethanol for storage.  
The GluK2- and GuA2-LBD eluted after 55 – 60 min. Peak fractions were pooled on 
the basis of the absorption at 280 nm, the concentration of the protein was 
determined and the purity was evaluated by SDS-PAGE. It was continued with co-
crystallization experiments (see 14.2.8).  
 
14.2.5 Protein digest 
Thrombin is commonly used for enzymatic cleavage271. The recognition site (LVPRG) 
is next to the N-terminal histidine tag, which needs to be removed. 
After Ni-NTA chromatography, the digest was performed for 1 h at room temperature 
or overnight at 4 °C with 10 mM CaCl2 using high activity thrombin at a molar ratio of 
substrate to protease of 600 : 1. Once the reaction was set up, aliquots were taken 
after different time intervals and were analysed by SDS-PAGE to confirm the success 
of the cleavage. The digest was stopped with PEFA (final concentration: 1 mM) and 
after five minutes EDTA (pH = 7.0, final concentration: 25 mM) was added. The 
sample was placed on ice and for further use the buffer was changed to cation 
exchange buffer A using a desalting column (see 14.2.4).  
 
14.2.6 Isothermal titration calorimetry 
Binding affinities can be determined with ITC260,272. In order to remove glutamate 
from the buffer after cation exchange, the protein was successively dialysed (1020 
fold dilution) against ITC buffer at 4 °C. The titration calorimetry experiments were 
carried out in an ITC-200 calorimeter at 10 °C. Samples were vacuum-degassed 
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while stirring at 10 °C for 20 minutes. The final protein concentration was 91.2 µM for 
the GluK2-LBD and 196 µM for the GluA2-LBD. The protein was placed in the 
sample cell and the ligand was added (16 injections at 2 µL per injection with a 
duration of 4 sec and a filter period of 5 sec; injections were spaced by 180 sec) from 
a stock solution (975 µM for glutamate binding to the GluK2-LBD, 1200 µM for 4-
Gluazo (2) binding to the GluK2-LBD, 1200 µM for glutamate binding to the GluA2-
LBD and 1580 µM for 4-Gluazo (2) binding to the GluA2-LBD) while stirring at 800 
rpm. For each titration, the heat effects of buffer dilution were measured in a control 
experiment in which the ITC buffer was titrated into the protein solution following the 
same injection schedule as the sample titration. After subtracting the control data, the 
sample titration was fit to a single-binding-site model. Data were analyzed using 
MicroCal Origin and parameters were determined using the following equations. 
                                                         ∆! =   −!"#$%                                                   (1) 
                                                      ∆! =   ∆! − !∆!                                                  (2) 
 
14.2.7 Microscale thermophoresis  
MST is a new and very powerful technology to measure affinities with high precision 
and low sample consumption7,273. Thermophoresis is the directed movement of 
particles in a temperature gradient. A temperature difference leads to a depletion of 
solvated biomolecules in the region of elevated temperature. The thermophoretic 
depletion depends on the interface between the molecules and the solvent, i. e. the 
size, charge and solvation entropy of the molecule274.  
Figure 10: Tryptophane residues of the GluK2-LBD, which are important for label-free microscale 
thermophoresis. Cartoon representation of the GluK2-LBD (D1: dark blue, D2: light blue) with tryptophane 
residues (gray spheres). 
EXPERIMENTS 
 87 
Until now, the thermophoretic movement has been detected using a fluorescent tag 
attached to one of the binding partners275. Recently, a label-free variant of MST has 
been developed using the intrinsic protein fluorescence7. The dominant intrinsic 
fluorophore is tryptophane and the four Trp residues of the GluK2-LBD are shown in 
figure 10.  
After cation exchange, glutamate was removed from the protein solution by 
exchanging into crystallization buffer by dialysis (1020 fold dilution) at 4 °C. For both 
LBDs a concentration of 2 µM gave a satisfactory UV-fluorescence intensity without 
significant bleaching. Protein solutions with constant concentrations were pre-mixed 
with the respective ligand. The ligands were titrated (from 7.6 nM to 125 µM for 4-
Gluazo (2) binding to the GluK2-LBD, from 7.6 nM to 250 µM for glutamate binding to 
the GluK2-LBD, from 30.5 nM to 250 µM for glutamate binding to the GluA2-LBD and 
from 122.1 nM to 500 µM for 4-Gluazo (2) binding to the GluA2-LBD) and the mixed 
solutions were incubated on ice for 1 h. After filling the capillaries, they were sealed 
with wax from both sides and the measurement was started. All measurements were 
performed at a capillary basis temperature of 20 °C. 
Using the law of mass action and solving its quadratic equation for the fraction of 
bound protein gives the following equation:   
                               [!!][!!] = [!!]![!!]!!! ± !! ![!!]!!! !!![!!][!!]![!!]                                  (3) 
The fraction of bound protein was fitted to the quadratic solution of the binding 
reaction equilibrium with KD being the single free parameter. Thus, the KD values of 
the different ligands binding to the LBDs can be obtained from the titration series275-
277.  
 
14.2.8 Protein–ligand co-crystallization  
After size-exclusion chromatography, the purified LBDs (12.4 µM GluK2-LBD, 14.8 
µM GluA2-LBD) were extensively dialyzed (1020 fold dilution) against crystallization 
buffer over a period of 36 h at 4 °C.  After further dialysis in the dark (106 fold dilution, 
12 h, 4 °C; crystallization buffer + 125 µM 4-Gluazo (2) for the GluK2-LBD; 
crystallization buffer + 460 µM 4-Gluazo (2) for the GluA2-LBD) to exchange 
remaining receptor bound glutamate for 4-Gluazo (2), the protein concentration was 
determined at this stage due to strong absorption of 4-Gluazo (2) at 280 nm at higher 
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concentrations of the ligand. 4-Gluazo (2) was added in the same buffer to give a 
final concentration of 1.3 mM and the protein concentration was adjusted to 
approximately 6 mg/mL for the GluK2-LBD and 6.4 mg/mL for the GluA2-LBD, 
estimated from the concentration measured in the presence of a minimal amount of 
4-Gluazo (2). Prior to crystallization, the protein solutions were passed through a 
filter.  
All crystallization experiments were set up under dimmed light and during 
crystallization the 96/24-well-plates were kept in the dark. Crystals were observed 
and manipulated under dimmed light using a Heliopan red filter (cutoff < 600 nm) in 
combination with the microscope. After a high throughput screening at 4 °C and 20 
°C (Hampton screenings) using the crystallization robot, all conditions were examined 
and a fine screening with macro- and micro-seeding was performed around the most 
promising conditions. Crystals were grown by the hanging drop vapor diffusion 
technique by gently mixing 1 µL reservoir solution with 1 µL protein solution278,279.  
GluK2-LBD cystals grew in the presence of 50 mM MES pH = 6.5, 2.05 M Li2SO4, 10 
mM MgCl2 and were transferred into reservoir solution supplemented with 0.75 M 
LiCl in order to cryo-protect them before freezing in liquid nitrogen. GluA2-LBD 
crystals grew in the presence of 50 mM MES pH = 5.6 – 6.5, 23 – 27% (w/v) 
PEG3350, 0.2 M Li2SO4 and were transferred into reservoir solution saturated with 4-
Gluazo (2) and containing 20% (v/v) ethylene glycol prior to cryo-cooling.  
 
14.2.9 Data collection and structure determination 
Data collection and structure determination were performed by Dr. André Schiefner. 
Diffraction data were collected at BESSY and were processed with the XDS 
Package280. Structures were solved by molecular replacement with PHASER using 
PDB entries 3G3F and 3BFU as starting models281-284. Model building and refinement 
was performed with COOT and REFMAC285,286. Ligand geometry restraints for 4-
Gluazo (2) were parameterized with PRODRG287. Planarity restraints for the 
azobenzene moiety were defined manually.  
 
14.2.10 Structural comparison and analyses 
Both LBD structures were validated with COOT and MolProbity288. Molecular 
interfaces and contacts were analyzed with PISA and CONTACT289,290. Structural 
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superpositions were performed with SUPERPOSE and molecular graphics were 
prepared with PyMOL291,292. 
The following domain definitions were used for structural comparisons: GluK2-LBD 
D1: residues 5 – 108 and 216 – 252, D2: residues 109 – 215 and 253 – 260; GluA2-
LBD D1: residues 4 – 108 and 219 – 255, D2: residues 109 – 218 and 256 – 264. As 
reference structures for comparison the wild-type GluK2-LBD in complex with 
glutamate (PDB entry 3G3F chain B) and the GluA2-LBD in complex with CNQX 
(PDB entry 3T9V chain A) were used282,293. 
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Chapter 15: Protein–4-Gluazo co-crystallization 
 
15.1 Synthesis of 4-Gluazo 
The overview of the synthesis of 4-Gluazo (2) is described in chapter 8 and 
experimental details are given in chapter 13.2. According to literature, the preparation 
has been achieved in good yields and spectra are shown in chapter 22.16.  
To gain higher yields, the synthetic route has been optimized. By introducing a 
bromine at the terminal alkyne position of propargyl pyroglutamate (11), the following 
hydrostannylation has been performed with a higher regioselectivity and yield294.  In 
contrast, direct stannylation of the alkyne without prior bromination results in a low 
yield with a 1:1 ratio of Markovnikov : anti-Markovnikov product.  
The Stille cross coupling reaction has also been changed slightly. It is well known, 
that a fluoride ion can increase the rate of the coupling reaction and moreover, 
electronically disfavoured coupling reactions can be performed. Also, the insoluble 
Bu3SnF byproduct is formed, which can be easily removed from the reaction mixture 
by filtration295. However, fluoride ions tend to isomerize substituents at the α-carbonyl 
position296. Therefore, in this particular case, the yield to give enantiomerically pure 
azobenzene pyroglutamate (17) via Stille cross coupling could has been increased by 
performing the reaction without CsF.  
In addition, a crystal structure of propargyl pyroglutamate (11) has been obtained, 
which is depicted in figure 11. The corresponding crystallographic data are tabulated 
in chapter 21.2. 
 
Figure 11: Crystal structure of propargyl pyroglutamate (11). 
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15.2 Verification of plasmid DNA 
Crystallizable constructs of the GluK2- and GluA2-LBD, which are schematically 
shown in the intruductory part (Fig. 1 C), have been available in pET22b(+) and 
pETGQ expression vectors, respectively. The plasmids have been sequenced and 
the results are shown in chapter 23.1 for GluK2-LBD and in chapter 23.2 for GluA2-
LBD with the individual elements boxed and colour coded. Translated protein primary 
structures are in accordance to the published ones54,61.  
GluK2-LBD S1 starts with S398NRS and ends with LYRK513. GluK2-LBD S2 starts with 
P636IDS and ends with GCPE775. After thrombin cleavage, a glycin is N-terminal of 
S1.  
GluA2-LBD S1 starts with S383GND and ends with MIKK506. GluA2-LBD S2 starts with 
P632IES and ends with ECGS775. The sequence GSAMG is N-terminal of S1 after the 
thrombin cleavage. The sequences are numbered with respect to the first amino acid 
in the full-length mature protein without the signal peptide for both, GluK2- and 
GluA2-LBD. 
  
15.3 Protein preparation 
After transformation and overexpression in E. coli, soluble proteins have been 
purified with Ni-NTA affinity chromatography, cation exchange chromatography and 
gel filtration. After Ni-NTA affinity chromatography a thrombin digest has been 
performed. Methods and conditions are described in chapter 14.2. During protein 
preparation aliquotes have been taken and have been analysed by SDS-PAGE. Gels 
are shown in figure 12 and 13 for the GluK2- and GluA2-LBD, respectively. 
In the gel concerning the GluK2-LBD, the individual bands of the marker (Fermentas 
#sm1891) in lane one did apparently not run accordingly to their molecular weight. 
The histidine-tagged GluK2-LBD recombinant protein should have a molecular weight 
of 31.2 kDa. Therefore, the prominent band in lane two, which represents the 
recombinant GluK2-LBD after Ni-NTA affinity chromatography, should be slightly 
shifted to the top. After this step of purification, the protein sample is already highly 
pure with a minimal contamination at the lower part of the lane, observable through a 
tender band. Thus, almost all endogenous proteins have been removed with the first 
step of purification. 
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Figure 12: SDS-PAGE analysis of the GluK2-LBD purification and thrombin digest.  MW marker,  after 
Ni-NTA,  after 10 sec thrombin digest,  after 30 min thrombin digest,  after 1 h thrombin digest,  after 
cation axchange,  after gel filtration. 
 
A histidine tag can influence the activity of proteins, which can lead to a different 
affinity in ligand binding assays. Moreover, the tag should be removed in order to 
perform structural studies, because it might induce different crystal packing. Lanes 
three to five illustrate the process of the thrombin digest. The gentle prothrombin 
band is at the very top of these lanes. The band of the his-tagged protein is getting 
less intense and the band of the digested protein intensifies over time. The cleaved-
off histidine tag appeares as a diagnostic, blurred band at the very bottom of the gel. 
The molecular weight of the protein without tag is 29.3 kDa and the difference of 2 
kDa between cleaved and uncleaved protein is in accordance with the gel. 
With cation exchange, which is the second step of purification, all remaining 
impurities have been removed, as can be seen in lane six. In addition, gel filtration 
has been performed to further purify the protein. Results are shown in lane seven 
and there is only one heavy band pointing out the high purity of the protein sample 
used for crystallization experiments. 
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Figure 13: SDS-PAGE analysis of GluA2-LBD purification and thrombin digest.  after Ni-NTA,  after 10 
sec thrombin digest,  after 30 min thrombin digest,  after 1 h thrombin digest,  after cation exchange,  MW 
marker. 
 
For GluA2-LBD individual bands of a fresh sample of the marker (Fermentas 
#sm1891), which was applied to lane six, did run accordingly to their molecular 
weight. In general, for the GluA2-LBD preparation the same results have been 
achieved. The protein sample is already very pure after Ni-NTA chromatography 
(lane one) and the octa histidine tag has been completely removed by the thrombin 
digest (lanes two to four). The molecular weight of the recombinant protein is 32.2 
kDa with his-tag and 30.3 kDa without tag. This shift can be observed in the gel as 
well. With cation exchange (lane five), remaining thrombin and other minor impurities 
have been completely seperated from the GluA2-LBD, represented by a single heavy 
band in the gel. Prior to crystallization experiments, a gel filtration has been 
performed (not shown) to further increase the purity and to exchange into 
crystallization buffer. 
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15.4 Isothermal titration calorimetry 
 
Figure 14: Isothermal titration calorimetry. (A – D) Thermodynamics of the interactions between (A) GluK2-
LBD and glutamate, (B) GluK2-LBD and 4-Gluazo (2), (C) GluA2-LBD and glutamate and (D) GluA2-LBD and 4-
Gluazo (2). Each panel presents raw data (top) and heat data after peak integration and substraction of control 
titrations (bottom). Heat changes are plotted as a function of the molar ratio of protein to ligand for each injection. 
Curves represent the best nonlinear least-squares fitting of the data to a one-site binding model. The ΔH, ΔS, 
stoichiometry and KD values of each reaction correspond to mean values of two experiments. 
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ITC directly measures the energy associated with a chemical reaction and the 
binding of glutamate and 4-Gluazo (2) to the GluK2- and GluA2-LBD has been 
investigated by combining protein and ligand for each case. Results are shown in 
figure 14. 
The interaction of the GluK2-LBD with gutamate (KD = 0.31 µM) is stronger when 
compared to the affinity towards 4-Gluazo (2, KD = 3.1 µM). Same results have been 
observed for the GluA2-LBD with the interaction between 4-Gluazo (2, KD = 28 µM) 
and the protein being weaker than the interaction of glutamate (KD = 0.90 µM) and 
the GluA2-LBD. Overall the GluK2-LBD has a higher affinity towards both ligands. 
However, the difference in affinity towards glutamate and 4-Gluazo (2) is much higher 
for GluA2-LBD.  
The different affinities can mainly be attributed to the different entropy changes (ΔS). 
For the GluK2-LBD, the entropy change is more favorable in the case of the binding 
of glutamate, which may be explained by a greater solvent release upon burial of 
more surface during binding and clam shell closure. Therefore, the clamshell is 
expected to close more tightly around glutamate than 4-Gluazo (2).  
Binding is in both cases an endothermic reaction. Simply put, this means that during 
the binding reaction more hydrogen bonds are broken than newly formed. The 
change in enthalpy (ΔH) is greater for the binding of 4-Gluazo (2). Because of the 
shape of 4-Gluazo (2), more hydrophobic interactions, which are the determining 
factors for heat capacity change, can take place between the ligand and the protein 
upon clamshell closure. Therefore, numerous hydrogen bonds between water 
molecules, or between the protein surface and water molecules, are additionally 
broken. 
Concerning the GluA2-LBD, the difference between the change in entropy is more 
dramatic between glutamate and 4-Gluazo (2) binding. This mainly explains the 
greater dissimilarity in affinity. Regarding the change of the enthalpy, the binding of 
glutamate is endothermic, whereas the binding of 4-Gluazo (2) is exothermic. In the 
case of glutamate binding, more hydrogen bonds are broken than newly formed. 
Thus, the mechanism of binding is similar to that of the binding of glutamate and 4-
Gluazo (2) to the GluK2-LBD. However, according to the ITC measurement, the 
binding mode of 4-Gluazo (2) binding to the GluA2-LBD, is different. During the 
binding mechanism, there are more hydrogen bonds formed than broken. It has 
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already been shown before that 4-Gluazo (2) functions as a weak photochromic 
antagonist of the GluA2-LBD in the presence of glutamate297. Upon binding of 4-
Gluazo (2) new hydrogen bonds are formed between the protein and the ligand. But 
the antagonistic action prevents clamshell closure and the concomitant break of 
hydrogen bonds between the protein and surface bound water molecules. This could 
explain the exothermic change in enthalpy. The proposed, different mechanism of 4-
Gluazo (2) binding to the GluA2- and GluK2-LBD, respectively, has been confirmed 
by this measurement. 
For each measurement the binding stoichiometry for ligand–LBD binding is much 
lower than one, which would be expected for a single binding mode. Either only a 
fraction of the protein has been properly folded, or the binding kinetics involve a very 
fast off-rate. As a consequence, the protein is not bound to the ligand all the time 
during the measurement. 
 
15.5 MST 
iGluR-LBDs undergo conformational changes when a ligand binds. This change of 
shape and solvation entropy of the molecule leads to a significant change in the 
thermophoretic behaviour, which is the movement of molecules in a thermal gradient. 
Therefore, the ligand–protein interactions can be measured by MST. The dissociation 
constants of glutamate and 4-Gluazo (2) towards the GluA2- and GluK2-LBD have 
been infered. Results are depicted in figure 15.  
 
Figure 15: MST binding curves. (A and B) Graphs are derived from specific changes in the thermophoretic 
mobility upon ligand titration of glutamate (green) and 4-Gluazo (2, yellow) to the GluK2- (A) and GluA2-LBD (B). 
KD values are given in the text. 
RESULTS AND DISCUSSION 
 98 
The number of independent measurements has been two for the GluK2-LBD and one 
for the GluA2-LBD. For the GluK2-LBD, the KD-values are almost perfect in 
agreement with the values determined by ITC. The KD has been determined with an 
upper limit of 0.36 µM for glutamate, and 4-Gluazo (2) bound to the GluK2-LBD with 
a clearly defined KD of 3.2 µM. For the GluA2-LBD, the KD of glutamate has been 
obtained to be 0.84 µM, which is consistent with results from ITC. The MST KD value 
of 4-Gluazo (2) binding to the GluA2-LBD is 19 µM and does not deviate significantly 
from the value determined by ITC. These results show that the affinities have been 
determined sufficiently precise with two different methods leading to the same 
results. Data measured by MST have been published7. 
 
15.6 Crystallization 
The GluK2-LBD4-Gluazo protomer crystallized together with the GluK2-LBDMES 
protomer as an overal dimer in the asymmetric unit and the structure has been 
solved at 2.0 Å resolution. Electron density has been observed for residues 3 – 258 
for both protomers as well as for both ligands, a chloride ion and a sulfate ion. Two 
GluK2-LBD crystals can be seen in figure 16. They show a hexagonal bipyramidal 
morphology and belong to space group P6122.  
 
           Figure 16: (GluK2-LBD)24-GluazoMES crystals. Two different crystals under the microscope.  
 
GluA2-LBD crystals grew in different lattices exhibiting a similar plate like morphology 
(not shown) and best crystals diffracted to 1.8 Å resolution and have been obtained in 
space group P212121 with four GluA2-LBD molecules per asymmetric unit. 
Reasonable density has been observed for residues 4 – 264, 4 – 262, 4 – 264, and 4 
– 261 of protomers A, B, C and D, respectively. Moreover, two MES molecules, 
twelve sulfate ions and five ethylene glycol molecules have been clearly observed. A 
table summarizing all crystallographic data and refinement statistics is depicted in 
chapter 21.1. 
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15.7 GluK2-LBD and GluA2-LBD structures 
 
15.7.1 GluK2-LBD dimer 
The GluK2-LBD crystallized as physiological dimer with two different LBD 
conformations. The mixed dimer is illustrated in figure 17 as cartoon with surface 
representation (Fig. 17 A). Additionally, the structure is depicted from different 
perspectives (Fig. 17 B). Similar mixed dimers have already been reported for the 
GluA2-LBD, but not for the GluK2-LBD60,298.  
 
Figure 17: Mixed GluK2-LBD dimer. (A) Translucent surface and cartoon representation of GluK2 with the 
closed, 4-Gluazo (2, yellow spheres) bound LBD (blue cartoon) and the open, MES (magenta spheres) occupied 
LBD (green cartoon). The central chloride ion is featured as an orange sphere. (B) The GluK2-LBD dimer 
consisting of individual protomers [(GluK2-LBD4-Gluazo: light gray cartoonyellow spheres), (GluK2-LBDMES: 
dark gray cartoonmagenta spheres)] is shown in three different orientations (left and middle perpendicular to and 
right along its dyad axis) with the chloride ion (orange sphere) occupying the dimer interface. 
 
One 4-Gluazo (2) bound protomer is closed, while the other one is open and 
accommodates a MES molecule, which has been present in the reservoir solution. 
Additionally, a chloride ion bound in a cavity formed at the interface between the 
subunits of this dimer pair. Chloride ions are essential structural components of 
kainate receptors and monovalent ions like sodium and chloride play a role in 
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allosteric modulation. Their absence in the extracellular solution leaves the receptor 
in a high-affinity closed state299-301.  
 
Figure 18: Overview of the GluK2 ligand-binding sites. (A and B) Important ligand (MES: magenta sticks, 4-
Gluazo (2): yellow sticks) receptor (gray sticks) interactions with trapped water molecules (red spheres). 
Hydrogen bonds and ion pair interactions are indicated by black dashed lines. GluK2 residues are numbered 
according to the mature protein including the signal peptide. (C and D) Omit 2FO−FC electron density maps are 
contoured at 0.4 σ and are shown as a gray mesh around the two ligands. (E – G) Superpositions of GluK2-
LBD4-Gluazo and GluK2-LBDMES (yellow and magenta sticks, respectively) with GluK2-LBDglutamate 
(green sticks, PDB entry 1S7Y). Superpositions have been performed with D1 aligned and D2 free to move and 
water molecules are shown as spheres and are coloured according to the structure they belong to. 
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The interactions of 4-Gluazo (2) and MES with receptor residues and surrounding 
water molecules with the given orientation in space are shown in figure 18 A and B, 
respectively. Electron densities for the two ligands are depicted in figure 18 C and D, 
and omit maps show unambiguous and contiguous density for both, MES and 4-
Gluazo (2). The electron density is not so well defined for the azobenzene part of 4-
Gluazo (2), indicating some flexibility of this part. This is reflected by the B-value, 
which is twice as high for the azobenzene group when compared to the glutamate 
moiety of the molecule. Additionally, the binding modes of 4-Gluazo (2) and MES are 
compared with one another and with the natural agonist glutamate in figure 18 E, F 
and G.  
Moreover, the premium positioning of 4-Gluazo (2), MES and glutamate within the 
LBD is illustrated in figure 19 A, B and C, respectively, with the protein shown as 
surface representation. Figure 19 D, E and F shows simplified, clearly arranged 
interaction networks between the protein and the different partners. 
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Figure 19: Premium positioning of 4-Gluazo (2) and MES in the GluK2-LBD and comparison with 
glutamate. (A – C) Surface representation of the GluK2-LBD (D1: dark blue, D2: light blue) with bound (A) 4-
Gluazo (2, yellow spheres), (B) MES (magenta spheres) and (C) glutamate (green spheres; PDB entry 1S7Y). 
(D – F) Overview of the molecular details. Receptor residues interacting with (D) 4-Gluazo (2, yellow sticks), (E) 
MES (magenta sticks) and (F) glutamate (green sticks) via hydrogen bonds or salt bridges (black, dashed lines) 
are shown as sticks, whereas residues mediating van der Waals contacts are depicted as ellipses. In general, 
protein residues are numbered according to the PDB file and are shown in shades of blue according to their 
location on D1 or D2. Water molecules are shown as gray spheres. For simplicity, all residues have been 
flattened onto the plane of the page. 
 
As expected, the glutamate part of 4-Gluazo (2) directly interacts with the same key 
residues of the receptor when compared to a glutamate bound structure61. Moreover, 
the amount of conserved water molecules contributing to the overall ligand–receptor 
interactions is the same with their positions deviating minimally for three out of five 
water molecules.  
Glutamate binds to a cavity, which is almost completely hidden from the external 
solution and which is formed at the interface between D1 and D261. In contrast, the 
azobenzene part of 4-Gluazo (2) protrudes from this cavity and interacts with the 
protein through van der Waals forces. This prevents the clamshell from a full closure 
and the angle of rotation of the rigid body movement of D2 to convert the two 
structures into each other is eight degree as shown in figure 20 A. 
The open, MES bound protomer shows the first GluK2-LBD in its apo-like form. The 
MES molecule is located in the glutamate binding cavity and all the protein residues 
that interact with MES are part of the binding pocket of the receptor. The oxygen 
atom of the morpholine ring of MES forms a hydrogen bond to a water molecule and 
the protonated nitrogen of the six membered ring interacts with the same glutamate 
residue of the receptor, which normally interacts with the α-amino group of the ligand 
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glutamate. This protein glutamate residue (E191) indirectly also interacts with the 
sulfonate moiety of MES, bridged via a water molecule. The sulfonate group 
additionally binds two more water molecules, forms a salt bridge with a highly 
conserved arginine (R523) and is stabilized by the backbone NH of an alanine 
(A518). The overall open conformation of the LBD is illustrated by comparing the 
surface representation of the protein or by considering the huge shift of important 
ligand binding cavity residues on D2. D2 is clearly separated from D1 and the angle 
of clamshell closure of the GluK2-LBDMES structure to match the glutamate bound 
conformation is 25 degree, which is pointed out in figure 20 A as well. 
 
Figure 20: Different conformations and configurations. (A) Superpositions of GluK2-LBD4-Gluazo (yellow 
tubespheres), GluK2-LBDMES (magenta tubespheres) and GluK2-LBDglutamate (green tube, PDB entry 
1S7Y) with D1 aligned and D2 free to move. The yellow and magenta arrows indicate the clamshell closure via 
rotation of D2 to match the glutamate bound conformation. Degree values are given and angles are exemplified 
by black lines. (B – D) Trans (yellow sticks) and cis (cyan sticks) 4-Gluazo (2) in the (B) closed and (C) open 
conformation of the GluK2-LBD with a (D) close-up view of the closed conformation. D1 (dark blue) and D2 (light 
blue) are shown as opaque (B and C) or transparent (D) surface representation. 
 
In figure 20 B, C and D the mechanism for activation and inactivation of the 
glutamate receptor by photoswitching between the different azobenzene 
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configurations of 4-Gluazo (2) with different wavelenghts of light, is depicted. For this 
purpose, the coordinates of a cis azobenzene have been downloaded from the 
cambridge crystallographic data centre (CCDC) and the two possible cis 
configurations have been docked onto the trans azobenzene part of 4-Gluazo (2) in 
the closed GluK2-LBD4-Gluazo structure (Fig. 20 B)140. Moreover, all possible 
configurations of 4-Gluazo (2) have been inserted into the open, apo-like GluK2-
LBDMES structure with the ligand occupying the same position relative to D1 of the 
closed protein conformation (Fig. 20 C). The open conformation of the LBD has 
enough room to host both cis configurations of the azobenzene unit of 4-Gluazo (2). 
On the other hand, in the case of the closed GluK2-LBD conformation, the distal 
penyl ring of the azobenzene part of 4-Gluazo (2) penetrates into the surface of the 
protein in both cis configurations. This is exemplified in an enlarged section with the 
protein shown with a transparent surface (Fig. 20 D). The phenyl ring of one cis 
configuration of 4-Gluazo (2) is fully buried in the protein and the ring of the second 
configuration to two third. Accordingly, the action of 4-Gluazo (2) on the glutamate 
receptor is in agreement with the proposed activation mechanism discussed in the 
introduction. In the cis configuration, 4-Gluazo (2) can bind to the open conformation 
of the protein, but the clamshell can barely close. Contrary, the degree of clamshell 
closure after binding of the ligand in the trans configuration is high enough to 
allosterically allow the pore to open. 
However, the question of inactivation of the receptor with 4-Gluazo (2) bound in trans 
and isomerized to cis remains unclear. One possibility would be a fast off-rate of 
bound trans 4-Gluazo (2) and the subsequent hindrance of clamshell closure upon 
isomerization to cis. With respect to the fast off-rate discussed in the context of the 
binding stoichiometry within the results of the ITC measurement, this mechanism is 
possible. The other option would be an active opening of the clamshell by 4-Gluazo 
(2), when isomerized from trans to cis.  
 
15.7.2 GluA2-LBD dimer of dimers 
Unfortunately, the solved structure of the GluA2-LBD does not show 4-Gluazo (2) 
bound to the protein. This can be explained by the low affinity and solubility of the 
ligand. On the basis of electrophysiological experiments and affinity measurements 
described above, 4-Gluazo (2) would have been expected to stabilize the open 
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conformation of the GluA2-LBD. The cavity of the GluA2-LBD is smaller than that of 
the GluK2-LBD61. A substantially less pronounced closure of the clamshell after 
binding of 4-Gluazo (2) could explain the antagonistic effect on GluA2. This closure 
would be insufficient to activate the channel.  
 
Figure 21: Dimers and ligand-binding site of the GluA2-LBD. (A) Translucent surface and cartoon 
representation of the non biological dimer of dimers structure of the GluA2-LBD with MES (salmon spheres) and 
sulfate ions (spheres) occupying two (protomer A and C) of the four LBDs (blue, yellow, green and red cartoons). 
Ethylene glycol and sulfate molecules (not shown) occupy the other two LBDs (protomer B and D). (B) One 
GluA2-LBD dimer (protomer A and B) consisting of two unequal protomers (light and dark gray cartoons, 
respectively) is shown in two different orientations (top perpendicular to and bottom along its dyad axis). Protomer 
A interacts with MES (salmon spheres) and a sulfate ion (spheres) and protomer B with ethylene glycol (cyan 
spheres) and a sulfate ion (spheres). (C) Interactions between MES (salmon sticks), a sulfate ion (sticks) and 
receptor residues (gray sticks). Trapped water molecules (red spheres) are shown and hydrogen bonds and ion 
pair interactions are indicated by black dashed lines. GluA2-LBD residues are numbered according to the mature 
protein without the signal peptide. (D) Omit 2FO−FC electron density map contoured at 1.0 σ is shown as a gray 
mesh around MES (salmon sticks) and the sulfate ion (sticks). 
 
Crystal packing produced a GluA2-LBD tetramer, as can bee seen in figure 21 A. 
The tetramer is non-physiological when compared to the structure of the full-length 
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receptor, but consists of a pair of two physiological dimers60. This crystal packing has 
already been observed for the GluA2-LBD56. The LBDs of both dimers resemble the 
open conformation of the GluA2-LBD and one of the dimers is depicted in different 
orientations in figure 21 B. In each dimer, the binding cavity of one protomer is 
occupied by MES and a sulfate ion from the reservoir solution, whereas the other 
ligand-binding site is filled by a sulfate ion and an ethylene glycol molecule from the 
cryo protecting solution. Interactions of the MES molecule and the sulfate ion with the 
protein and associated water molecules are illustrated in figure 21 C. All the residues 
of the protein contacting either MES or the sulfate ion are part of the binding cavity of 
the natural ligand glutamate. The electron density of MES and the sulfate ion is 
shown in figure 21 D.  
The sulfonate group of MES is in contact with a water molecule, is the counter ion of 
a highly conserved arginine (R485) and forms a hydrogen bond to the backbone NH 
of a threonine (T480). The protonated nitrogen atom of the morpholine ring forms a 
hydrogen bond to the γ-carboxyl group of a glutamate (E705) residue of the protein, 
which is additionally connected to the sulfate ion via a water-mediated hydrogen 
bond. Moreover, the backbone NH of this glutamate residue donates a proton to the 
sulfate ion. The sulfate ion forms hydrogen bonds to four more water molecules with 
one mediating an indirect contact to the backbone NH of a threonine (T655). When 
the ligand glutamate binds to the protein, the side chain of this threonine interacts 
with the γ-carboxyl group of glutamate56. Howerver, in this structure the side chain of 
the threonine forms a contact to the sulfate ion. Overall, the sulfate ion forms a cross-
linked cluster of hydrogen bond contacts to water molecules as well as to the protein. 
In figure 22 important key interactions of the GluA2-LBD with different ligands are 
pointed out. The structures have been aligned to the GluA2-LBDMES structure and 
ligand–receptor contacts and orientations are compared (Fig. 22 A – D). The apo 
form of the GluA2-LBD is also considered (Fig. 22 E). Moreover, an alignment of the 
GluA2-LBDMES structure and the GluK2-LBDMES structure with interacting 
residues is shown (Fig. 22 F), but a statement comparing the structures of two 
different receptor subtypes with respect to the state would be highly speculative. 
However, as can be seen in the different alignments, the best match is achieved 
between the GluA2-LBDMES structure and the apo structure. This similarity could 
indicate to consider the GluK2-LBDMES structure as the first apo structure of 
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GluK2. Additionally, an alignment of the entire LBD in conjugation to the different 
ligands is shown (Fig. 22 G and H). 
Figure 22: Superpositions of GluA2-LBDMES with previously determined structures. (A – H) All 
superpositions have been made with D1 aligned and D2 free to move. (A – F) Illustration of superimposed 
binding-site residues of GluA2-LBDMES (salmon sticks) with (A) GluA2-LBDglutamate (green sticks, PDB entry 
2UXA), (B) GluA2-LBDDNQX (brown sticks, PDB entry 1FTL), (C) GluA2-LBDATPO (orange sticks, PDB entry 
1N0T), (D) GluA2-LBDZK200775 (blue sticks, PDB entry 3KGC), (E) apo GluA2-LBD (dark gray sticks, PDB 
entry 1FTO) and (F) GluK2-LBDMES (magenta sticks). In (A) and (F) water molecules are shown as spheres 
coloured according to the different residues. (G and H) Cartoon-tube representation of  superimposed GluA2-
LBDs with similar colours applying. 
 
In all superpositions D1 has been aligned and D2 has been free to move. Therefore, 
D1 residues occupy similar positions, but D2 residues differ. The degree of rotation of 
D2 upon domain closure, which is in this case illustrated by the movement of D2 
residues, is the greatest for the shown glutamate bound structure. While the full 
agonist glutamate induces a domain closure of 19° when compared to the apo 
structure, the antagonists DNQX, ATPO and ZK200775 stabilize the open 
conformation of the receptor59,60. The demonstrated domain closure decreases from 
the GluA2-LBDDNQX structure over the GluA2-LBDATPO structure to the GluA2-
LBDZK200775 structure.  
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With the LBD being in an open apo-conformation or being bound to antagonists, the 
formation of an interdomain contact between a glutamate (E402, PDB file: E13) and a 
threonine (T686, PDB file: T174) residue is prevented302. Interdomain salt bridges 
and hydrogen bonds have an effect on a number of channel properties like 
deactivation rates and affinity, and these interdomain contacts underlie the 
differences between AMPA and kainate receptors in their rate of recovery from 
desensitization303. In the closed, glutamate bound structure this bridge is present, 
which is illustrated in figure 23. However, in the GluA2-LBDMES structure this 
interdomain hydrogen bond is absent.  
Figure 23: Interdomain contact. Superposition of GluA2-LBDMES, GluA2-LBDDNQX (PDB entry 1FTL), 
GluA2-LBDATPO (PDB entry 1N0T), GluA2-LBDZK200775 (PDB entry 3KGC), GluA2-LBDapo (PDB entry 
1FTO) and GluA2-LBDglutamate (PDB entry 2UXA). D1 residues have been aligned and D2 has been free to 
move with similar colours applying as in figure 22. The hydrogen bond between Glu402 and Thr686 of the 
glutamate bound structure is shown as black dashed line. 
 
In figure 24 the positioning of MES and the selected three different antagonists 
within the GluA2-LBD is shown. All four cases represent the open conformation of the 
LBD, which is unambiguously pointed out by directly looking towards the ligand-
binding cavity (Fig. 24 A – D). An observation of the ligand from this point of view is 
not possible in a closed, agonist bound state of the receptor (not shown, PDB entry 
2UXA)304. Even partial agonist bound structures of the GluA2-LBD do not provide this 
intimate insight (not shown; PDB entries 3T96 and 3T9H)293.  
Interactions between proteins and ligands are simplified and clearly laid out in the 
right part of the picture (Fig. 24 E – H). When comparing the protein–ligand 
interactions of the GluA2-LBDMES structure (Fig. 24 E) with interactions of 
antagonist bound structures, some similarities draw the attention.  
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Figure 24: Premium positioning of MES in the GluA2-LBD and comparisons. (A – D) Surface representation 
of the GluA2-LBD (D1: dark green, D2: light green) with bound (A) MES (salmon spheres), (B) DNQX (brown 
spheres, PDB entry 1FTL), (C) ATPO (orange spheres, PDB entry 1N0T) and (D) ZK200775 (blue spheres, PDB 
entry 3KGC). (E – H) Overview of the molecular details. Receptor residues interacting with (E) MES and sulfate 
(salmon sticks), (F) DNQX (brown sticks), (G) ATPO (orange sticks) and (H) ZK200775 (blue sticks) via hydrogen 
bonds or salt bridges (black dashed lines) are shown as sticks, whereas residues mediating van der Waals 
contacts are depicted as ellipses. In general, protein residues are numbered according to the PDB file and are 
shown in shades of green according to their location on D1 or D2. Water molecules are shown as gray spheres. 
For simplicity, all residues have been flattened onto the plane of the page. 
 
The structure with bound DNQX shows a sulfate ion interacting with residues of the 
protein contributing to the ligand-binding cavity (Fig. 24 F). The phosphonate group 
of ATPO is located at a similar position and is involved in an extensive hydrogen-
bonding network with protein residues and water molecules (Fig. 24 G). This leads to 
the assumption that this site in GluA2 is favorable for being occupied by a large and 
negatively charged group. The antagonist ZK200775 can be considered as a hybrid 
of DNQX and ATPO, but the phosphonate group of ZK200775 is positioned at a 
slightly different site (Fig. 24 H). While the phosphonate of ATPO and the sulfate ion 
of the DNQX structure both form contacts to a serine (S142), a threonine (T143) and 
a glutamate (E193) residue of the protein, the phosphonate group of ZK200775 only 
interacts with the serine and glutamate residue. The sulfate ion of the GluA2-
LBDMES structure is stabilized by two out of three of these residues, namely the 
threonine and the glutamate residue of the protein. The spatial location of this sulfate 
ion differs from the position of the sulfate in the DNQX structure and from the position 
of the phosphonates of ATPO and ZK200775 as well. However, these different 
positions are antagonised and balanced by different degrees of clamshell closure.  
With respect to the marked similarities, the MES molecule can, in combination with 
the sulfate ion, be considered as a lead structure for the design of a new class of 
GluA2 antagonists. For example, MES and the sulfate ion could be connected via a 
phenyl moiety. This is demonstrated and described more in detail in chapter 10. 
Finally, it should be mentioned that MES interestingly not only interacts with iGluRs, 
but also occupies the extracellular region of an mGluR, though in a different mode of 
action305.  
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Chapter 16: Synthesis of BAG  
BAG (3) has been synthesized in good overall yields, when compared to similar 
literature5,258,259,296,306-308. The overview and the experimental part is desribed in 
chapter 9 and 13.3, respectively, and spectra are shown in chapter 22.2. Ribosome 
display experiments with the molecule are currently under investigation in the group 
of Prof. A. Plückthun. If the group in Zurich will succeed in evolving a DARPin that 
binds specifically to this enantiomer, a novel protein scaffold recognizing and binding 
azobenzenes would have been created. Possible applications are in the field of life 
science research as well as in the biopharmaceutical industry and medical sciences.  
 
Chapter 17: Synthesis, electrophysiological characterization and 
proposed binding mode of MOBIPHOS  
After designing MOBIPHOS (4), the molecule and its derivative MOBIPHOSen (38) 
have been prepared in a good overall yield referring to related literature309-312. The 
design and the synthetic overview are given in chapter 10, the synthetic proceeding 
is described in chapter 13.5 and spectra are shown in chapter 22.4. A crystal 
structure of the bisphosphonate (40), which is depicted in figure 25, has been 
observed. Crystallographic data thereof are detailed in chapter 21.2.  
 
Figure 25: Crystal structure of bisphosphonate (40). 
 
Electrophysiology experiments with HEK-293T cells expressing GluA2 have been 
performed by Dr. Martin Sumser and results thereof are shown in figure 26. As can 
be seen, MOBIPHOS (4) acts as a GluA2 antagonist (Fig. 26 A).  
24 hours after transiently transfecting HEK293T cells with the non-desensitizing 
mutant GluA2 L504Y construct, cells have been voltage-clamped at −50 mV. Without 
MOBIPHOS (4) currents are triggered by application of a short pressure ejection 
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pulse of glutamate (100 ms; 100 μM) from a glass pipette located in proximity to the 
patched cell. After wash-in of an extracellular solution containing 2 mM 
(±)MOBIPHOS (4), the same application of glutamate is completely blocked. 
Glutamate-evoked currents are fully restored when MOBIPHOS (4) is washed out 
again.  
With 2 mM (±)MOBIPHOSen (38) present in the extracellular solution, outward 
currents have been observed when glutamate has been applied (data not shown). 
However, without MOBIPHOSen (38) normal inward currents have occured upon 
application of glutamate. Measurements have been repeated with MOBIPHOS (4) 
and led to the same results with outward currents appearing at this day of 
measurement. These contradictory results cannot be further explained without 
additional experiments that need to be performed in the future.  
Figure 26: Electrophysiology results and proposed MOBIPHOS–receptor interactions in the binding 
pocket. (A) Voltage-clamp recordings in HEK cells. Glutamate applications are indicated by a short bar and the 
presence of MOBIPHOS (4) is shown as a long bar. (B) Proposed interactions between MOBIPHOS (4, dark gray 
sticks) and receptor residues (light gray sticks). Trapped water molecules (red spheres), hydrogen bonds and ion 
pair interactions (black dashed lines) are shown. GluA2 residues are numbered according to the mature protein 
without the signal peptide. 
 
A proposed, modeled binding mode of MOBIPHOS (4) is shown in real space (Fig. 
26 B). The MES part of the molecule would interact with an arginine (R485) and the 
backbone NH of a threonine (T480) residue of the protein via its substituted 
phosphonate group. This moiety would also form a hydrogen bond to a water 
molecule. The protonated nitrogen of the morpholine ring would donate a proton to 
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the γ-carboxyl group of a glutamate residue (E705) of the protein, which would be 
additionally bridged to the second phosphonate via a water molecule. Moreover, the 
backbone NH of this glutamate would contact the second phosphonate, which would 
be additionally stabilized by the side chain of a threonine (T655). Furthermore, the 
phosphonate would be connected to the backbone NH of this threonine in an indirect, 
water mediated fashion and would bind three more water molecules.  
Although there is no X-ray structure of GluA2-LBDMOBIPHOS, yet, a possible 
mechanism of binding to and acting on the receptor might be as follows. First, 
MOBIPHOS (4) might compete against the contact sites of the ligand glutamate on 
D1 within the open conformation of the binding pocket. Second, the phosphonate 
might occupy the position of the sulfate ion in the GluA2-LBDMES structure. The 
phosphonate might interact with the same residues of D2 when compared to the γ-
carboxyl group of the ligand glutamate, but would better fit into this position within the 
apo-like conformation of the protein. Third, the stiff phenyl ring might sterically inhibit 
clamshell closure via a foot in the closing door mechanism. Moreover, the open 
pocket might be stabilized by additional water molecules forming a hydrogen bonding 
network as already observed with the phosphonate group of ATPO and the sulfate 
ion of the GluA2-LBDMES structure. 
 
Chapter 18: Synthesis of ABA  
ABA (5) has been synhesized following a literature procedure, but experiments 
towards a molecular motor in the group of Prof. T. Hugel are currently stalled at an 
early stage due to another part of the research involved313. The synthetic overview is 
detailed in chapter 11, experiments are explained in chapter 13.6 and spectra are 
shown in chapter 22.5.  
 
Chapter 19: Synthesis of ortho-substituted azobenzenes 
The compounds have been prepared with good yields compared to literature, 
synthetic schemes are shown in chapter 9, the accomplishment is described in 
chapter 13.3 and 13.4 and spectra are shown in chapter 22.2 and 22.3185. At the time 
of writing, optical activity measurements with 2,2',6,6'-tetramethyl-QAQ (6) and 
further experiments towards 2,2',6,6'-tetrachloro-MAG (7) have just been performed 
in the groups of Prof. E. Riedle and Prof. A. Woolley, respectively.  
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The GluK2- and GluA2-LBDs have been overexpressed and purified and the 
synthesis of 4-Gluazo (2) has been achieved and even optimised. The affinity of 4-
Gluazo (2) to different iGluRs has been determined by ITC and by the newly 
developed technique of label-free MST. Moreover, crystallization conditions have 
been developed to co-crystallize azobenzene ligands and proteins.  
With the structure of the GluK2-LBD bound to 4-Gluazo (2), deeper mechanistic 
insights of the mode of action of a photoswitch on a receptor protein could be gained. 
Other experiments concerning the mechanism are currentlly under investigation by 
means of quantum-mechanical calculations and molecular dynamic simulations.  
By illustrating the molecular details, the structure will help to design new molecules 
with higher affinity or selectivity. One can be sure, that with time, hard work and the 
already available methods and data more answers can be given to several important 
questions concerning the specificity of 4-Gluazo (2) to the different channel isotypes. 
4-Gluazo (2) is already known to be a trans-agonist of kainate receptors, which is 
further confirmed by this structure. With affinity measurements the activity on AMPA 
receptors has been proved and newer data show 4-Gluazo (2) to act as a cis-agonist 
on NMDA receptors. Moreover, these data allow for the exact selection of attachment 
sites of PTLs. Also, the possibility to introduce further substituents on the phenyl 
rings in order to change the absorption behaviour of the photoswitch can be 
inspected. A red shifted version of 4-Gluazo (2) could for example have an impact on 
the ultimate, long-term goal of vision restoration.  
 
BAG (3), the target molecule for DARPins during the ribosome display selection cycle 
has been synthesized. If the research concerning the development of a designed 
ankyrin repeat azobenzene binding protein will be crowned with success, completely 
new dimensions of applications regarding azobenzenes in biology will be 
accomplishable. 
DARPins surpass antibodies in biophysical properties and can bridge the gap 
between chemistry and biology. Applications with fusion proteins and chemical 
conjugates would be possible. By fusing the azobenzene binding scaffold to other 
proteins of interest, they could thereby in turn be controled with light. For example 
applications as intracellular protein binders or enzyme inhibitors could be possible, 
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with DARPins being an attractive, more stable and highly specific alternative to 
intrabodies314.  
Synthetic, switchable enzymes through domain fusion have already been reported315. 
The technique to modulate enzyme function would be a key regulatory feature and 
the control of enzymes by a light signal would enable a wide array of sensing 
applications and therapeutics and would provide a powerful tool for the basic study of 
biology. DARPins have already been used as viral surface protein adapters, as tumor 
targeting molecules and could serve as diagnostic toolbox in general316-319. They 
could also serve as recognition molecules on protein chips for light-controllable 
proteomics studies in connection with target discovery and functional identification. 
 
With the tetrameric structure of the GluA2-LBD harboring MES and a sulfate ion, a 
new binding mode has been identified and a novel class of GluA2 antagonists has 
been developed. MOBIPHOS (4) and MOBIPHOSen (38) have been prepared and 
electrophysiological experiments proved the antagonistic effect on GluA2. 
When the mode of action of the molecules is further confirmed by additional crystal 
structures and thereby understood and described by a single molecular mechanism, 
high affinity drugs may possibly be designed and synthesized. Moreover, a 
photoswitchable version of this antagonist might be possible.  
Although glutamate receptor antagonists have proven to be an effective research tool 
in receptor pharmacology, compounds modulating iGluR function have not yielded 
major successes as therapeutic agents, yet. An important characteristic of the 
effectiveness of substances in inhibiting nerve conduction depends in part on its 
solubility. To be taken up by the extracellular medium and to be conveyed to its 
binding position, the molecule has to be soluble in water. The antagonist DNQX and 
analogues thereof are highly insoluble in water, which led to their abandonment in 
clinical trials59. In contrast MOBIPHOS (4) and MOBIPHOSen (38) are highly soluble 
in water, but the affinity to the receptor is expected to be not very high. However, 
upon structure-guided improvements this series may be of clinical interest. With the 
development of more potent compounds, many promising and exciting opportunities 
are tantalizingly close. 
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ABA (5) has been prepared, but experiments towards the creation of a molecular 
motor are currently stalling. With a molecular motor moving on a track in a light-
driven fashion, specific operations or tasks at the molecular level could be performed 
in the future in the field of nanoscience. The molecular motor could possibly act as a 
transport device or it could perform other mechanical functions when incorporated 
into bigger structures. With artificial molecular motors a real nanomachinery built up 
of individual basis modules could be imaginable. 
 
The key characteristic of 2,2',6,6'-tetramethyl-QAQ (6) is the stability of the chiral 
structure in the Z isomer and the synthesis of the molecule has been performed. 
Next, the molecular chirality needs to be detected, and the enatiomeric enrichment 
with circular polarized light needs to be induced. Further experiments, like circular 
dichroism could be used to investigate the photochemical isomerization and 
additionally the two enantiomers could possibly be seperated by chiral HPLC. This 
molecule could for example be used as a chiral sensor. 
The selective expression of LiGluRs in retinal ganglion cells could restore light 
sensitivity to the blind rd1 mouse retina and to the TKO mouse retina8. In order to 
perform further experiments to achieve the goal of vision restoration, the applied 
compounds need to be red-shifted. Therefore, treated mice could respond to more 
natural stimuli. MAG with its conventional azobenzene core is activated in the long-
wave UV to blue range. However, most UV light cannot even reach the retina, but is 
filtered out by the cornea. A building block of the red-shifted 2,2',6,6'-tetrachloro-MAG 
(7) has been prepared and when the synthesis is completed, the molecule can be 
tested on rd1 mice. By using the adeno-associated viral vector gene therapy, 
chemically engineered LiGluRs can be expressed selectively in retinal ganglion cells, 
which consequently can be targeted with 2,2',6,6'-tetrachloro-MAG (7). The next step 
would be the synthesis of red-shifted PCLs for iGluRs. With PCLs there is no need to 
introduce genes and wild type endogeneous receptors can be targeted. A possibility 
would be a red-shifted 4-Gluazo (2) compound to target iGluRs, present in retinal 
ganglion cells320. 
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Chapter 20: Abbreviations 
 
3-D three-dimensional 
ABA azobenzene 
bis(iodoacetamide) 
ABP azobenzene-binding 
protein 
AcOH acetic acid 
AMPA α-amino-3-hydroxy-5-
methyl-4-
isoxazolepropionic acid 
A/NTD amino- or N-terminal 
domain 
APS ammonium persulfate 
ATPO 2-amino-3-[5-tert-butyl-
3-(phosphonomethoxy)-
4-isoxazolyl] propionic 
acid 
ATR attenuated total 
reflection 
BAG biotin azobenzene 
glutamate 
br broad 
BSA bovine serum albumin 
Ca2+ calcium ion 
CaCl2 calcium chloride 
calc calculated 
CAM cerium ammonium 
molybdate 
CCDC cambridge 
crystallographic data 
centre 
CDCl3 deuterated chloroform 
Ce(SO4)2 cerium sulphate 
CH2Cl2 dichloromethane 
CNS central nervous system 
conc. concentrated 
CsF caesium fluoride 
CTD C-terminal domain 
CV column volume 
D1 domain1 
D2 domain2 
d doublet 
DARPin designed ankyrin repeat 
protein 
dd double doublet 
DIPEA diisopropylethylamine 
DMF dimethylformamide 
  
  
DNA deoxyribonucleic acid 
DNAse deoxyribonuclease 
DNQX 6,7-dinitroquinoxaline-
2,3-dione 
dt double triplet 
DTT dithiothreitol 
EC50 half-maximal effective 
concentration 
E. coli Escherichia coli 
EDCl 1-ethyl-3-(3-
dimethylaminopropyl) 
carbodiimide 
EDTA Ethylenediamine 
tetraacetic acid 
EI electron ionization 
ER endoplasmic reticulum 
ESI electrospray ionization 
Et2O diethylether 
EtOAc ethyl acetate 
FeSO4 ferrous sulphate 
GABA γ-aminobutyric acid 
GluA glutamate receptor 
AMPA 
GluK glutamate receptor 
kainate 
GRIA glutamate receptor, 
ionotropic, AMPA 
GRIK glutamate receptor, 
ionotropic, kainate 
h hour 
H proton 
HCl hydrochloric acid 
HEPES 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic 
acid 
HOAc acetic acid 
HOBt 1-hydroxybenzotriazole 
HPLC high performance liquid 
chromatography 
(HR-)MS (high resolution)-mass 
spectrometry 
H2SO4 sulphuric acid 
HWE Horner-Wadsworth-
Emmons 
Hz hertz 
i.e. id est 
APPENDIX 
 120 
iGluR ionotropic glutamate 
receptor 
IPTG isopropyl-β-D-
thiogalactopyranoside 
IR infrared 
ITC isothermal titration 
calorimetry 
IUPHAR international union of 
basic and clinical 
pharmacology 
J coupling constant 
K+ potassium ion 
K2CO3 potassium carbonate 
KcsA potassium channel from 
S. lividans 
KD equilibrium dissociation 
constant 
KF potassium fluoride 
kJ kilojoule 
KMnO4 potassium 
permanganate 
KOH potassium hydroxide 
LB lysogeny broth 
LBD ligand-binding domain 
LC-MS liquid chromatography – 
mass spectrometry 
LGIC ligand-gated ion channel 
LiCl lithium chloride 
LiGluR light-gated ionotropic 
glutamate receptor 
LiHMDS lithium 
hexamethyldisilazide 
LMU Ludwig-Maximilians-
Universität 
LiOH lithium hydroxide 
Li2SO4 lithium sulfate 
m NMR: multiplet,  
IR: medium 
MAG maleimide – 
azobenzene – glutamate 
MeCN acetonitrile 
MeOH methanol 
MES 2-(N-morpholino) 
ethane 
sulfonic acid  
MgCl2 magnesium chloride 
mGluR metabotropic glutamate 
receptor 
min minute 
MOBIPHOS morpholino 
bisphosphonate 
MOBIPHOS
en 
unsaturated morpholino 
bisphosphonate 
mRNA messenger ribonucleic 
acid 
MST microscale 
thermophoresis 
MW molecular weight 
MWCO molecular weight cut off 
m/z   mass to charge ratio 
n n-orbital 
NaCl sodium chloride 
Na sodium 
Na+ sodium ion 
NH4Cl ammonium chloride 
NaHCO3 sodium hydrogen 
carbonate 
NaOAc sodium acetate 
NaOH sodium hydroxide 
Na2S sodium sulphide 
Na2SO4 sodium sulphate 
NBQX 2,3-dihydroxy-6-nitro-7-
sulfamoyl-
benzo[f]quinoxaline 
n-BuLi n-butyllithium 
NEB new england biolabs 
Ni-NTA nickel-nitrilotriacetic acid 
NMDA N-methyl-D-aspartate  
NMR nuclear magnetic 
resonance 
OD600 optical density at 600 
nm 
ORF open reading frame 
π, π∗  π-, π∗-orbital 
p.a. pro analysi 
PCL photochromic ligand 
PCR polymerase chain 
reaction 
PDB protein data bank 
Pd/C palladium on carbon 
PEG polyethylene glycol 
PFP-TFA pentafluorophenyl 
trifluoroacetate 
  
Φ quantum yield 
pH potentia hydrogenii 
ppm parts per million 
Pt/C platinum on carbon 
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PTL photoswitched tethered 
ligand 
P2X purinergic receptor 2X 
q quartet 
QAQ quaternary-ammonium – 
azobenzene – 
quaternary-ammonium 
quint quintet 
RBS ribosome binding site 
Rf  retarding factor 
RNase ribonuclease 
RP reverse phase 
rpm revolutions per minute 
RT-PCR reverse transcriptase-
polymerase chain 
reaction 
s NMR: singlet , IR: strong 
scFv single-chain Fv 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate 
polyacrylamide gel 
electrophoresis 
sec second 
SELEX systematic evolution of 
ligands by exponential 
enrichment 
SOC super optimal broth with 
catabolite repression 
t triplet 
TE Tris EDTA 
TEA triethylamine 
TEMED tetramethylethylen-
diamine 
TFA trifluoroacetic acid 
THF tetrahydrofurane 
TKO triple knockout 
TLC thin layer 
chromatography 
TMD transmembrane domain 
TMS tetramethylsilane 
TMSI trimethylsilyl iodide 
Tris tris(hydroxymethyl)-
aminomethane 
tRNA transfer ribonucleic acid 
TUM technische Universität 
München 
UoT University of Toronto 
UV ultraviolet 
vs very strong 
w weak 
ZnCl2 zinc chloride 
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Chapter 21: Crystallographic data 
 
21.1 GluK2-LBD and GluA2-LBD 
 
 GluK2-LBD GluA2-LBD 
Data collection 
Space group P6122 P212121 
Unit cell parameters [Å]; [°] a = b = 102.61, c = 282.51; 
α = β = 90, γ = 120 
a = 61.99, b = 92.02, c = 196.51; 
α = β = γ = 90 
Wavelength [Å] 0.9184 0.9184 
Resolution [Å] 20.0 – 2.0 (2.1 – 2.0) 20.0 – 1.8 (1.9 – 1.8) 
Completeness [%] 99.8 (100.0) 99.9 (100.0) 
Unique reflections 60248 (8042) 104825 (15487) 
Multiplicity 10.6 (10.5) 8.1 (8.2) 
Mean I/σ(I) 27.5 (3.9) 15.2 (3.9) 
Rmeas.[%] 7.4 (63.6) 11.2 (55.6) 
Wilson B-factor [Å2] 34.3 21.1 
Refinement 
Resolution [Å] 19.92 – 2.00 (2.05 – 2.00) 19.93 – 1.80 (1.85 – 1.80) 
Reflections (working) 57203 (4115) 99587 (7227) 
Reflections (test) 3042 (217) 5237 (354) 
Rcryst [%] 17.3 (21.9) 17.4 (21.2) 
Rfree [%] 20.4 (27.2) 22.1 (26.1) 
Number of atoms 
Proteins / ligands / ions / waters 
4122 / 39 / 6 / 478 8109 / 44 / 60 / 1104 
    Table 11: Crystallographic data of the GluK2- and GluA2-LBD.  
 
Values in parentheses refer to the highest resolution shell. 
 
Coordinates and structure factors of the GluK2- and GluA2-LBD have been deposited 
in the Protein Data Bank with the accession codes 4H8I and 4H8J, respectively. 
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21.2 Propargyl pyroglutamate (11) and bisphosphonate (40) 
 
 Propargyl pyroglutamate (11) Bisphosphonate (40) 
Space group P212121 Cmc21 
Unit cell parameters [Å]; [°] a = 8.91, b = 10.61, c = 16.88; 
α = β = γ = 90 
a = 12.70, b = 17.07, c = 9.99; 
α = β = γ = 90 
V [Å3] 1596.3(5) 2166.7(3) 
Z 4 4 
ρcalc. [g ⋅ cm-3] 1.229 1.233 
µ [mm-1] 0.092 0.229 
Reflections measured 8656 5889 
Rint 0.0479 0.0304 
Mean σ(I)/I 0.0488 0.0296 
θ range 4.28 – 26.37 4.42 – 26.37 
Observed reflections 2727 2112 
Flack parameter -0.8(17) 0.04(13) 
Reflections in refinement 3237 2266 
parameters 204 142 
restraints 0 3 
R(Fobs) 0.0563 0.0409 
RW(F2) 0.1494 0.1100 
S 1.067 1.046 
ρmax [e ⋅ Å-3] 0.315 0.370 
ρmin [e ⋅ Å-3] -0.248 -0.325 
      Table 12: Crystallographic data of propargyl pyroglutamate (11) and bisphosphonate (40). 
 
Propargyl pyroglutamate: 
The flack parameter is meaningless. The absolute structure has been deduced from 
the synthesis. The disorder in an ethyl group has been handled by using the split 
model, with a sof ratio of 0.76/0.24. 
 
Bisphosphonate: 
The disorder of an ethyl group has been handled by using the split model, with a sof 
ratio of 0.46/0.54, split atoms have been refined isotropically. 
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Chapter 22: NMR Spectra 
22.1 Spectra of 4-Gluazo and intermediates 
22.1.1 N-Boc-L-pyroglutamic acid ethyl ester (10) 
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22.1.2 Propargyl pyroglutamate (11) 
 
 
??
?
?
?
?
?
?
?
?
?
?
??
??
??
??
??
???
??
?
??
??
?
???
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
APPENDIX 
 126 
22.1.3 Bromoalkyne (12)  
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22.1.4 Vinyl stannane (13) 
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22.1.5 Iodoazobenzene (14) 
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22.1.6 Azobenzene pyroglutamate (17)  
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22.1.7 N-Boc azobenzene glutamic acid (18) 
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22.1.8 4-Gluazo (2) 
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22.2 Spectra of BAG and intermediates  
22.2.1 N-tosyl-2,6-dimethylaniline (26) 
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22.2.2 N-tosyl-2,6-dimethyl-4-nitroaniline (27) 
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22.2.3 2,6-dimethyl-4-nitroaniline (24)  
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22.2.4 Nitroazobenzene (28)  
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22.2.5 Aminoazobenzene (29) 
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22.2.6 N-Boc-L-pyroglutamic acid tert-butyl ester (20)  
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22.2.7 Allylpyroglutamate (21-trans)  
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22.2.8 Cis-allylpyroglutamate (21-cis) 
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22.2.9 Acrylic acid pyroglutamate (22) 
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22.2.10 Carboxylic acid pyroglutamate (23) 
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22.2.11 Aminoazobenzene pyroglutamate (30) 
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22.2.12 N-acyl-aminoazobenzene pyroglutamate (31)  
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22.2.13 Azobenzene glutamic acid ester (32) 
 
 
??
??
?
?
?
?
?
?
?
?
?
?
??
??
??
??
??
??
???
??
?
??
??
???
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
??
??
??
??
??
??
??
??
??
????
????
????
????
????
????
????
?????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
APPENDIX 
 158 
 
 
 
??
?
?
??
??
??
??
??
??
??
??
??
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
???
??
?
??
?
?????????????????????
?
??
?
??
?
??
?
??
?
?????
?????
?????
?????
?????
?????
?????
?????
?????
?????
?????
?????
??????
??????
??????
??????
??????
??????
??????
??????
??????
??????
??????
??????
??????
APPENDIX 
 159 
22.2.14 Biotin azobenzene glutamic acid ester γ-amide (34) 
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22.2.15 BAG (3) 
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22.2.16 Azobenzene glutamic acid γ-amide (35) 
 
 
??
?
?
?
?
?
?
?
?
?
?
??
??
??
??
??
???
??
?
??
??
??
???
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
????
????
????
????
?????
????
????
????
?????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
APPENDIX 
 164 
 
 
 
??
?
?
??
??
??
??
??
??
??
??
??
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
???
??
?
??
??
?
???
??
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
?????
?????
?????
?????
?????
?????
?????
?????
?????
?????
?????
?????
?????
?????
?????
?????
??????
??????
??????
??????
??????
??????
??????
??????
??????
??????
??????
APPENDIX 
 165 
22.3 Spectra of 2,2',6,6'-tetramethyl-QAQ (6) 
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22.4 Spectra of MOBIPHOS, MOBIPHOSen and intermediates  
22.4.1 Bisphosphonate (40)  
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22.4.2 Morpholino bisphosphonate (41)  
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22.4.3 Morpholino dihydrobisphosphonate (42)  
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22.4.4 MOBIPHOS (4) 
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22.4.5 MOBIPHOSen (38) 
 
 
??
??
?
?
?
?
?
?
?
?
?
?
??
??
??
??
??
??
???
??
?
??
?
???????????
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
????
APPENDIX 
 180 
 
 
 
??
?
?
??
??
??
??
??
??
??
??
??
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
???
??
?
??
?
??
?
??
?
?????????????????????
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
?????
?????
?????
?????
?????
?????
??????
??????
??????
??????
??????
??????
??????
??????
?
??????
??????
??????
APPENDIX 
 181 
 
 
 
??
??
??
??
??
??
??
??
??
??
??
??
??
?
??
?
??
?
??
?
?
??
??
??
??
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
?
??
???
??
?
??
??
?
??
??
?
???
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
??
??
?
?????
?????
APPENDIX 
 182 
22.5 Spectra of ABA (5) 
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Chapter 23: Protein primary structures 
23.1 GluK2-LBD amino acid sequence 
 
 
The N-terminal octa histidine tag, the thrombin cleavage site and the GT dipeptide 
are framed red, whereas the beginning and ending of S1 and S2 are framed blue.  
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23.2 GluA2-LBD amino acid sequence 
 
 
The N-terminal octa histidine tag, the thrombin cleavage site and the GT dipeptide 
are framed red, whereas the beginning and ending of S1 and S2 are framed green. 
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